

VINAY BHUSHAN & ASSOCIATES CHARTERED ACCOUNTANTS

726, 7th Floor, D - Wing, Neelkanth Business Park, Near Bus Depot, Vidyavihar (West), Mumbai - 86. Maharashtra (INDIA). Office : + 91 - 22 - 2513 8323 • Email : info@vbaconsult.com GSTIN NO. : 27AAPFV6885P1ZS

Independent Auditor's Report

To the members of Aegean Properties Limited Report on Audit of the Financial Statements

Opinion

We were engaged to audit the accompanying IND AS financial statements of **Aegean Properties Limited** ("the Company"), which comprise the Balance Sheet as at March 31, 2023, the Statement of Profit and Loss (including other comprehensive income), the Statement of Changes in Equity and the Cash Flow Statement for the year then ended and notes to financial statements, including a summary of the significant accounting policies and other explanatory information.

We do not express an opinion on the accompanying IND AS financial statements of the Company. Because of the significance of the matter described in the Basis for Disclaimer of Opinion and Material Uncertainty Relating to Going Concern section of our report, we have not been able to obtain sufficient appropriate audit evidence to provide a basis for an audit opinion on these IND AS financial statements.

Basis for Opinion

We conducted our audit in accordance with the Standards on Auditing (SAs) specified under section 143(10) of the Companies Act, 2013. Our responsibilities under those Standards are further described in the Auditor's Responsibilities for the Audit of the Financial Statements section of our report. We are independent of the Company in accordance with the Code of Ethics issued by the Institute of Chartered Accountants of India together with the ethical requirements that are relevant to our audit of the standalone Ind AS financial statements under the provisions of the Companies Act, 2013 and the Rules thereunder, and we have fulfilled our other ethical responsibilities in accordance with these requirements and the Code of Ethics. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion.

Information Other than the Financial Statements and Auditor's Report Thereon

The Company's Board of Directors is responsible for the other information. The other information comprises the information included in the Board's Report including Annexures to Board's Report, but does not include the financial statements and our auditor's report thereon. The other information is expected to be made available to us after the date of this auditor's report.

Our opinion on the financial statements does not cover the other information and we do not express any form of assurance conclusion thereon.

In connection with our audit of the financial statements, our responsibility is to read the other information identified above and, in doing so, consider whether the other information is materially inconsistent with the financial statements or our knowledge obtained in the audit, or otherwise appears to be materially misstated. If, based on the work we have performed, we conclude that there is a material misstatement of this other information; we are required to report that fact. We have nothing to report in this regard.



Management's Responsibility for the Financial Statements

The Company's Board of Directors is responsible for the matters stated in Section 134(5) of the Companies Act, 2013 ("the Act") with respect to the preparation and presentation of these financial statements that give a true and fair view of the financial position, financial performance, changes in equity and cash flows of the Company in accordance with the accounting principles generally accepted in India, including the Indian Accounting Standards (Ind AS) specified under Section 133 of the Act. This responsibility also includes maintenance of adequate accounting records in accordance with the provisions of the Act for safeguarding of the assets of the Company and for preventing and detecting frauds and other irregularities; selection and application of appropriate accounting policies; making judgments and estimates that are reasonable and prudent; and design, implementation and maintenance of adequate internal financial controls, that were operating effectively for ensuring the accuracy and completeness of the accounting records, relevant to the preparation and presentation of the Ind AS financial statements that give a true and fair view and are free from material misstatement, whether due to fraud or error.

In preparing the financial statements, management is responsible for assessing the Company's ability to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless management either intends to liquidate the Company or to cease operations, or has no realistic alternative but to do so.

Those Board of Directors are also responsible for overseeing the Company's financial reporting process.

Auditor's Responsibility for the Audit of the Financial Statements

Our objectives are to obtain reasonable assurance about whether the standalone Financial Statements as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable Assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with SAs will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these Financial Statements.

As part of an audit in accordance with SAs, we exercise professional judgment and maintain professional skepticism throughout the audit. We also:

- Identify and assess the risks of material misstatement of the Financial Statements, whether due to fraud or error, design and perform audit procedures responsive to those risks, and obtain audit evidence that is sufficient and appropriate to provide a basis for our opinion. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control.
- Obtain an understanding of internal control relevant to the audit in order to design audit procedures that are appropriate in the circumstances. Under section 143(3)(i) of the Companies Act, 2013, we are also responsible for expressing our opinion on whether the company has adequate internal financial controls system in place and the operating effectiveness of such controls
- Evaluate the appropriateness of accounting policies used and the reasonableness of accounting estimates and related disclosures made by management.
- Conclude on the appropriateness of management's use of the going concern basis of accounting and, based on the audit evidence obtained, whether a material uncertainty exists related to events or conditions that may cast significant doubt on the Company's ability to continue as a going concern. If we conclude that a material uncertainty exists, we are



required to draw attention in our auditor's report to the related disclosures in the Financial Statements or, if such disclosures are inadequate, to modify our opinion. Our conclusions are based on the audit evidence obtained up to the date of our auditor's report. However, future events or conditions may cause the Company to cease to continue as a going concern.

• Evaluate the overall presentation, structure and content of the Financial Statements, including the disclosures, and whether the Financial Statements represent the underlying transactions and events in a manner that achieves fair presentation.

Materiality is the magnitude of misstatements in the financial statements that, individually or in aggregate, makes it probable that the economic decisions of a reasonably knowledgeable user of the financial statements may be influenced. We consider quantitative materiality and qualitative factors in (i) planning the scope of our audit work and in evaluating the results of our work; and (ii) to evaluate the effect of any identified misstatements in the financial statements.

We communicate with those charged with governance regarding, among other matters, the planned scope and timing of the audit and significant audit findings, including any significant deficiencies in internal control that we identify during our audit.

We also provide those charged with governance with a statement that we have complied with relevant ethical requirements regarding independence, and to communicate with them all relationships and other matters that may reasonably be thought to bear on our independence, and where applicable, related safeguards.

Report on Other Legal and Regulatory Requirements

- 1. As required by the Companies (Auditor's Report) Order, 2020 ("the Order"), issued by the Central Government of India in terms of sub-section (11) of section 143 of the Companies Act, 2013, we give in the **"Annexure A"**, a statement on the matters specified in paragraph 3 and 4 of the Order, to the extent applicable.
- 2. As required by Section 143 (3) of the Act, we report that:
 - a) We have sought all the information and explanations, which to the best of our knowledge and belief were necessary for the purposes of our audit;
 - b) In our opinion, proper books of account as required by law have been kept by the Company so far as it appears from our examination of those books.
 - c) The Balance Sheet, the Statement of Profit and Loss, the Cash Flow Statement and the Statement of Changes in Equity dealt with by this report are in agreement with the books of accounts.
 - d) In our opinion, the aforesaid financial statements comply with the Accounting Standards specified under Section 133 of the Act, read with Rule 7 of the Companies (Accounts) Rules, 2014.
 - e) On the basis of the written representations received from the directors as on 31st March, 2023 taken on record by the Board of Directors, none of the directors is disqualified as on 31st March, 2023 from being appointed as a director in terms of Section 164 (2) of the Act.
 - f) With respect to the adequacy of the internal financial controls over financial reporting of the Company and the operating effectiveness of such controls, refer to our separate report in "Annexure B". That report expresses a disclaimer of opinion on the Company's internal



controls over financial reporting for the reasons stated therein.

- g) With respect to the other matters to be included in the Auditor's Report in accordance with Rule 11 of the Companies (Audit and Auditors) Rules, 2014, in our opinion and to the best of our information and according to the explanations given to us:
 - 1. The Company does not have any pending litigations which would impact its financial position.
 - ii. The Company did not have any long-term contracts including derivative contracts for which there were any material foreseeable losses
 - iii. There were no amounts which were required to be transferred to the Investor Education and Protection Fund by the Company.
 - iv. The management has represented that, to the best of its knowledge and belief, other than as disclosed in the notes to the accounts, no funds have been advanced or loaned or invested (either from borrowed funds or share premium or any other sources or kind of funds) by the company to or in any other persons or entities, including foreign entities ("Intermediaries"), with the understanding, whether recorded in writing or otherwise, that the Intermediary shall, whether, directly or indirectly lend or invest in other persons or entities identified in any manner whatsoever by or on behalf of the company ("Ultimate Beneficiaries") or provide any guarantee, security or the like on behalf of the Ultimate Beneficiaries;
 - v. The management has represented, that, to the best of its knowledge and belief, other than as disclosed in the notes to the accounts, no funds have been received by the company from any persons or entities, including foreign entities ("Funding Parties"), with the understanding, whether recorded in writing or otherwise, that the company shall, whether, directly or indirectly, lend or invest in other persons or entities identified in any manner whatsoever by or on behalf of the Funding Party ("Ultimate Beneficiaries") or provide any guarantee, security or the like on behalf of the Ultimate Beneficiaries; and
 - vi. Based on audit procedures which we considered reasonable and appropriate in the circumstances, nothing has come to our notice that has caused us to believe that the representations under sub-clause (i) and (ii) contain any material mis-statement.
 - vii. The Company has not declared or paid dividend during the year

For Vinay Bhushan & Associates **Chartered Accountants** Firm's Reg No.1/30529W CA. Vinay Bhushan Partner Membership No. 5026325500

Place: Mumbai Date: 22nd May, 2023 UDIN Z35DZ63ZBGXNQK4442

Annexure - A to the Independent Auditors' Report

The Annexure referred to in Independent Auditors' Report to the members of the Company on the financial statements for the year ended 31 March 2023

Report as required by the Companies (Auditor's Report) Order, 2020 ("the Order"), issued by the Central Government of India in terms of sub-section (11) of section 143 of the Companies Act, 2013 (Refer to in paragraph 1 under 'Report on Other Legal and Regulatory Requirements' section of our report of even date). With reference to the Annexure A referred to in the Independent Auditors' Report to the members of the Company on the financial statements for the year ended March 31, 2023, we report the following:

(i) (a)

- A. The Company has proper records related to full particulars including quantitative details and situation of Property, Plant and Equipment.
- B. The company is not having any intangible asset. Therefore, the provisions of Clause (i)(a)(B) of paragraph 3 of the order are not applicable to the company.
- (b) In our opinion Property, Plant and Equipment have been physically verified by the management at reasonable intervals. No material discrepancies were noticed on such verification during the year.
- (c) As explained to us, and as per information provided to us, the title deeds of immovable property disclosed in the financial statements are held in the name of the Company.
- (d) The Company has not revalued its Property, Plant and Equipment during the year. Therefore, the provisions of Clause (i)(d) of paragraph 3 of the order are not applicable to the company.
- (e) No proceedings have been initiated or are pending against the company for holding any benami property under the Benami Transactions (Prohibition) Act, 1988 (45 of 1988) and rules made thereunder. Therefore, the provisions of Clause (i)(e) of paragraph 3 of the order are not applicable to the company.

(ii)

- (a) As the Company does not have any inventory, clause 3(ii) (a) of the order is not applicable to the Company.
- (b) During any point of time of the year, the company has not been sanctioned any working capital limits, from banks or financial institutions on the basis of security of current assets. Therefore, the provisions of Clause (ii)(b) of paragraph 3 of the order are not applicable to the company.
- (iii) During the year, the Company has not made any investments in, provided any guarantee or security or granted any loans or advances in the nature of loans, secured or unsecured, to companies, firms, Limited Liability Partnerships or any other parties. Therefore, the provisions of clause 3(iii) of the said Order are not applicable to the company.
- (iv) The Company has not made any loans, investments, guarantees and security on which provisions of section 185 and 186 of the Companies Act 2013 are applicable. Therefore, the provisions of clause 3(iv) of the said Order are not applicable to the company.



- (v) In our opinion and according to the information and explanations given to us, the Company has not accepted any deposits from public. Therefore, the provisions of Clause (v) of paragraph 3 of the order are not applicable to the Company.
- (vi) As explained to us, the Central Government of India has not specified the maintenance of cost records under sub-section (1) of Section 148 of the Act for any of the products of the Company. Therefore, the provisions of Clause (vi) of paragraph 3 of the order are not applicable to the Company.

(vii)

- (a) In our opinion and according to the information and explanations given to us, the Company is generally regular in depositing undisputed statutory dues including Provident Fund, Employees State Insurance, Income tax, Duty of Customs, GST, Cess and other statutory dues with the appropriate authorities to the extent applicable to it. There are no undisputed amounts payable in respect of income tax, wealth tax, service tax, sales tax, value added tax, duty of customs, duty of Excise or Cess which have remained outstanding as at March 31, 2023 for a period of more than 6 months from the date they became payable.
- (b) According to the information and explanations given to us, there is no dues referred in sub-clause
 (a) which have not been deposited on account of any dispute. Therefore, the provisions of Clause (vii)(b) of paragraph 3 of the order are not applicable to the Company.
- (viii) In our opinion and according to the information and explanations given to us, there is no any transaction not recorded in the books of account have been surrendered or disclosed as income during the year in the tax assessments under the Income Tax Act, 1961 (43 of 1961).
- (ix)
 - (a) In our opinion and according to the information and explanations given to us, the Company has not defaulted in repayment of any loan or other borrowings or any interest due thereon to any lender.
 - (b) In our opinion and according to the information and explanations given to us, the company has not been a declared willful defaulter by any bank or financial institution or other lender.
 - (c) In our opinion and according to the information and explanations given to us, no loans were obtained by the company in the current year.
 - (d) According to the information and explanations given to us, the Company has not raised any funds on short term basis during the year.
 - (e) According to the information and explanations given to us, the company has not taken any funds from any entity or person on account of or to meet the obligations of its subsidiaries, associates or joint ventures.
 - (f) According to the information and explanations given to us, the company has not raised loans during the year on the pledge of securities held in its subsidiaries, joint ventures or associate companies.

(X)

(a) According to the information and explanations given to us, The Company has not raised money by way of initial public offer or further public offer (including debt instruments). Therefore, the provisions of Clause (x)(a) of paragraph 3 of the order are not applicable to the Company.



(b) According to the information and explanations given to us, the company has not made any preferential allotment or private placement of shares during the year and the requirements of section 42 and section 62 of the Companies Act, 2013 have been complied with and the funds raised have been used for the purposes for which the funds were raised.

(xi)

- (a) According to the information and explanations given to us and based on our examination of the records of the Company, no fraud by the company or on the Company has been noticed or reported during the course of our audit.
- (b) During the year no report under sub-section (12) of section 143 of the Companies Act has been filed by the auditors in Form ADT-4 as prescribed under rule 13 of Companies (Audit and Auditors) Rules, 2014 with the Central Government.
- (c) As represented to us by the management, there are no whistle-blower complaints received during the year.
- (xii) The Company is not a Nidhi Company. Therefore, the provisions of Clause (xii) of paragraph 3 of the order are not applicable to the Company.
- (xiii) As per the information and explanations received to us and based on our examination of the records of the Company, transactions with the related parties are in compliance with sections 177 and 188 of Companies Act where applicable, and the details have been disclosed in the financial statements, etc., as required by the applicable accounting standards. Further the Company is not required to constitute an Audit Committee under section 177 of the Act, and accordingly, to this extent, the provision of clause 3(xiii) of the order is not applicable to the Company.
- (xiv) The Company is not covered by section 138 of the Companies Act, 2013, related to appointment of internal auditor of the company. Therefore, the company is not required to appoint any internal auditor. Therefore, the provisions of Clause (xiv) of paragraph 3 of the order are not applicable to the Company.
- (xv) The Company has not entered into any non-cash transactions with directors or persons connected with him. Therefore, the provisions of Clause (xv) of paragraph 3 of the order are not applicable to the Company.

(xvi)

- (a) The Company is not required to be registered under section 45-IA of the Reserve Bank of India Act, 1934.
- (b) The company has not conducted any Non-Banking Financial or Housing Finance activities during the year.
- (c) The company is not a Core Investment Company (CIC) as defined in the regulations made by the Reserve Bank of India.
- (d) As per the information and explanations received, the group does not have any CIC as part of the group.
- (xvii) The company has not incurred any cash loss during the current financial year



- (xviii) The Previous Statutory Auditor of the Company M/s Anil A Dikshit & Co. has resigned during the F.Y 2022-23.
- (xix) On the basis of the financial ratios, ageing and expected dates of realization of financial assets and payment of financial liabilities, other information accompanying the financial statements, the auditor's knowledge of the Board of Directors and management plans, we are of the opinion that no material uncertainty exists as on the date of the audit report that company is capable of meeting its liabilities existing at the date of balance sheet as and when they fall due within a period of one year from the balance sheet date.

(XX)

- (a) According to information and explanation given to us, there are no ongoing projects of the Company, and accordingly, the provisions of Clause 3(xx) of the Order are not applicable to the Company
- (b) According to information and explanation given to us, the Company does not have any ongoing projects. Therefore, the provisions of Clause (xx)(b) of paragraph 3 of the order are not applicable to the Company.
- (xxi) The Company does not have any subsidiary company. Therefore, the company does not require to prepare consolidated financial statement. Therefore, the provisions of Clause (xxi) of paragraph 3 of the order are not applicable to the Company.

For Vinay Bhushan & Associates **Chartered Accountants** Firm's Reg No.130529 Vinay Bhu Panner Membership No. 502632

Place: Mumbai Date: 22nd May, 2023 UDIN:235026328GX NQK 4442

Annexure - B to the Independent Auditors' Report

Report on the Internal Financial Controls under Clause (i) of Sub-section 3 of Section 143 of the Companies Act, 2013 ("the Act")

We have audited the internal financial controls over financial reporting of **Aegean Properties Limited** ("the Company") as of 31st March, 2023 in conjunction with our audit of the standalone Ind AS financial statements of the Company for the year ended on that date.

Management's Responsibility for Internal Financial Controls

The Company's management is responsible for establishing and maintaining internal financial controls based on the internal control over financial reporting criteria established by the Company considering the essential components of internal control stated in the Guidance Note on Audit of Internal Financial Controls over Financial Reporting issued by the Institute of Chartered Accountants of India ('ICAI'). These responsibilities include the design, implementation and maintenance of adequate internal financial controls that were operating effectively for ensuring the orderly and efficient conduct of its business, including adherence to company's policies, the safeguarding of its assets, the prevention and detection of frauds and errors, the accuracy and completeness of the accounting records, and the timely preparation of reliable financial information, as required under the Companies Act, 2013.

Auditors' Responsibility

Our responsibility is to express an opinion on the Company's internal financial controls over financial reporting of the company based on our audit. We conducted our audit in accordance with the Guidance Note on Audit of Internal Financial Controls Over Financial Reporting (the "Guidance Note") issued by the Institute of Chartered Accountants of India and the Standards on Auditing as specified under section 143(10) of the Companies Act, 2013, to the extent applicable to an audit of internal financial controls. Those Standards and the Guidance Note require that we comply with ethical requirements and plan and perform the audit to obtain reasonable assurance about whether adequate internal financial controls over financial reporting was established and maintained and if such controls operated effectively in all material respects.

Our audit involves performing procedures to obtain audit evidence about the adequacy of the internal financial controls system over financial reporting and their operating effectiveness. Our audit of internal financial controls over financial reporting included obtaining an understanding of internal financial controls over financial reporting, assessing the risk that a material weakness exists, and testing and evaluating the design and operating effectiveness of internal control based on the assessed risk. The procedures selected depend on the auditor's judgment, including the assessment of the risks of material misstatement of the financial statements, whether due to fraud or error.

We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our audit opinion on the internal financial controls system over financial reporting of the Company.

Meaning of Internal Financial Controls over Financial Reporting

A Company's internal financial control over financial reporting is a process designed to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles. A company's internal financial control over financial reporting includes those policies and procedures that (1) pertain to the maintenance of records that, in reasonable detail, accurately and fairly reflect the transactions and dispositions of the assets of the company;(2) provide reasonable assurance that transactions are recorded as necessary to permit preparation of financial statements in accordance with Generally Accepted Accounting Principles, and that receipts and expenditures of the company



are being made only in accordance with authorizations of management and directors of the company; and (3) provide reasonable assurance regarding prevention or timely detection of unauthorized acquisition, use, or disposition of the company's assets that could have a material effect on the financial statements.

Inherent Limitations of Internal Financial Controls Over Financial Reporting

Because of the inherent limitations of internal financial controls over financial reporting, including the possibility of collusion or improper management override of controls, material misstatements due to error or fraud may occur and not be detected. Also, projections of any evaluation of the internal financial controls over financial reporting to future periods are subject to the risk that the internal financial control over financial reporting may become inadequate because of changes in conditions, or that the degree of compliance with the policies or procedures may deteriorate.

Opinion

In our opinion, to the best of our information and according to the explanations given to us, the Company has, in all material the Company has, in all material respects, an adequate internal financial controls system over financial reporting and such internal financial controls over financial reporting were operating effectively as at March 31, 2023, based on the internal control over financial reporting criteria established by the Company considering the essential components of internal control stated in the Guidance Note on Audit of Internal Financial Controls Over Financial Reporting issued by the Institute of Chartered Accountants of India.

For Vinay Bhushan & Associates **Chartered Accountants** Firm Reg No 130529W CA. Vinav Bhusha Partner Membership No. 502632

Place: Mumbai Date: 22nd May, 2023 UDIN: えろうして6328GXN&K4442

AEGEAN PROPERTIES LIMITED CIN:U45200MH1995PLC084766 BALANCE SHEET AS AT MARCH 31, 2023

DALANCE ONLET AS AT MARCH 51, 2025		As at March 31, 2023	As at March 31, 2022
	Notes	(Rs. in '000)	(Rs. in '000)
ASSETS			
NON-CURRENT ASSETS			
a) Investment in Property	3	4,792.02	4,900.44
b) Income tax assets (net)	4	<u>.</u>	38.44
		4,792.02	4,938.87
CURRENT ASSETS			
a) Financial Assets			
i) Trade receivables	5	11,124.08	9,963.33
ii) Cash and Cash Equivalents	6	158.99	25.89
b) Deferred tax assets (net)	7	62.58	64.76
c) Other current assets	8	28.41	53.33
		11,374.05	10,107.31
TOTAL		16,166.07	15,046.19
EQUITY AND LIABILITIES EQUITY a) Equity Share Capital b) Other equity	9 10	3,000.00 13,072.99	3,000.00 12,003.32
		16,072.99	15,003.32
a) Financial Liabilities			
 i) Trade payables a) Total outstanding dues of micro and small enterprises 		-	
 b) Total outstanding dues of creditors other than micro and small enterprises 		15.00	16.50
b) Other current liabilities	11	25.83	26.37
c) Income Tax liabilities (net)	12	52.25	(=)
		93.08	42.87
TOTAL		16,166.07	15,046.19
See accompanying notes forming part of the Ind AS financial statements.	1-26	3	

As per our report of even date attached

For Vinay Bhushan & Associates

Chartered Accountants

Firm Registration No. 130529W



For and on behalf of the Board of Directc of Aegean Properties Limited

Cail

Krishna Datla Director DIN:00003247

Srikant Sharma Director DIN:07552040

Place: Thane Date: May 22, 2023

AEGEAN PROPERTIES LIMITED CIN:U45200MH1995PLC084766 STATEMENT OF PROFIT AND LOSS FOR THE YEAR ENDED MARCH 31, 2023


	Notes	Year ended March 31 , 2023 (Rs. in '000)	Year ended March 31 , 2022 (Rs. in '000)
Income: Revenue from operations	13	1,800.00	1 800 00
	13		1,800.00
Total revenue (I)		1,800.00	1,800.00
Expenses:			
Depreciation and amortization expense	14	108.42	108.42
Other expenses	15	268.56	495.27
Total (II)		376.98	603.69
Profit/(Loss) before tax		1,423.02	1,196.31
Tax expense:			
Current tax	22	355.97	295.69
Tax Expense related to Prior Year	22	(4.80)	1.00
Deferred tax	22	2.18	5.64
Total tax expense		353.35	301.33
Profit/(Loss) for the year		1,069.68	894.98
Earning per share (equity shares, par value Rs 10	16		
each) Computed on the basis of total profit for the year			
Basic / Diluted (Rs.)		35.66	29.83
See accompanying notes forming part of the Ind AS financial statements.	1-26		

As per our report of even date attached

For Vinay Bhushan & Associates

Chartered Accountants

Firm Registration No. 130529W



Place: Mumbai Date: May 22, 2023 UDIN: 235026328GXN&K4442 For and on behalf of the Board of Director of Aegean Properties Limited

Krishna Datla Director DIN:00003247 Srikant Sharma Director DIN:07552040

Place: Thane Date: May 22, 2023

PARTICULARS	Year ended March 31, 2023	Year ended March 31, 2022
	(Rs. in '000)	(Rs. in '000)
A. Cash flow from operating activities		
Profit before tax	1,423.02	1,196.31
Adjustment to reconcile profit before tax to net cash flows:		
Depreciation and amortization expense	108.42	108.42
Operating profit before working capital changes	1,531.44	1,304.73
Movements in working capital :		
Decrease/(increase) in other financial assets	(1,160.75)	985.50
Decrease/(increase) in other assets	24.92	30.21
Increase/(decrease) in trade payables & Other liabilities	(2.04)	· 198.18
Increase/(decrease) in provisions	-	(a)
Cash generation used in operations	393.58	151.27
Direct taxes paid (net of refunds)	(260.48)	- 303.96
Net cash flow used in operating activities	(A) <u>133.10</u>	- 152.69
B. Cash flow from investing activities		
Net cash flow from/(used in) investing activities	(B)	
C. Cash flow from financing activities		
Net cash flow from/ (used in) in financing activities	(C)	
Net increase/(decrease) in cash and cash equivalents (A+E	3+C) 133.10	- 152.69
Cash and cash equivalents at the beginning of the year	25.89	178.59
Cash and cash equivalents at the end of the year	158.99	25.89
Components of cash and cash equivalents		
Cash on hand	ŝ.	0.05
With scheduled banks on:		
Current account	158.99	25.85
Total cash and cash equivalents (Refer Note 5)	158.99	25.89
Note		

1) Cash flow statement has been prepared under indirect method as set out in the Accounting Standard (AS-3) "Cash Flow Statements" as specified by Companies (Accounts) Rules, 2014.

2) Previous year's figures have been regrouped/rearranged wherever necessary.

As per our report of even date attached For Vinay Bhushan & Associates Chartered Accountants Firm Registration No. 130529W SHUSHAN & 0 Vinay Bhushan FRN No. Partner 130529W Membership No.: 5 Place: Mumbai Accourt Date: May 22, 2023 UDIN: 235026328GXN8K4442

For and on behalf of the Board of Directo of Aegean Properties kimited

are

Krishna Datla Director DIN:00003247

Director DIN:07552040

Place: Thane Date: May 22, 2023

Srikant Sharma

AEGEAN PROPERTIES LIMITED CIN:U45200MH1995PLC084766 STATEMENT OF CHANGES IN EQUITY FOR THE YEAR ENDED MARCH 31, 2023

(a) Equity share capital:

	Number of shares	Amount
		(Rs. in '000)
Balance as at 1 April, 2021	30,000	3,000
Changes in equity share capital during the year		
Balance as at 31 March, 2022	30,000	3,000
Changes in equity share capital during the year	-	
Balance as at 31 March, 2023	30,000	3,000

(b) Other equity

	Reserves and surplus
	Retained
Balance as at April 01, 2021	11,108.34
Profit for the year	894.98
Balance as at March 31, 2022	12,003.32
Profit for the year	1,069.68
Balance as at March 31, 2023	13,072.99

See accompanying notes forming part of the Ind AS financial statements.

As per our report of even date attached

For Vinay Bhushan & Associates

Chartered Accountants Firm Registration No. 130529W



Place: Mumbai Date: May 22, 2023 UDIN: 235026328GXN&K4442 For and on behalf of the Board of Director: of Aegean Properties Limited

Krishna Datla Director DIN:00003247

Srikant Sharma Director DIN:07552040

Place: Thane Date: May 22, 2023

1. Corporate information

Aegean Properties Limited ('the Company') is a public company domiciled in India and incorporated under the provisions of the Companies Act, 1956. The Company is engaged in the business of renting property.

2. Significant accounting policies

(a) Statement of compliance

These standalone financial statements of the Company have been in accordance with Indian Accounting Standards (Ind AS) notified under the Companies (Indian Accounting Standards) Rules, 2015 (as amended) together with the comparative period data as at and for the year ended March 31, 2023.

(b) Basis of accounting

The Company maintains accounts on accrual basis following the historical cost convention, except for certain financial instruments that are measured at fair value in accordance with Ind AS The carrying value of all the items of property, plant and equipment and investment property as on date of transition is considered as the deemed cost.

(c) Fair Value Measurement

The Company measures financial instruments, at fair value at each balance sheet date.

Fair value is the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. The fair value measurement is based on the presumption that the transaction to sell the asset or transfer the liability takes place either:

- In the principal market for the asset or liability, or
- In the absence of a principal market, in the most advantageous market for the asset or liability
- The principal or the most advantageous market must be accessible by the Company.

The fair value of an asset or a liability is measured using the assumptions that market participants would use when pricing the asset or liability, assuming that market participants act in their economic best interest.

The Company uses valuation techniques that are appropriate in the circumstances and for which sufficient data are available to measure fair value, maximising the use of relevant observable inputs and minimising the use of unobservable inputs.

All assets and liabilities for which fair value is measured or disclosed in the financial statements are categorised within the fair value hierarchy, described as follows, based on the lowest level input that is significant to the fair value measurement as a whole:

- Level 1 Quoted (unadjusted) market prices in active markets for identical assets or liabilities
- Level 2 Valuation techniques for which the lowest level input that is significant to the fair value
 - measurement is directly or indirectly observable
- Level 3 Valuation techniques for which the lowest level input that is significant to the fair value
 - measurement is unobservable

For assets and liabilities that are recognised in the financial statements on a recurring basis, the Company determines whether transfers have occurred between levels in the hierarchy by re-assessing categorisation(based on the lowest level input that is significant to the fair value measurement as a whole) at the end of each reporting period.

For the purpose of fair value disclosures, the Company has determined classes of assets and liabilities on the basis of the nature, characteristics and risks of the asset or liability and the level of the fair value hierarchy as explained above.

(d) Presentation of financial statements

The Balance Sheet and the Statement of Profit and Loss are prepared and presented in the format prescribed in the Schedule III to the Companies Act, 2013 ("the Act"). The statement of cash flows has been prepared and presented as per the requirements of Ind AS 7 "Statement of Cash flows". The disclosure requirements with respect to items in the Balance Sheet and Statement of Profit and Loss, as prescribed in the Schedule III to the Act, are presented by way of notes forming part of the financial statements along with the other notes required to be disclosed under the notified Accounting Standards. Amounts in the financial statements are presented in Indian Rupees. Per share data are presented in Indian Rupees to two decimals places.

(e) Current versus non-current classification

The Company presents assets and liabilities in the balance sheet based on current/non-current classification. An asset is treated as current when it is:

- Expected to be realised or intended to be sold or consumed in normal operating cycle
- Held primarily for the purpose of trading
- Expected to be realised within twelve months after the reporting period, or

- Cash or cash equivalent unless restricted from being exchanged or used to settle a liability for at least twelve months after the reporting period All other assets are classified as non-current.

A liability is current when:

- It is expected to be settled in normal operating cycle
- It is held primarily for the purpose of trading
- it is due to be settled within twelve months after the reporting period, or
- There is no unconditional right to defer the settlement of the liability for at least twelve months after
- the reporting period

The Company classifies all other liabilities as non-current.

Deferred tax assets and liabilities are classified as non-current assets and liabilities.

The operating cycle is the time between the acquisition of assets for processing and their realisation in cash and cash equivalents. Operating cycle for the business activities of the company covers the duration of the specific project/contract/product line/service including the defect liability period wherever applicable and extends up to the realisation of receivables (including retention monies) within the agreed credit period normally applicable to the respective lines of business.



(f) Revenue recognition

Revenue is recognised to the extent that it is probable that the economic benefits will flow to the Company and the revenue can be reliably measured, regardless of when the payment is being made. Revenue is measured at the fair value of the consideration received or receivable, taking into account contractually defined terms of payment and excluding taxes or duties collected on behalf of the government. The Company has concluded that it is the principal in all of its revenue arrangements since it is the primary obligor in all the revenue arrangements as it has pricing latitude and is also exposed to inventory and credit risks. Based on the Educational Material on Ind AS 18 issued by The Institute of Chartered Accountants of India (ICAI), sales tax/ value added tax (VAT) / service tax/GST is not received by the Company on its own account. Rather, it is tax collected on service provided or value added to the commodity by the seller or service provider on behalf of the government. Accordingly, it is excluded from revenue.

Revenue is recognised based on nature of activity when consideration can be reasonably measured and recovered with reasonable certainty. Revenue is measured at the fair value of the consideration received or receivable and is reduced for estimated customer returns, rebates and other similar allowances

i) Revenue from operations

Rental income from operating leases (net of any incentives given to the lessees) is recognized as per the lease term.

ii) Other income

Interest income on loans and deposits is recognized on a time proportion basis taking into account the amount outstanding and the rate applicable.

Interest on income tax refund is recognized on receipt of the refund order.

(g) Exceptional items

An item of income or expense which by its size, type or incidence requires disclosure in order to improve an understanding of the performance of the company is treated as an exceptional item and the same is disclosed in the notes to accounts.

(h) Property, Plant and Equipment (PPE)

PPE is recognised when it is probable that future economic benefits associated with the item will flow to the company and the cost of the item can be measured reliably. PPE is stated at original cost net of tax/duty credits availed, if any, less accumulated depreciation and cumulative impairment, if any. Property, plant and equipment acquired on hire purchase basis are recognised at their cash values. Cost includes professional fees related to the acquisition of PPE and for qualifying assets, borrowing costs capitalised in accordance with the company's accounting policy.

For transition to Ind AS, the company has elected to adopt as deemed cost, the carrying value of PPE measured as per I-GAAP less accumulated depreciation and cumulative impairment on the transition date of April 1, 2016. In respect of revalued assets, the value as determined by valuers as reduced by accumulated depreciation and cumulative impairment is taken as cost on transition date.

Own manufactured PPE is capitalised at cost including an appropriate share of overheads. Administrative and other general overhead expenses that are specifically attributable to construction or acquisition of PPE or bringing the PPE to working condition are allocated and capitalised as a part of the cost of the PPE.

An item of property, plant and equipment and any significant part initially recognised is derecognised upon disposal or when no future economic benefits are expected from its use or disposal. Any gain or loss arising on derecognition of the asset (calculated as the difference between the net disposal proceeds and the carrying amount of the asset) is included in the income statement when the asset is derecognised.

The residual values, useful lives and methods of depreciation of property, plant and equipment are reviewed at each financial year end and adjusted prospectively, if appropriate.

PPE not ready for the intended use on the date of the Balance Sheet are disclosed as "capital work-in-progress". (Also refer to policies on leases, borrowing costs, impairment of assets and foreign currency transactions infra).

Depreciation is recognised using straight line method so as to write off the cost of the assets (other than freehold land and properties under construction) less their residual values over their useful lives specified in Schedule II to the Companies Act, 2013, or in the case of assets where the useful life was determined by technical evaluation, over the useful life so determined. Depreciation method is reviewed at each financial year end to reflect the expected pattern of consumption of the future economic benefits embodied in the asset. The estimated useful life and residual values are also reviewed at each financial year end and the effect of any change in the estimates of useful life/residual value is accounted on prospective basis.

Where cost of a part of the asset ("asset component") is significant to total cost of the asset and useful life of that part is different from the useful life of the remaining asset, useful life of that significant part is determined separately and such asset component is depreciated over its separate useful life.

Depreciation on additions to/deductions from, owned assets is calculated pro rata to the period of use.

Depreciation charge for impaired assets is adjusted in future periods in such a manner that the revised carrying amount of the asset is allocated over its remaining useful life.

Assets acquired under finance leases are depreciated on a straight line basis over the lease term. Where there is reasonable certainty that the company shall obtain ownership of the assets at the end of the lease term, such assets are depreciated based on the useful life prescribed under Schedule II to the Companies Act, 2013 or based on the useful life adopted by the company for similar assets.

Depreciation on PPE is calculated on a straight-line basis using the rates arrived at based on the useful lives estimated by the management. The identified components are depreciated separately over their useful lives; the remaining components are depreciated over the life of the principal asset. The Company has used the following rates to provide depreciation on its PPE.



	Estimated useful lives (in years)
Building	
Leased improvements/Façade	30
Plant & Machinery	15

(i) Impairment of fixed assets

As at the end of each accounting year, the company reviews the carrying amounts of its PPE, investment property, intangible assets and investments in subsidiary, associate and joint venture companies to determine whether there is any indication that those assets have suffered an impairment loss. If such indication exists, the said assets are tested for impairment so as to determine the impairment loss, if any. Goodwill and the intangible assets with indefinite life are tested for impairment each year.

Impairment loss is recognised when the carrying amount of an asset exceeds its recoverable amount. Recoverable amount is determined:

(i) in the case of an individual asset, at the higher of the net selling price and the value in use; and

(ii) in the case of a cash generating unit (a Company of assets that generates identified, independent cash flows), at the higher of the cash generating unit's net selling price and the value in use.

(The amount of value in use is determined as the present value of estimated future cash flows from the continuing use of an asset and from its disposal at the end of its useful life. For this purpose, the discount rate (pre-tax) is determined based on the weighted average cost of capital of the company suitably adjusted for risks specified to the estimated cash flows of the asset).

For this purpose, a cash generating unit is ascertained as the smallest identifiable company of assets that generates cash inflows that are largely independent of the cash inflows from other assets or company of assets.

If recoverable amount of an asset (or cash generating unit) is estimated to be less than its carrying amount, such deficit is recognised immediately in the Statement of Profit and Loss as impairment loss and the carrying amount of the asset (or cash generating unit) is reduced to its recoverable amount.

When an impairment loss subsequently reverses, the carrying amount of the asset (or cash generating unit) is increased to the revised estimate of its recoverable amount, but so that the increased carrying amount does not exceed the carrying amount that would have been determined had no impairment loss is recognised for the asset (or cash generating unit) in prior years. A reversal of an impairment loss is recognised immediately in the Statement of Profit and Loss.

(j) Financial instruments

A financial instrument is any contract that gives rise to a financial asset of one entity and a financial liability or equity instrument of another entity.

Financial assets

Initial recognition and measurement

All financial assets are recognised initially at fair value plus, in the case of financial assets not recorded at fair value through profit or loss, transaction costs that are attributable to the acquisition of the financial asset. Purchases or sales of financial assets that require delivery of assets within a time frame established by regulation or convention in the market place (regular way trades) are recognised on the trade date, i.e., the date that the Company commits to purchase or sell the asset.

Subsequent measurement

For purposes of subsequent measurement, financial assets are classified in four categories -

- 1 Debt instruments at amortised cost
- 2 Debt instruments at fair value through other comprehensive income (FVTOCI)
- 3 Debt instruments, derivatives and equity instruments at fair value through profit or loss (FVTPL)
- 4 Equity instruments measured at fair value through other comprehensive income (FVTOCI)

The Company does not have any financial assets falling under category 1 to 3 above.

Debt instruments at amortised cost

A 'debt instrument' is measured at the amortised cost if both the following conditions are met:

- a) The asset is held within a business model whose objective is to hold assets for collecting contractual cash flows, and
- b) Contractual terms of the asset give rise on specified dates to cash flows that are solely payments of principal and interest (SPPI) on the principal amount outstanding.

This category is the most relevant to the Company. After initial measurement, such financial assets are subsequently measured at amortised cost using the effective interest rate (EIR) method. Amortised cost is calculated by taking into account any discount or premium on acquisition and fees or costs that are an integral part of the EIR. The EIR amortisation is included in finance income in the profit or loss. The losses arising from impairment are recognised in the profit or loss. This category generally applies to trade and other receivables.

Debt instrument at FVTPL

FVTPL is a residual category for debt instruments. Any debt instrument, which does not meet the criteria for categorization as at amortised cost or as FVTOCI, is classified as at FVTPL. In addition, the Company may elect to designate a debt instrument, which otherwise meets amortised cost or FVTOCI criteria, as at FVTPL. However, such election is allowed only if doing so reduces or eliminates a measurement or recognition inconsistency (referred to as 'accounting mismatch'). The Company has not designated any debt instrument as at FVTPL. Debt instruments included within the FVTPL category are measured at fair value with all changes recognised in



AEGEAN PROPERTIES LIMITED

CIN:U45200MH1995PLC084766

NOTES TO FINANCIAL STATEMENTS FOR THE YEAR ENDED MARCH 31, 2023

Equity investments

All equity investments in scope of Ind AS 109 are measured at fair value. Equity instruments which are held for trading classified as at FVTPL and are measured at fair value with all changes recognised in the profit or loss. For all other equity instruments, the Company may make an irrevocable election to present in other comprehensive income subsequent changes in the fair value. The Company makes such election on an instrument- by-instrument basis. The classification is made on initial recognition and is irrevocable.

If the Company decides to classify an equity instrument as FVTOCI, then all fair value changes on the instrument, excluding dividends, are recognised in the OCI. There is no recycling of the amounts from OCI to P&L, even on sale of investment. However, the Company may transfer the cumulative gain or loss within equity.

Derecognition

A financial asset (or, where applicable, a part of a financial asset or part of a Company of similar financial assets) is primarily derecognised (i.e. removed from the Company's balance sheet) when:

1) The rights to receive cash flows from the asset have expired, or

2) The Company has transferred its rights to receive cash flows from the asset or has assumed an obligation to

pay the received cash flows in full without material delay to a third party under a 'pass through' arrangement; and either

(a) The Company has transferred substantially all the risks and rewards of the asset, or

(b) The Company has neither transferred nor retained substantially all the risks and rewards of the asset, but has transferred control of the asset.

When the Company has transferred its rights to receive cash flows from an asset or has entered into a pass-through arrangement, it evaluates if and to what extent it has retained the risks and rewards of ownership. When it has neither transferred nor retained substantially all of the risks and rewards of the asset, nor transferred control of the asset, the Company continues to recognise the transferred asset to the extent of the Company's continuing involvement. In that case, the Company also recognises an associated liability. The transferred asset and the associated liability are measured on a basis that reflects the rights and obligations that the Company has retained.

Continuing involvement that takes the form of a guarantee over the transferred asset is measured at the lower of the original carrying amount of the asset and the maximum amount of consideration that the Company could be required to repay.

Impairment of financial assets

In accordance with Ind AS 109, the Company applies expected credit loss (ECL) model for measurement and recognition of impairment loss.

ECL is the difference between all contractual cash flows that are due to the Company in accordance with the contract and all the cash flows that the entity expects to receive (i.e., all cash shortfalls), discounted at the original EIR. ECL impairment loss allowance (or reversal) recognised during the period is recognised as income/ expense in the statement of profit and loss.

For assessing increase in credit risk and impairment loss, the Company combines financial instruments on the basis of shared credit risk characteristics with the objective of facilitating an analysis that is designed to enable significant increases in credit risk to be identified on a timely basis.

Financial liabilities

Initial recognition and measurement

Financial liabilities are classified, at initial recognition, as financial liabilities at fair value through profit or loss, loans and borrowings, payables, or as derivatives designated as hedging instruments in an effective hedge, as appropriate.

All financial liabilities are recognised initially at fair value and, in the case of loans and borrowings and payables, net of directly attributable transaction costs.

The Company's financial liabilities include trade and other payables, loans and borrowings including bank overdrafts and financial Subsequent measurement

The measurement of financial liabilities depends on their classification, as described below:

Loans and borrowings

This is the category most relevant to the Company. After initial recognition, interest-bearing loans and borrowings are subsequently measured at amortised cost using the EIR method. Gains and losses are recognised in profit or loss when the liabilities are derecognised as well as through the EIR amortisation process.

Amortised cost is calculated by taking into account any discount or premium on acquisition and fees or costs that are an integral part of the EIR. The EIR amortisation is included as finance costs in the statement of profit and loss.

This category generally applies to borrowings.

Financial guarantee contracts

Financial guarantee contracts issued by the Company are those contracts that require a payment to be made to reimburse the holder for a loss it incurs because the specified debtor fails to make a payment when due in accordance with the terms of a debt instrument. Financial guarantee contracts are recognised initially as a liability at fair value, adjusted for transaction costs that are directly attributable to the issuance of the guarantee. Subsequently, the liability is measured at the higher of the amount of loss allowance determined as per impairment requirements of Ind AS 109 and the amount recognised less cumulative amortisation.



AEGEAN PROPERTIES LIMITED CIN:U45200MH1995PLC084766

NOTES TO FINANCIAL STATEMENTS FOR THE YEAR ENDED MARCH 31, 2023

The Company does not have any financial liabilities at fair value through profit or loss.

Derecognition

A financial liability is derecognised when the obligation under the liability is discharged or cancelled or expires. When an existing financial liability is replaced by another from the same lender on substantially different terms, or the terms of an existing liability are substantially modified, such an exchange or modification is treated as the derecognition of the original liability and the recognition of a new liability. The difference in the respective carrying amounts is recognised in the statement of profit or loss.

Embedded derivatives

An embedded derivative is a component of a hybrid (combined) instrument that also includes a non-derivative host contract – with the effect that some of the cash flows of the combined instrument vary in a way similar to a stand-alone derivative. An embedded derivative causes some or all of the cash flows Notes to the financial statements that otherwise would be required by the contract to be modified according to a specified interest rate, financial instrument price, or other variable, provided in the case of a non-financial variable that the variable is not specific to a party to the contract. Reassessment only occurs if there is either a change in the terms of the contract that significantly modifies the cash flows that would otherwise be required or a reclassification of a financial asset out of the fair value through profit or loss.

If the hybrid contract contains a host that is a financial asset within the scope of Ind AS 109, the Company does not separate embedded derivatives. Rather, it applies the classification requirements contained in Ind AS 109 to the entire hybrid contract.

Derivatives embedded in all other host contracts are accounted for as separate derivatives and recorded at fair value if their economic characteristics and risks are not closely related to those of the host contracts and the host contracts are not held for trading or designated at fair value through profit or loss. These embedded derivatives are measured at fair value with changes in fair value recognised in profit or loss, unless designated as effective hedging instruments.

Reclassification of financial assets

The Company determines classification of financial assets and liabilities on initial recognition. After initial recognition, no reclassification is made for financial assets which are equity instruments and financial liabilities. For financial assets which are debt instruments, a reclassification is made only if there is a change in the business model for managing those assets. Changes to the business model are expected to be infrequent. The Company's senior management determines change in the business model as a result of external or internal changes which are significant to the Company's operations. Such changes are evident to external parties.

A change in the business model occurs when the Company either begins or ceases to perform an activity that is significant to its operations. If the Company reclassifies financial assets, it applies the reclassification prospectively from the reclassification date which is the first day of the immediately next reporting period following the change in business model. The Company does not restate any previously recognised gains, losses (including impairment gains or losses) or interest.

Offsetting of financial instruments

Financial assets and financial liabilities are offset and the net amount is reported in the balance sheet if there is a currently enforceable legal right to offset the recognised amounts and there is an intention to settle on a net basis, to realise the assets and settle the liabilities simultaneously.

(k) Leases

The determination of whether an agreement is, or contains, a lease is based on the substance of the agreement at the date of inception. The arrangement is, or contains, a lease if fulfillment of the arrangement is dependent on the use of a specific asset or assets and the arrangement conveys a right to use the asset or assets, even if that right is not explicitly specified in an arrangement. For arrangements entered into prior to April 1, 2016, the Company has determined whether the arrangement contain lease on the basis of facts and circumstances existing on the date of transition.

i) Finance leases:

- A) Leases where the company has substantially all the risks and rewards of ownership of the related assets are classified as finance leases. Assets under finance leases are capitalised at the commencement of the lease at the lower of the fair value or the present value of minimum lease payments and a liability is created for an equivalent amount. Each lease rental paid is allocated between the liability and the interest cost, so as to obtain a constant periodic rate of interest on the outstanding liability for each period.
- B) Assets given under a finance lease are recognised as a receivable at an amount equal to the net investment in the lease. Lease income is recognised over the period of the lease so as to yield a constant rate of return on the net investment in the lease.

ii) Operating leases:

The leases which are not classified as finance lease are operating leases.

- A) Lease rentals on assets under operating lease are charged to the Statement of Profit and Loss on a straight line basis over the term of the relevant lease.
- B) Assets leased out under operating leases are continued to be shown under the respective class of assets. Rental income is recognised on a straight line basis over the term of the relevant lease.

(I) Taxes on income

Tax on income for the current period is determined on the basis of taxable income and tax credits computed in accordance with the provisions of the Income tax Act 1961, and based on the expected outcome of assessments/appeals.

Deferred tax is recognised on temporary differences between the carrying amounts of assets and liabilities in the company's financial statements and the corresponding tax bases used in computation of taxable profit and quantified using the tax rates and laws enacted or substantively enacted as on the Balance Sheet date.

Deferred tax liabilities are generally recognised for all taxable temporary differences including the temporary differences associated with investments in subsidiaries and associates, and interests in joint ventures, except where the company is able to control the reversal of the temporary difference and it is probable that the temporary difference will not reverse in the foreseeable future.



Deferred tax assets are generally recognised for all taxable temporary differences to the extent that is probable that taxable profits will be available against which those deductible temporary differences can be utilised. The carrying amount of deferred tax assets is reviewed at the end of each reporting period and reduced to the extent that it is no longer probable that sufficient taxable profits will be available to allow all or part of the asset to be recovered.

Deferred tax assets relating to unabsorbed depreciation/business losses/losses under the head "capital gains" are recognised and carried forward to the extent of available taxable temporary differences or where there is convincing other evidence that sufficient future taxable income will be available against which such deferred tax assets can be realised.

The measurement of deferred tax liabilities and assets reflects the tax consequences that would follow from the manner in which the company expects, at the end of reporting period, to recover or settle the carrying amount of its assets and liabilities. Transaction or event which is recognised outside profit or loss, either in other comprehensive income or in equity, is recorded along with

Minimum alternate tax (MAT) paid in a year is charged to the statement of profit and loss as current tax. The Company recognizes MAT credit available as an asset only to the extent that there is convincing evidence that the Company will pay normal income tax during the specified period, i.e., the period for which MAT credit is allowed to be carried forward. In the year in which the Company recognizes MAT credit as an asset in accordance with the Guidance Note on Accounting for Credit Available in respect of Minimum Alternative Tax under the Income-tax Act, 1961, the said asset is created by way of credit to the statement of profit and loss and shown as "MAT Credit Entitlement." The Company reviews the "MAT credit entitlement" asset at each reporting date and writes down the asset to the extent the Company does not have convincing evidence that it will pay normal tax during the specified period.

(m) Provisions

A provision is recognized when the Company has a present obligation as a result of past events, it is probable that an outflow of resources will be required to settle the obligation, and a reliable estimate can be made of the amount of the obligation. Provisions are not discounted to their present value and are determined based on best estimate required to settle the obligation at the balance sheet date. These are reviewed at each balance sheet date and adjusted to reflect the current best estimates.

(n) Contingent liabilities

Contingent assets are not recognized in the financial statements of the Company. A contingent liability is a possible obligation that arises from past events whose existence will be confirmed by the occurrence or non-occurrence of one or more uncertain future events beyond the control of the Company or a present obligation that is not recognized because it is not probable that an outflow of resources will be required to settle the obligation. A contingent liability also arises in extremely rare case where there is a liability that cannot be recognized because it cannot be measured reliably. The Company does not recognize a contingent liability but discloses its existence in the financial statements.

(o) Earnings per share

Basic earnings per share are calculated by dividing the net profit or loss for the period attributable to equity shareholders by the weighted average number of equity shares outstanding during the period. The Company does not have any potential equity shares, and accordingly, the basic earnings per share and diluted earnings per share are the same.

(p) Cash and bank balances

Cash and bank balances also include fixed deposits, margin money deposits, earmarked balances with banks and other bank balances which have restrictions on repatriation. Short term and liquid investments being subject to more than insignificant risk of change in value, are not included as part of cash and cash equivalents.



AEGEAN PROPERTIES LIMITED

CIN:U45200MH1995PLC084766

NOTES TO FINANCIAL STATEMENTS FOR THE YEAR ENDED MARCH 31, 2023

(q) Borrowing costs

Borrowing costs include interest expense calculated using the effective interest method, finance charges in respect of assets acquired on finance lease and exchange differences arising on foreign currency borrowings to the extent they are regarded as an adjustment to interest costs.

Borrowing costs net of any investment income from the temporary investment of related borrowings, that are attributable to the acquisition, construction or production of a qualifying asset are capitalised/inventoried as part of cost of such asset till such time the asset is ready for its intended use or sale. A qualifying asset is an asset that necessarily requires a substantial period of time to get ready for its intended use or sale. All other borrowing costs are recognised in profit or loss in the period in which they are incurred.

(r) Cash Dividends to equity holders in the company

The Company recognises a liability to make cash or non-cash distributions to equity holders of the parent when the distribution is authorised and the distribution is no longer at the discretion of the Company. As per the corporate laws in India, a distribution is authorised when it is approved by the shareholders. A corresponding amount is recognised directly in equity.

(s) Presentation of financial statements

The Balance Sheet and the Statement of Profit and Loss are prepared and presented in the format prescribed in the Schedule III to the Companies Act, 2013 ("the Act"). The statement of cash flows has been prepared and presented as per the requirements of Ind AS 7 "Statement of Cash flows". The disclosure requirements with respect to items in the Balance Sheet and Statement of Profit and Loss, as prescribed in the Schedule III to the Act, are presented by way of notes forming part of the financial statements along with the other notes required to be disclosed under the notified Accounting Standards and the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. Amounts in the financial statements are presented in Indian Rupees in lakhs rounded off to two decimal places as permitted by Schedule III to the Companies Act, 2013. Per share data are presented in Indian Rupees to two decimals places.

(t) New Accounting Pronouncement

Ministry of Corporate Affairs ("MCA") notifies new standards or amendments to the existing standards under Companies (Indian Accounting Standards) Rules as issued from time to time. On March 31, 2023, MCA amended the Companies (Indian Accounting Standards) Amendment Rules, 2023, as below:

Ind AS 1 - Presentation of Financial Statements - This amendment requires the entities to disclose their material accounting policies rather than their significant accounting policies. The effective date for adoption of this amendment is annual periods beginning on or after April 1, 2023. The Company has evaluated the amendment and the impact of the amendment is insignificant in the financial statements.

Ind AS 8 - Accounting Policies, Changes in Accounting Estimates and Errors - This amendment has introduced a definition of 'accounting estimates' and included amendments to Ind AS 8 to help entities distinguish changes in accounting policies from changes in accounting estimates. The effective date for adoption of this amendment is annual periods beginning on or after April 1, 2023. The Company has evaluated the amendment and there is no impact on its financial statements.

Ind AS 12 - Income Taxes - This amendment has narrowed the scope of the initial recognition exemption so that it does not apply to transactions that give rise to equal and offsetting temporary differences. The effective date for adoption of this amendment is annual periods beginning on or after April 1, 2023. The Company has evaluated the amendment and there is no impact on its financial statement.



1. Corporate information

Aegean Properties Limited ('the Company') is a public company domiciled in India and incorporated under the provisions of the Companies Act, 1956. The Company is engaged in the business of renting property.

2. Significant accounting policies

(a) Statement of compliance

These standalone financial statements of the Company have been in accordance with Indian Accounting Standards (Ind AS) notified under the Companies (Indian Accounting Standards) Rules, 2015 (as amended) together with the comparative period data as at and for the year ended March 31, 2023.

(b) Basis of accounting

The Company maintains accounts on accrual basis following the historical cost convention, except for certain financial instruments that are measured at fair value in accordance with Ind AS. The carrying value of all the items of property, plant and equipment and investment property as on date of transition is considered as the deemed cost.

(c) Fair Value Measurement

The Company measures financial instruments, at fair value at each balance sheet date.

Fair value is the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. The fair value measurement is based on the presumption that the transaction to sell the asset or transfer the liability takes place either:

- In the principal market for the asset or liability, or

- In the absence of a principal market, in the most advantageous market for the asset or liability

The principal or the most advantageous market must be accessible by the Company.

The fair value of an asset or a liability is measured using the assumptions that market participants would use when pricing the asset or liability, assuming that market participants act in their economic best interest.

The Company uses valuation techniques that are appropriate in the circumstances and for which sufficient data are available to measure fair value, maximising the use of relevant observable inputs and minimising the use of unobservable inputs.

All assets and liabilities for which fair value is measured or disclosed in the financial statements are categorised within the fair value hierarchy, described as follows, based on the lowest level input that is significant to the fair value measurement as a whole:

- Level 1 Quoted (unadjusted) market prices in active markets for identical assets or liabilities
- Level 2 Valuation techniques for which the lowest level input that is significant to the fair value
- measurement is directly or indirectly observable
- Level 3 Valuation techniques for which the lowest level input that is significant to the fair value
 - measurement is unobservable

For assets and liabilities that are recognised in the financial statements on a recurring basis, the Company determines whether transfers have occurred between levels in the hierarchy by re-assessing categorisation(based on the lowest level input that is significant to the fair value measurement as a whole) at the end of each reporting period.

For the purpose of fair value disclosures, the Company has determined classes of assets and liabilities on the basis of the nature, characteristics and risks of the asset or liability and the level of the fair value hierarchy as explained above.

(d) Presentation of financial statements

The Balance Sheet and the Statement of Profit and Loss are prepared and presented in the format prescribed in the Schedule III to the Companies Act, 2013 ("the Act"). The statement of cash flows has been prepared and presented as per the requirements of Ind AS 7 "Statement of Cash flows". The disclosure requirements with respect to items in the Balance Sheet and Statement of Profit and Loss, as prescribed in the Schedule III to the Act, are presented by way of notes forming part of the financial statements along with the other notes required to be disclosed under the notified Accounting Standards. Amounts in the financial statements are presented in Indian Rupees. Per share data are presented in Indian Rupees to two decimals places.

(e) Current versus non-current classification

The Company presents assets and liabilities in the balance sheet based on current/non-current classification. An asset is treated as current when it is:

- Expected to be realised or intended to be sold or consumed in normal operating cycle
- Held primarily for the purpose of trading
- Expected to be realised within twelve months after the reporting period, or
- Cash or cash equivalent unless restricted from being exchanged or used to settle a liability for at least twelve months after the

reporting period

All other assets are classified as non-current.

A liability is current when:

- It is expected to be settled in normal operating cycle
- It is held primarily for the purpose of trading
- it is due to be settled within twelve months after the reporting period, or
- There is no unconditional right to defer the settlement of the liability for at least twelve months after
- the reporting period

The Company classifies all other liabilities as non-current.

Deferred tax assets and liabilities are classified as non-current assets and liabilities.

The operating cycle is the time between the acquisition of assets for processing and their realisation in cash and cash equivalents. Operating cycle for the business activities of the company covers the duration of the specific project/contract/product line/second including the defect liability period wherever applicable and extends up to the realisation of receivables (including retention of the specific project contract) of the specific project of the spec

> FRN No 1305290

Fored Acco

(f) Revenue recognition

Revenue is recognised to the extent that it is probable that the economic benefits will flow to the Company and the revenue can be reliably measured, regardless of when the payment is being made. Revenue is measured at the fair value of the consideration received or receivable, taking into account contractually defined terms of payment and excluding taxes or duties collected on behalf of the government. The Company has concluded that it is the principal in all of its revenue arrangements since it is the primary obligor in all the revenue arrangements as it has pricing latitude and is also exposed to inventory and credit risks. Based on the Educational Material on Ind AS 18 issued by The Institute of Chartered Accountants of India (ICAI), sales tax/ value added tax (VAT) / service tax/GST is not received by the Company on its own account. Rather, it is tax collected on service provided or value added to the commodity by the seller or service provider on behalf of the government. Accordingly, it is excluded from revenue.

Revenue is recognised based on nature of activity when consideration can be reasonably measured and recovered with reasonable certainty. Revenue is measured at the fair value of the consideration received or receivable and is reduced for estimated customer returns, rebates and other similar allowances

i) Revenue from operations

Rental income from operating leases (net of any incentives given to the lessees) is recognized as per the lease term.

ii) Other income

Interest income on loans and deposits is recognized on a time proportion basis taking into account the amount outstanding and the rate applicable.

Interest on income tax refund is recognized on receipt of the refund order.

(g) Exceptional items

An item of income or expense which by its size, type or incidence requires disclosure in order to improve an understanding of the performance of the company is treated as an exceptional item and the same is disclosed in the notes to accounts.

(h) Property, Plant and Equipment (PPE)

PPE is recognised when it is probable that future economic benefits associated with the item will flow to the company and the cost of the item can be measured reliably. PPE is stated at original cost net of tax/duty credits availed, if any, less accumulated depreciation and cumulative impairment, if any. Property, plant and equipment acquired on hire purchase basis are recognised at their cash values. Cost includes professional fees related to the acquisition of PPE and for qualifying assets, borrowing costs capitalised in accordance with the company's accounting policy.

For transition to Ind AS, the company has elected to adopt as deemed cost, the carrying value of PPE measured as per I-GAAP less accumulated depreciation and cumulative impairment on the transition date of April 1, 2016. In respect of revalued assets, the value as determined by valuers as reduced by accumulated depreciation and cumulative impairment is taken as cost on transition date.

Own manufactured PPE is capitalised at cost including an appropriate share of overheads. Administrative and other general overhead expenses that are specifically attributable to construction or acquisition of PPE or bringing the PPE to working condition are allocated and capitalised as a part of the cost of the PPE.

An item of property, plant and equipment and any significant part initially recognised is derecognised upon disposal or when no future economic benefits are expected from its use or disposal. Any gain or loss arising on derecognition of the asset (calculated as the difference between the net disposal proceeds and the carrying amount of the asset) is included in the income statement when the asset is derecognised.

The residual values, useful lives and methods of depreciation of property, plant and equipment are reviewed at each financial year end and adjusted prospectively, if appropriate.

PPE not ready for the intended use on the date of the Balance Sheet are disclosed as "capital work-in-progress". (Also refer to policies on leases, borrowing costs, impairment of assets and foreign currency transactions infra).

Depreciation is recognised using straight line method so as to write off the cost of the assets (other than freehold land and properties under construction) less their residual values over their useful lives specified in Schedule II to the Companies Act, 2013, or in the case of assets where the useful life was determined by technical evaluation, over the useful life so determined. Depreciation method is reviewed at each financial year end to reflect the expected pattern of consumption of the future economic benefits embodied in the asset. The estimated useful life and residual values are also reviewed at each financial year end and the effect of any change in the estimates of useful life/residual value is accounted on prospective basis.

Where cost of a part of the asset ("asset component") is significant to total cost of the asset and useful life of that part is different from the useful life of the remaining asset, useful life of that significant part is determined separately and such asset component is depreciated over its separate useful life.

Depreciation on additions to/deductions from, owned assets is calculated pro rata to the period of use.

Depreciation charge for impaired assets is adjusted in future periods in such a manner that the revised carrying amount of the asset is allocated over its remaining useful life.

Assets acquired under finance leases are depreciated on a straight line basis over the lease term. Where there is reasonable certainty that the company shall obtain ownership of the assets at the end of the lease term, such assets are depreciated based on the useful life prescribed under Schedule II to the Companies Act, 2013 or based on the useful life adopted by the company for similar assets.

Depreciation on PPE is calculated on a straight-line basis using the rates arrived at based on the useful lives estimated by the management. The identified components are depreciated separately over their useful lives; the remaining components are depreciated over the life of the principal asset. The Company has used the following rates to provide depreciation on its PPE.



	Estimated useful lives (in years)
Building	
Leased improvements/Façade	30
Plant & Machinery	15

(i) Impairment of fixed assets

As at the end of each accounting year, the company reviews the carrying amounts of its PPE, investment property, intangible assets and investments in subsidiary, associate and joint venture companies to determine whether there is any indication that those assets have suffered an impairment loss. If such indication exists, the said assets are tested for impairment so as to determine the impairment loss, if any. Goodwill and the intangible assets with indefinite life are tested for impairment each year.

Impairment loss is recognised when the carrying amount of an asset exceeds its recoverable amount. Recoverable amount is determined:

(i) in the case of an individual asset, at the higher of the net selling price and the value in use; and

(ii) in the case of a cash generating unit (a Company of assets that generates identified, independent cash flows), at the higher of the cash generating unit's net selling price and the value in use.

(The amount of value in use is determined as the present value of estimated future cash flows from the continuing use of an asset and from its disposal at the end of its useful life. For this purpose, the discount rate (pre-tax) is determined based on the weighted average cost of capital of the company suitably adjusted for risks specified to the estimated cash flows of the asset).

For this purpose, a cash generating unit is ascertained as the smallest identifiable company of assets that generates cash inflows that are largely independent of the cash inflows from other assets or company of assets.

If recoverable amount of an asset (or cash generating unit) is estimated to be less than its carrying amount, such deficit is recognised immediately in the Statement of Profit and Loss as impairment loss and the carrying amount of the asset (or cash generating unit) is reduced to its recoverable amount.

When an impairment loss subsequently reverses, the carrying amount of the asset (or cash generating unit) is increased to the revised estimate of its recoverable amount, but so that the increased carrying amount does not exceed the carrying amount that would have been determined had no impairment loss is recognised for the asset (or cash generating unit) in prior years. A reversal of an impairment loss is recognised immediately in the Statement of Profit and Loss.

(j) Financial instruments

A financial instrument is any contract that gives rise to a financial asset of one entity and a financial liability or equity instrument of another entity.

Financial assets

Initial recognition and measurement

All financial assets are recognised initially at fair value plus, in the case of financial assets not recorded at fair value through profit or loss, transaction costs that are attributable to the acquisition of the financial asset. Purchases or sales of financial assets that require delivery of assets within a time frame established by regulation or convention in the market place (regular way trades) are recognised on the trade date, i.e., the date that the Company commits to purchase or sell the asset.

Subsequent measurement

For purposes of subsequent measurement, financial assets are classified in four categories -

- 1 Debt instruments at amortised cost
- 2 Debt instruments at fair value through other comprehensive income (FVTOCI)
- 3 Debt instruments, derivatives and equity instruments at fair value through profit or loss (FVTPL)
- 4 Equity instruments measured at fair value through other comprehensive income (FVTOCI)

The Company does not have any financial assets falling under category 1 to 3 above.

Debt instruments at amortised cost

A 'debt instrument' is measured at the amortised cost if both the following conditions are met:

- a) The asset is held within a business model whose objective is to hold assets for collecting contractual cash flows, and
- b) Contractual terms of the asset give rise on specified dates to cash flows that are solely payments of principal and interest (SPPI) on the principal amount outstanding.

This category is the most relevant to the Company. After initial measurement, such financial assets are subsequently measured at amortised cost using the effective interest rate (EIR) method. Amortised cost is calculated by taking into account any discount or premium on acquisition and fees or costs that are an integral part of the EIR. The EIR amortisation is included in finance income in the profit or loss. The losses arising from impairment are recognised in the profit or loss. This category generally applies to trade and other receivables.

Debt instrument at FVTPL

FVTPL is a residual category for debt instruments. Any debt instrument, which does not meet the criteria for categorization as at amortised cost or as FVTOCI, is classified as at FVTPL. In addition, the Company may elect to designate a debt instrument, which otherwise meets amortised cost or FVTOCI criteria, as at FVTPL. However, such election is allowed only if doing so reduces or eliminates a measurement or recognition inconsistency (referred to as 'accounting mismatch'). The Company has not designated any debt instrument as at FVTPL. Debt instruments included within the FVTPL category are measured at fair value with all changes recognised in



AEGEAN PROPERTIES LIMITED CIN:U45200MH1995PLC084766

NOTES TO FINANCIAL STATEMENTS FOR THE YEAR ENDED MARCH 31, 2023

Equity investments

All equity investments in scope of Ind AS 109 are measured at fair value. Equity instruments which are held for trading classified as at FVTPL and are measured at fair value with all changes recognised in the profit or loss. For all other equity instruments, the Company may make an irrevocable election to present in other comprehensive income subsequent changes in the fair value. The Company makes such election on an instrument- by-instrument basis. The classification is made on initial recognition and is irrevocable.

If the Company decides to classify an equity instrument as FVTOCI, then all fair value changes on the instrument, excluding dividends, are recognised in the OCI. There is no recycling of the amounts from OCI to P&L, even on sale of investment. However, the Company may transfer the cumulative gain or loss within equity.

Derecognition

A financial asset (or, where applicable, a part of a financial asset or part of a Company of similar financial assets) is primarily derecognised (i.e. removed from the Company's balance sheet) when:

1) The rights to receive cash flows from the asset have expired, or

2) The Company has transferred its rights to receive cash flows from the asset or has assumed an obligation to

pay the received cash flows in full without material delay to a third party under a 'pass through' arrangement;

and either

- (a) The Company has transferred substantially all the risks and rewards of the asset, or
- (b) The Company has neither transferred nor retained substantially all the risks and rewards of the asset, but has transferred control of the asset.

When the Company has transferred its rights to receive cash flows from an asset or has entered into a pass-through arrangement, it evaluates if and to what extent it has retained the risks and rewards of ownership. When it has neither transferred nor retained substantially all of the risks and rewards of the asset, nor transferred control of the asset, the Company continues to recognise the transferred asset to the extent of the Company's continuing involvement. In that case, the Company also recognises an associated liability. The transferred asset and the associated liability are measured on a basis that reflects the rights and obligations that the Company has retained.

Continuing involvement that takes the form of a guarantee over the transferred asset is measured at the lower of the original carrying amount of the asset and the maximum amount of consideration that the Company could be required to repay.

Impairment of financial assets

In accordance with Ind AS 109, the Company applies expected credit loss (ECL) model for measurement and recognition of impairment loss.

ECL is the difference between all contractual cash flows that are due to the Company in accordance with the contract and all the cash flows that the entity expects to receive (i.e., all cash shortfalls), discounted at the original EIR. ECL impairment loss allowance (or reversal) recognised during the period is recognised as income/ expense in the statement of profit and loss.

For assessing increase in credit risk and impairment loss, the Company combines financial instruments on the basis of shared credit risk characteristics with the objective of facilitating an analysis that is designed to enable significant increases in credit risk to be identified on a timely basis.

Financial liabilities

Initial recognition and measurement

Financial liabilities are classified, at initial recognition, as financial liabilities at fair value through profit or loss, loans and borrowings, payables, or as derivatives designated as hedging instruments in an effective hedge, as appropriate.

All financial liabilities are recognised initially at fair value and, in the case of loans and borrowings and payables, net of directly attributable transaction costs.

The Company's financial liabilities include trade and other payables, loans and borrowings including bank overdrafts and financial **Subsequent measurement**

The measurement of financial liabilities depends on their classification, as described below:

Loans and borrowings

This is the category most relevant to the Company. After initial recognition, interest-bearing loans and borrowings are subsequently measured at amortised cost using the EIR method. Gains and losses are recognised in profit or loss when the liabilities are derecognised as well as through the EIR amortisation process.

Amortised cost is calculated by taking into account any discount or premium on acquisition and fees or costs that are an integral part of the EIR. The EIR amortisation is included as finance costs in the statement of profit and loss.

This category generally applies to borrowings.

Financial guarantee contracts

Financial guarantee contracts issued by the Company are those contracts that require a payment to be made to reimburse the holder for a loss it incurs because the specified debtor fails to make a payment when due in accordance with the terms of a debt instrument. Financial guarantee contracts are recognised initially as a liability at fair value, adjusted for transaction costs that are directly attributable to the issuance of the guarantee. Subsequently, the liability is measured at the higher of the amount of loss allowance determined as per impairment requirements of Ind AS 109 and the amount recognised less cumulative amortisation.



AEGEAN PROPERTIES LIMITED CIN:U45200MH1995PLC084766

NOTES TO FINANCIAL STATEMENTS FOR THE YEAR ENDED MARCH 31, 2023

The Company does not have any financial liabilities at fair value through profit or loss.

Derecognition

A financial liability is derecognised when the obligation under the liability is discharged or cancelled or expires. When an existing financial liability is replaced by another from the same lender on substantially different terms, or the terms of an existing liability are substantially modified, such an exchange or modification is treated as the derecognition of the original liability and the recognition of a new liability. The difference in the respective carrying amounts is recognised in the statement of profit or loss.

Embedded derivatives

An embedded derivative is a component of a hybrid (combined) instrument that also includes a non-derivative host contract – with the effect that some of the cash flows of the combined instrument vary in a way similar to a stand-alone derivative. An embedded derivative causes some or all of the cash flows Notes to the financial statements that otherwise would be required by the contract to be modified according to a specified interest rate, financial instrument price, or other variable, provided in the case of a non-financial variable that the variable is not specific to a party to the contract. Reassessment only occurs if there is either a change in the terms of the contract that significantly modifies the cash flows that would otherwise be required or a reclassification of a financial asset out of the fair value through profit or loss.

If the hybrid contract contains a host that is a financial asset within the scope of Ind AS 109, the Company does not separate embedded derivatives. Rather, it applies the classification requirements contained in Ind AS 109 to the entire hybrid contract.

Derivatives embedded in all other host contracts are accounted for as separate derivatives and recorded at fair value if their economic characteristics and risks are not closely related to those of the host contracts and the host contracts are not held for trading or designated at fair value through profit or loss. These embedded derivatives are measured at fair value with changes in fair value recognised in profit or loss, unless designated as effective hedging instruments.

Reclassification of financial assets

The Company determines classification of financial assets and liabilities on initial recognition. After initial recognition, no reclassification is made for financial assets which are equity instruments and financial liabilities. For financial assets which are debt instruments, a reclassification is made only if there is a change in the business model for managing those assets. Changes to the business model are expected to be infrequent. The Company's senior management determines change in the business model as a result of external or internal changes which are significant to the Company's operations. Such changes are evident to external parties.

A change in the business model occurs when the Company either begins or ceases to perform an activity that is significant to its operations. If the Company reclassifies financial assets, it applies the reclassification prospectively from the reclassification date which is the first day of the immediately next reporting period following the change in business model. The Company does not restate any previously recognised gains, losses (including impairment gains or losses) or interest.

Offsetting of financial instruments

Financial assets and financial liabilities are offset and the net amount is reported in the balance sheet if there is a currently enforceable legal right to offset the recognised amounts and there is an intention to settle on a net basis, to realise the assets and settle the liabilities simultaneously.

(k) Leases

The determination of whether an agreement is, or contains, a lease is based on the substance of the agreement at the date of inception. The arrangement is, or contains, a lease if fulfillment of the arrangement is dependent on the use of a specific asset or assets and the arrangement conveys a right to use the asset or assets, even if that right is not explicitly specified in an arrangement. For arrangements entered into prior to April 1, 2016, the Company has determined whether the arrangement contain lease on the basis of facts and circumstances existing on the date of transition.

i) Finance leases:

- A) Leases where the company has substantially all the risks and rewards of ownership of the related assets are classified as finance leases. Assets under finance leases are capitalised at the commencement of the lease at the lower of the fair value or the present value of minimum lease payments and a liability is created for an equivalent amount. Each lease rental paid is allocated between the liability and the interest cost, so as to obtain a constant periodic rate of interest on the outstanding liability for each period.
- B) Assets given under a finance lease are recognised as a receivable at an amount equal to the net investment in the lease. Lease income is recognised over the period of the lease so as to yield a constant rate of return on the net investment in the lease.

ii) Operating leases:

The leases which are not classified as finance lease are operating leases.

- A) Lease rentals on assets under operating lease are charged to the Statement of Profit and Loss on a straight line basis over the term of the relevant lease.
- B) Assets leased out under operating leases are continued to be shown under the respective class of assets. Rental income is recognised on a straight line basis over the term of the relevant lease.

(I) Taxes on income

Tax on income for the current period is determined on the basis of taxable income and tax credits computed in accordance with the provisions of the Income tax Act 1961, and based on the expected outcome of assessments/appeals.

Deferred tax is recognised on temporary differences between the carrying amounts of assets and liabilities in the company's financial statements and the corresponding tax bases used in computation of taxable profit and quantified using the tax rates and laws enacted or substantively enacted as on the Balance Sheet date.

Deferred tax liabilities are generally recognised for all taxable temporary differences including the temporary differences associated with investments in subsidiaries and associates, and interests in joint ventures, except where the company is able to control the reversal of the temporary difference and it is probable that the temporary difference will not reverse in the foreseeable future.



Deferred tax assets are generally recognised for all taxable temporary differences to the extent that is probable that taxable profits will be available against which those deductible temporary differences can be utilised. The carrying amount of deferred tax assets is reviewed at the end of each reporting period and reduced to the extent that it is no longer probable that sufficient taxable profits will be available to allow all or part of the asset to be recovered.

Deferred tax assets relating to unabsorbed depreciation/business losses/losses under the head "capital gains" are recognised and carried forward to the extent of available taxable temporary differences or where there is convincing other evidence that sufficient future taxable income will be available against which such deferred tax assets can be realised.

The measurement of deferred tax liabilities and assets reflects the tax consequences that would follow from the manner in which the company expects, at the end of reporting period, to recover or settle the carrying amount of its assets and liabilities. Transaction or event which is recognised outside profit or loss, either in other comprehensive income or in equity, is recorded along with

Minimum alternate tax (MAT) paid in a year is charged to the statement of profit and loss as current tax. The Company recognizes MAT credit available as an asset only to the extent that there is convincing evidence that the Company will pay normal income tax during the specified period, i.e., the period for which MAT credit is allowed to be carried forward. In the year in which the Company recognizes MAT credit as an asset in accordance with the Guidance Note on Accounting for Credit Available in respect of Minimum Alternative Tax under the Income-tax Act, 1961, the said asset is created by way of credit to the statement of profit and loss and shown as "MAT Credit Entitlement." The Company reviews the "MAT credit entitlement" asset at each reporting date and writes down the asset to the extent the Company does not have convincing evidence that it will pay normal tax during the specified period.

(m) Provisions

A provision is recognized when the Company has a present obligation as a result of past events, it is probable that an outflow of resources will be required to settle the obligation, and a reliable estimate can be made of the amount of the obligation. Provisions are not discounted to their present value and are determined based on best estimate required to settle the obligation at the balance sheet date. These are reviewed at each balance sheet date and adjusted to reflect the current best estimates.

(n) Contingent liabilities

Contingent assets are not recognized in the financial statements of the Company. A contingent liability is a possible obligation that arises from past events whose existence will be confirmed by the occurrence or non-occurrence of one or more uncertain future events beyond the control of the Company or a present obligation that is not recognized because it is not probable that an outflow of resources will be required to settle the obligation. A contingent liability also arises in extremely rare case where there is a liability that cannot be recognized because it cannot be measured reliably. The Company does not recognize a contingent liability but discloses its existence in the financial statements.

(o) Earnings per share

Basic earnings per share are calculated by dividing the net profit or loss for the period attributable to equity shareholders by the weighted average number of equity shares outstanding during the period. The Company does not have any potential equity shares, and accordingly, the basic earnings per share and diluted earnings per share are the same.

(p) Cash and bank balances

Cash and bank balances also include fixed deposits, margin money deposits, earmarked balances with banks and other bank balances which have restrictions on repatriation. Short term and liquid investments being subject to more than insignificant risk of change-in value, are not included as part of cash and cash equivalents.



AEGEAN PROPERTIES LIMITED

CIN:U45200MH1995PLC084766

NOTES TO FINANCIAL STATEMENTS FOR THE YEAR ENDED MARCH 31, 2023

(q) Borrowing costs

Borrowing costs include interest expense calculated using the effective interest method, finance charges in respect of assets acquired on finance lease and exchange differences arising on foreign currency borrowings to the extent they are regarded as an adjustment to interest costs.

Borrowing costs net of any investment income from the temporary investment of related borrowings, that are attributable to the acquisition, construction or production of a qualifying asset are capitalised/inventoried as part of cost of such asset till such time the asset is ready for its intended use or sale. A qualifying asset is an asset that necessarily requires a substantial period of time to get ready for its intended use or sale. All other borrowing costs are recognised in profit or loss in the period in which they are incurred.

(r) Cash Dividends to equity holders in the company

The Company recognises a liability to make cash or non-cash distributions to equity holders of the parent when the distribution is authorised and the distribution is no longer at the discretion of the Company. As per the corporate laws in India, a distribution is authorised when it is approved by the shareholders. A corresponding amount is recognised directly in equity.

(s) Presentation of financial statements

The Balance Sheet and the Statement of Profit and Loss are prepared and presented in the format prescribed in the Schedule III to the Companies Act, 2013 ("the Act"). The statement of cash flows has been prepared and presented as per the requirements of Ind AS 7 "Statement of Cash flows". The disclosure requirements with respect to items in the Balance Sheet and Statement of Profit and Loss, as prescribed in the Schedule III to the Act, are presented by way of notes forming part of the financial statements along with the other notes required to be disclosed under the notified Accounting Standards and the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. Amounts in the financial statements are presented in Indian Rupees in lakhs rounded off to two decimal places as permitted by Schedule III to the Companies Act, 2013. Per share data are presented in Indian Rupees to two decimals places.

(t) New Accounting Pronouncement

Ministry of Corporate Affairs ("MCA") notifies new standards or amendments to the existing standards under Companies (Indian Accounting Standards) Rules as issued from time to time. On March 31, 2023, MCA amended the Companies (Indian Accounting Standards) Amendment Rules, 2023, as below:

Ind AS 1 - Presentation of Financial Statements - This amendment requires the entities to disclose their material accounting policies rather than their significant accounting policies. The effective date for adoption of this amendment is annual periods beginning on or after April 1, 2023. The Company has evaluated the amendment and the impact of the amendment is insignificant in the financial statements.

Ind AS 8 - Accounting Policies, Changes in Accounting Estimates and Errors - This amendment has introduced a definition of 'accounting estimates' and included amendments to Ind AS 8 to help entities distinguish changes in accounting policies from changes in accounting estimates. The effective date for adoption of this amendment is annual periods beginning on or after April 1, 2023. The Company has evaluated the amendment and there is no impact on its financial statements.

Ind AS 12 - Income Taxes - This amendment has narrowed the scope of the initial recognition exemption so that it does not apply to transactions that give rise to equal and offsetting temporary differences. The effective date for adoption of this amendment is annual periods beginning on or after April 1, 2023. The Company has evaluated the amendment and there is no impact on its financial statement.



Note 3. - Investment in Property

Note

Buildings	Amount
	(Rs. in '000)
Gross Block	
As at April 1, 2021	6,651.40
Additions	100
Disposal	
As at Mar 31, 2022	6,651.40
As at April 1, 2022	6,651.40
Additions	100
Disposal	140
As at Mar 31, 2023	6,651.40
Accumulated Depreciation	
As at April 1, 2021	1,642.54
Charge for the period	108.42
Disposal	
At March 31, 2022	1,750.96
As at April 1, 2022	1,750.96
Charge for the period	108.42
Disposal	
At March 31, 2023	1,859.38
Net Block	
At March 31, 2022	4,900.44
At March 31, 2023	4,792.02
me Tax Assets (net)	As at March 31, 2023 (Rs. in '000)
vance income-tax (net of provision for taxation)	



As at March 31, 2022 (Rs. in '000)

38.44

38.44

	As at March 31, 2023	As at March 31, 2022
e 5 - Trade receivables (unsecured)	(Rs. in '000)	(Rs. in '000)
Unsecured, considered good unless stated otherwise		
Unsecured considered good	11,124.08	9,963.33
	11,124.08	9,963.33

Ageing of trade receivables :as at March 31, 2023

Note

	Outstanding for the following period from due date					of payments		
Particulars	Unbilled	Not Due	Less than 6 months	6 months- 1 year	1-2 years	2-3 years	More than 3 years	Total
(i) Undisputed Trade receivables – considered good								
	<u> </u>	162.00	1,767.66	815.03	1,205.31	1,474.88	5,699.19	11,124.08
 (ii) Undisputed Trade Receivables – which have significant ncrease in credit risk 	2	÷	243	-		-	a	540
(iii) Undisputed Trade Receivables – credit impaired		2		2	2		-	343
(iv) Disputed Trade Receivables – considered good	-			-	2			
(v) Disputed Trade Receivables – which have significant ncrease in credit risk	-	÷			-	÷	-	
(vi) Disputed Trade Receivables – credit Impaired								
Total		162.00	1,767.66	815.03	1,205.31	#####	5,699.19	11,124.08

Ageing of trade receivables : as at March 31, 2022

	ĺ		Outstanding for the following period from due date of payments						
Partículars	Unbilled	Not Due	Less than 6 months	6 months- 1 year	1-2 years	2-3 years	More than 3 years	Total	
(i) Undisputed Trade receivables – considered good		162.00	1,294.16	612.61	1,474.88	2,136.30	4,283.38	9,963.33	
 (ii) Undisputed Trade Receivables – which have significant increase in credit risk 				-			5	-	
iii) Undisputed Trade Receivables – credit impaired		-		-	×.	::+:	-	-	
(iv) Disputed Trade Receivables – considered good				+	-		-	-	
(iv) Disputed Trade Receivables – considered good	(a)					(A)	-		
(v) Disputed Trade Receivables ~ which have significant increase in credit risk	-	(a)	(#C	-		7.40		_	
(vi) Disputed Trade Receivables – credit Impaired			(#)			-		_	
Total		162.00	1,294.16	612.61	1,474.88	2,136.30	4,283.38	9,963.33	

	As at March 31, (Rs. in '000)	As at March 31, 2022 (Rs. in '000)
Note 6 Cash and Cash Equivalents	((
Balances with banks:		
With scheduled banks on:		
Current account	158.99	25.85
Cash on hand		0.05
	158.99	25.89
Note 7 - Deferred tax Assets (net):		
Deferred tax assets		
Fixed assets: Impact of difference between tax depreciation and depreciation/ amortization charged for the financial	62.58	64.76
Gross deferred tax liability	62.58	64.76
Note 8 - Loans and advances		
Deferred Security Deposits	a	10.00
Prepaid expenses	28.41	43.33
Balances with statutory / government authorities		
	28.41	53.33



		As at March 31, 2023	As at March 31, 2022
		(Rs. in '000)	(Rs. in '000)
Note 9 - Share capital:			
Authorised Shares:			
30,000 (March 31, 2022 - 30,000) Equity shares of Rs. 100/- each		3,000.00	3,000.00
		3,000.00	3,000.00
Issued, Subscribed and fully paid up shares:			
30,000 (March 31, 2022 - 30,000) Equity shares of Rs. 100/- each fully paid-up		3,000.00	3,000.00
		3,000.00	3,000.00
a) Details of shareholders holding more than 5% shares in the Company			
Name of the shareholder	As at Ma	rch 31, 2023	As at March 31, 2022
Equity shares of Rs. 100/- each fully paid,	No of Shares	% holding in the class	No of Shares % holding in
Fermenta Biotech Limited along with its nominees	30,000	100%	30,000 100%
b) Shares held by holding company			
Out of equity shares issued by the Company, shares held by its holding Company are as below.			
	As at Ma	rch 31, 2023	As at March 31, 2022
Fermenta Biotech Limited			
30,000 (March 31, 2022 - 30,000) Equity shares of `. 100/- each		3,000.00	3,000.00

c) Reconciliation of the number of shares and amount outstanding at the beginning and at the end of the year:

Equity shares with voting rights	Opening balance	Issued during the year	Closing balance
As at 31.03.2023			
Number of shares	30,000	190	30,000
Amount (Rs. '000)	3,000.00	592	3,000.00
As at 31.03.2022			
Number of shares	30,000	-	30,000
- Amount (Rs. '000)	3,000.00	-	3,000.00

d) Share Held by Promoters at the end of the year

Name of promoters	As at 31 March 2023				As at 31 March 2022		
	No. of Share	% of Total Share	% Change during the year	No. of Share	% of Total Share	% Change during the year	
Fermenta Biotech Limited along with its nominees	30,000	100%	125	30,000	100%		

Note 10 - Other equity

Reserves and surplus Retained Earnings

Balance at the beginning of the reporting period - 1st April 2021	11,108.34
Profit for the year	894.98
Balance at the end of the reporting period 31st March 2022	12,003.32
Balance at the beginning of the reporting period - 1st April 2022	12,003.32
Profit for the period	1,069.68
Balance at the end of the reporting period 31st March 2023	13,072.99



As at March 31, 2023	As at March 31, 2022
(Rs. in '000)	(Rs. in '000)
Ē.	~
15.00	241.05
15.00	241.05
	March 31, 2023 (Rs. in '000) - 15.00

Ageing of trade	pavables:	as at March 3	1, 2023

As at March 31, 2023

Particulars		Outstanding for the following period from due date of payments				
	Not due -	Less than 1 year	1-2 years	2-3 years	More than 3	Total
Dues of MSME	-		64 U.	Ê	i i i	3
Dues of creditors other than MSME	15.00		-		-	15.00
Disputed dues of MSME		2 8 2	-	÷	-	-
Disputed dues of creditors other than MSME		- 19 5 1	-	-		
Total	15.00	40	-	•		15.00

Particulars	Not due	Outstanding for the following period from due date of payments				
Faillulais	Not due	Less than 1 year	1-2 years	2-3 years	More than 3	Total
Dues of MSME	*	*	-	/1	-	3
Dues of creditors other than MSME		241.05	2	(÷	-	241.05
Disputed dues of MSME		5	5	()	-	
Disputed dues of creditors other than MSME		-	-	190		
Total	5 2 2	241.05	:#:		510	241.05

	As at March 31, 2023	As at March 31, 2022
Note 11 - Other current liabilities	(Rs. in '000)	(Rs. in '000)
Statutory dues	25.83	26.37
	25.83	26.37
Note 12 - Income Tax liabilities (net)		
Income Tax liabilities (net)	52.25	1. E
	52.25	



	Year Ended March 31, 2023	Year Ended March 31, 2022
Note 17 Devenue from exampliant	(Rs. in '000)	(Rs. in '000)
Note 13 - Revenue from operations Rent Income	1,800.00	1 800 00
Kent Income	1,800.00	1,800.00 1,800.00
		1,800.00
	Year Ended March 31, 2023	Year Ended March 31, 2022
Note 14 - Depreciation and amortization expense	(Rs. in '000)	(Rs. in '000)
Depreciation of Property, Plant and Equipment	108.42	108.42
	108.42	108.42
	Year Ended March 31, 2023	Year Ended March 31, 202
	(Rs. in '000)	(Rs. in '000)
Note 15 - Other expenses:	(= ==	
Rates and taxes Rent	15.39	7.53
	30.00	30.00
Insurance Charges Legal and professional charges	184.92 12.70	264.36
Payment to auditors (refer note below)	15.00	174.00
Interest on Income-tax	15.00	0.25
Balance Written off	10.00	0.22
Miscellaneous expenses	0.55	9.14
	268.56	495.27
Notes:		
(i) Payments to auditors comprises (exclusive of GST)		
(a) To statutory auditors	15.00	10.00
-statutory audit	15.00	10.00
	Year Ended March 31, 2023	Year Ended March 31, 2022
	(Rs. in '000)	(Rs. in '000)
Note 16 - Earnings per share (EPS):		
The following table sets forth the computation of basic and diluted earnings per share :		
Basic/Diluted		
Net profit for the year attributable to equity shareholders	1,069.68	894.98
Weighted average number of equity shares of Rs 100 each used for calculation of basic earnings per share (Rs. '000)	30.00	30.00
Earnings per share (Basic) {Rs. 100 per Share}	35.66	29.83



9/5/23

Registered number 03308303

FERMENTA BIOTECH (U K) LTD

Report and Management Accounts

31 March 2023

FERMENTA BIOTECH (UK) LTD Report and accounts Contents

Page

Company information	1
Directors' report	2-3
Profit and loss account	4
Balance sheet	5
Notes to the accounts	6

9/5/23

FERMENTA BIOTECH (UK) LTD Company Information

Directors

Mr Satish Varma Mr Srikant Sharma

Secretary

Mr Srikant Sharma

Auditors

Lall Ondhia Ltd Charter House 8-10 Station Road Manor Park London E12 5BT

Bankers

National Westminster Bank Plc 5 Market Place Kingston Upon Thames Surrey KT1 1JX

Registered office

Charter House 8-10 Station Road Manor Park London E12 5BT

Registered number 03308303

00000000

FERMENTA BIOTECH (UK) LTD Registered number: 03308303 Directors' Report

The directors present their report and accounts for the year ended 31 March 2023.

Principal activities

The company's principal activity during the year was to pursue the research and development programme on Phenyramidol.

However, having undertaken a critical review of the development on Phenyramidol project and an independent advice from a Patent and Trade Mark Attorney, it was sadly concluded that to persue further research and development on this project would be uncommercial and hence the board has decided to stop the project and write off all the costs to profit and loss account incurred todate.

Directors

The following persons served as directors during the year:

Mr Satish Varma Mr Srikant Sharma

Directors' responsibilities

The directors are responsible for preparing the report and accounts in accordance with applicable law and regulations.

Company law requires the directors to prepare accounts for each financial year. Under that law the directors have elected to prepare the accounts in accordance with United Kingdom Generally Accepted Accounting Practice (United Kingdom Accounting Standards and applicable law). Under company law the directors must not approve the accounts unless they are satisfied that they give a true and fair view of the state of affairs of the company and of the profit or loss of the company for that period. In preparing these accounts, the directors are required to:

- select suitable accounting policies and then apply them consistently;
- make judgements and estimates that are reasonable and prudent;
- prepare the accounts on the going concern basis unless it is inappropriate to presume that the company will continue in business.

The directors are responsible for keeping adequate accounting records that are sufficient to show and explain the company's transactions and disclose with reasonable accuracy at any time the financial position of the company and enable them to ensure that the accounts comply with the Companies Act 2006. They are also responsible for safeguarding the assets of the company and hence for taking reasonable steps for the prevention and detection of fraud and other irregularities.

Disclosure of information to auditors

Each person who was a director at the time this report was approved confirms that:

- so far as he is aware, there is no relevant audit information of which the company's auditor is unaware; and
- he has taken all the steps that he ought to have taken as a director in order to make himself aware of any relevant audit information and to establish that the company's auditor is aware of that information.

Small company provisions

This report has been prepared in accordance with the provisions in Part 15 of the Companies Act 2006 applicable to companies subject to the small companies regime.

FERMENTA BIOTECH (U K) LTDRegistered number:03308303Directors' Report03308303

This report was approved by the board on

/2023 and signed on its behalf.

Mr S Sharma Director

FERMENTA BIOTECH (UK) LTD Independent auditor's report to the members of FERMENTA BIOTECH (UK) LTD

Opinion

We have audited the accounts of FERMENTA BIOTECH (UK) LTD for the year ended 31 March 2023 which comprise the Profit and Loss Account, the Balance Sheet, the Statement of Changes in Equity and notes to the accounts, including a summary of significant accounting policies. The financial reporting framework that has been applied in their preparation is applicable law and United Kingdom Accounting Standards, including FRS 102 'The Financial Reporting Standard applicable in the UK and the Republic of Ireland' (United Kingdom Generally Accepted Accounting Practice).

This report is made solely to the company's members, as a body, in accordance with Chapter 3 of Part 16 of the Companies Act 2006. Our audit work has been undertaken so that we might state to the company's members those matters we are required to state to them in an auditor's report and for no other purpose. To the fullest extent permitted by law, we do not accept or assume responsibility to anyone other than the company and the company's members as a body, for our audit work, for this report, or for the opinions we have formed.

In our opinion the accounts:

- give a true and fair view of the state of the company's affairs as at 31 March 2023 and of its loss for the year then ended;
- have been properly prepared in accordance with United Kingdom Generally Accepted Accounting Practice;
- have been prepared in accordance with the requirements of the Companies Act 2006.

Basis of opinion

We conducted our audit in accordance with International Standards on Auditing (UK) (ISAs (UK)) and applicable law. Our responsibilities under those standards are further described in the Auditor's responsibilities for the audit of the accounts section of our report. We are independent of the company in accordance with the ethical requirements that are relevant to our audit of the accounts in the UK, including the FRC's Ethical Standard, and the provisions available for small entities, in the circumstances set out below, and we have fulfilled our other ethical responsibilities in accordance with these requirements. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion.

In accordance with the exemption provided by FRC's Ethical Standard - Provisions Available for Audits of Small Entities, we have prepared and submitted the company's returns to the tax authorities and assisted with the preparation of the accounts.

Conclusions relating to going concern

We have nothing to report in respect of the following matters in relation to which the ISAs (UK) require us to report to you where:

- the directors' use of the going concern basis of accounting in the preparation of the accounts is not appropriate; or
- the directors have not disclosed in the accounts any identified material uncertainties that may cast significant doubt about the company's ability to continue to adopt the going concern basis of accounting for a period of at least twelve months from the date when the accounts are authorised for issue.

Other information

The other information comprises the information included in the report and accounts, other than the accounts and our auditor's report thereon. The directors are responsible for the other information. Our opinion on the accounts does not cover the other information and, except to the extent otherwise explicitly stated in our report, we do not express any form of assurance conclusion thereon. In connection with our audit of the accounts, our responsibility is to read the other information and, in doing so, consider whether the other information is materially inconsistent with the accounts or our knowledge obtained in the audit or otherwise appears to be materially misstated. If we identify such material inconsistencies or apparent material misstatements, we are required to determine whether there is a material misstatement of the other information. If, based on the work we have performed, we conclude that there is a material misstatement of this other information, we are required to report that fact.

We have nothing to report in this regard.

Opinions on other matters prescribed by the Companies Act 2006

In our opinion, based on the work undertaken in the course of the audit:

- the information given in the directors' report for the financial year for which the accounts are prepared is consistent with the accounts; and
- the directors' report has been prepared in accordance with applicable legal requirements.

FERMENTA BIOTECH (UK) LTD Independent auditor's report to the members of FERMENTA BIOTECH (UK) LTD

Matters on which we are required to report by exception

In the light of the knowledge and understanding of the company and its environment obtained in the course of the audit, we have not identified material misstatements in the directors' report.

We have nothing to report in respect of the following matters in relation to which the Companies Act 2006 requires us to report to you if, in our opinion:

- adequate accounting records have not been kept, or returns adequate for our audit have not been received from branches not visited by us; or
- the accounts are not in agreement with the accounting records and returns; or
- certain disclosures of directors' remuneration specified by law are not made; or
- we have not received all the information and explanations we require for our audit; or
- the directors were not entitled to prepare the accounts in accordance with the small companies regime and take advantage of the small companies' exemptions in preparing the directors' report and from the requirement to prepare a strategic report.

Responsibilities of directors

As explained more fully in the directors' responsibilities statement, the directors are responsible for the preparation of the accounts and for being satisfied that they give a true and fair view, and for such internal control as the directors determine is necessary to enable the preparation of accounts that are free from material misstatement, whether due to fraud or error.

In preparing the accounts, the directors are responsible for assessing the company's ability to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless the directors either intend to liquidate the company or to cease operations, or have no realistic alternative but to do so.

Auditor's responsibilities for the audit of the accounts

Our objectives are to obtain reasonable assurance about whether the accounts as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with ISAs (UK) will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these accounts.

A further description of our responsibilities for the audit of the accounts is located on the Financial Reporting Council's website at www.frc.org.uk/auditorsresponsibilities. This description forms part of our auditor's report.

Harsh Kantilal Ondhia (Senior Statutory Auditor) for and on behalf of Lall Ondhia Ltd Accountants and Statutory Auditors /2023

Charter House 8-10 Station Road Manor Park London E12 5BT 9/5/23

í. **9/5/23**

FERMENTA BIOTECH (UK) LTD Profit and Loss Account for the year ended 31 March 2023

	2023 £	2022 £
Administrative expenses	(1,260)	(1,260)
Operating loss	(1,260)	(1,260)
Loss on ordinary activities before taxation	(1,260)	(1,260)
Tax on loss on ordinary activities	120	
Loss for the financial year	(1,260)	(1,260)



6

FERMENTA BIOTECH (UK) LTDRegistered number:03308303Balance Sheetas at 31 March 2023

	Notes		2023 £		2022 £
Current assets Debtors Cash at bank and in hand	4	227 40,064 40,291	-	227 40,124 40,351	_
Creditors: amounts falling du within one year	e 5	(6,280)		(5,080)	
Net current assets		d 	34,011		35,271
Net assets			34,011	-	35,271
Capital and reserves Called up share capital Profit and loss account			220,001 (185,990)		220,001 (184,730)
Shareholders' funds			34,011	-	35,271

The accounts have been prepared and delivered in accordance with the special provisions applicable to companies subject to the small companies regime. The profit and loss account has not been delivered to the Registrar of Companies.

Mr S Varma Director Approved by the board on

/2023

D)

FERMENTA BIOTECH (UK) LTD Notes to the Accounts for the year ended 31 March 2023

1 Accounting policies

Basis of preparation

The accounts have been prepared under the historical cost convention and in accordance with FRS 102, The Financial Reporting Standard applicable in the UK and Republic of Ireland (as applied to small entities by section 1A of the standard).

Turnover

Turnover is measured at the fair value of the consideration received or receivable, net of discounts and value added taxes. Turnover includes revenue earned from the sale of goods and from the rendering of services. Turnover from the sale of goods is recognised when the significant risks and rewards of ownership of the goods have transferred to the buyer. Turnover from the rendering of services is recognised by reference to the stage of completion of the contract. The stage of completion of a contract is measured by comparing the costs incurred for work performed to date to the total estimated contract costs.

Intangible fixed assets

Intangible fixed assets are measured at cost less accumulative amortisation and any accumulative impairment losses.

Investments

Investments in subsidiaries, associates and joint ventures are measured at cost less any accumulated impairment losses. Listed investments are measured at fair value. Unlisted investments are measured at fair value unless the value cannot be measured reliably, in which case they are measured at cost less any accumulated impairment losses. Changes in fair value are included in the profit and loss account.

Debtors

Short term debtors are measured at transaction price (which is usually the invoice price), less any impairment losses for bad and doubtful debts. Loans and other financial assets are initially recognised at transaction price including any transaction costs and subsequently measured at amortised cost determined using the effective interest method, less any impairment losses for bad and doubtful debts.

Creditors

Short term creditors are measured at transaction price (which is usually the invoice price). Loans and other financial liabilities are initially recognised at transaction price net of any transaction costs and subsequently measured at amortised cost determined using the effective interest method.

FERMENTA BIOTECH (UK) LTD Notes to the Accounts for the year ended 31 March 2023

Taxation

A current tax liability is recognised for the tax payable on the taxable profit of the current and past periods. A current tax asset is recognised in respect of a tax loss that can be carried back to recover tax paid in a previous period. Deferred tax is recognised in respect of all timing differences between the recognition of income and expenses in the financial statements and their inclusion in tax assessments. Unrelieved tax losses and other deferred tax assets are recognised only to the extent that it is probable that they will be recovered against the reversal of deferred tax liabilities or other future taxable profits. Deferred tax is measured using the tax rates and laws that have been enacted or substantively enacted by the reporting date and that are expected to apply to the reversal of the timing difference, except for revalued land and investment property where the tax rate that applies to the sale of the asset is used. Current and deferred tax assets and liabilities are not discounted.

Provisions

Provisions (ie liabilities of uncertain timing or amount) are recognised when there is an obligation at the reporting date as a result of a past event, it is probable that economic benefit will be transferred to settle the obligation and the amount of the obligation can be estimated reliably.

Pensions

Contributions to defined contribution plans are expensed in the period to which they relate.

2 Audit information

The audit report is unqualified.

Senior statutory auditor:	Harsh Kantilal Ondhia
Firm:	Lall Ondhia Ltd
Date of audit report:	/2023

3 Exceptional items

The directors have decided to write off Patent and Research and Development cost totalling £117,657 incurred to date based on negative expert opinion on the commercial viability and hence have ceased further activity on the project.

2023	2022
£	£
	117,657





L 🤣 9/5/23

FERMENTA BIOTECH (UK) LTD Notes to the Accounts for the year ended 31 March 2023

4	Debtors	2023 £	2022 £
	Other debtors	227	227
5	Creditors: amounts falling due within one year	2023 £	2022 £
	Other creditors	6,280	5,080

6 Controlling party

The holding company, Fermenta Biotech Ltd registered in India, controls the company by virtue of holding 100% of the issued shares capital.

7 Other information

FERMENTA BIOTECH (UK) LTD is a private company limited by shares and incorporated in England. Its registered office is: Charter House 8-10 Station Road Manor Park London E12 5BT



FERMENTA BIOTECH (UK) LTD Detailed profit and loss account for the year ended 31 March 2023

This schedule does not form part of the statutory accounts

	2023 £	2022 £
Administrative expenses	(1,260)	(1,260)
Operating loss	(1,260)	(1,260)
Loss before tax	(1,260)	(1,260)

ME

FERMENTA BIOTECH (U K) LTD Detailed profit and loss account

for the year ended 31 March 2023

This schedule does not form part of the statutory accounts

	2023	2022
	£	£
Administrative expenses		
General administrative expenses:		
Bank charges	60	60
0	60	60
Legal and professional costs:		
Accountancy fees	1,200	1,200
	1,200	1,200
	3	
	1,260	1,260

BIC Σ THAN

Consolidated Financial Information March 31, 2023 and March 31, 2022

TABLE OF CONTENTS

Consolidated Financial Information	3
Consolidated balance sheets	4
Consolidated statements of profit and loss	5
Consolidated statements of cash flows	6
Consolidated statements of changes in equity	7
Notes to Consolidated Financial Information	8

Fermenta Biotech USA LLC Consolidated Financial Information March 31, 2023 and March 31, 2022

Consolidated Financial Information

Consolidated Financial Information March 31, 2023 and March 31, 2022

Consolidated balance sheets

Consolidated balance sneets		AS UI		
(All amounts stated in United States Dollars, unles otherwise stated)	^s Notes	March 31, 2023	March 31, 2022	
Assets				
Non-current assets				
Goodwill	2	900,845	900,845	
Other intangible assets	3	318,503	437,942	
Deferred tax assets, net	19	-	139,682	
Total non-current assets	-	1,219,348	1,478,469	
Current assets				
Inventories, net	4	721,969	1,338,453	
Financial assets				
Trade receivables, net of allowances	5	243,433	654,036	
Cash and cash equivalents	6	184,433	217,811	
Other current assets	7	50,939	45,588	
Total current assets	-	1,200,774	2,255,888	
Total assets		2,420,122	3,734,357	
Equity and liabilities				
Equity				
Member's equity	8	1,600,000	1,600,000	
Accumulated deficit	8	(1,029,693)	(610,380)	
Equity attributable to equity holders of the parent	-	570,307	989,620	
Non-controlling interest		(370,259)	(90,064)	
Total equity	-	200,048	899,556	
Non-current liabilities				
Financial liabilities				
Borrowings	9	850,000	850,000	
Total non current liabilities		850,000	850,000	
Current liabilities				
Financial liabilities				
Trade payables	10	1,317,083	1,971,527	
Other financial liabilities	11	52,991	13,274	
Total current liabilities	-	1,370,074	1,984,801	
Total liabilities	:	2,220,074	2,834,801	
Total equity and liabilities	•	2,420,122	3,734,357	

As of

Consolidated Financial Information March 31, 2023 and March 31, 2022

Consolidated statements of profit and loss

(All amounts in stated United States Dollars, unless otherwise stated)

stated)	Notes	March 31, 2023	March 31, 2022
Revenue from operations	12	4,421,789	4,696,135
Other income	13	-	100,000
Total revenue		4,421,789	4,796,135
Changes in inventories of traded goods	14	616,484	(620,627)
Purchase of traded goods		3,134,980	4,367,261
Employee benefits expense	15	377,501	347,581
Amortization expense	16	119,439	119,439
Finance costs	17	42,500	13,274
Other expenses	18	690,711	822,008
Total expenses		4,981,615	5,048,936
Operating loss		(559,826)	(252,801)
Loss before tax		(559,826)	(252,801)
Deferred tax expense (benefit)	19	139,682	(34,278)
Net loss for the year, net of tax		(699,508)	(218,523)
Net loss attributable to:			
Equity holders of the parent		(419,313)	(163,263)
Non-controlling interest		(280,195)	(55,260)

For the year ended

Consolidated Financial Information March 31, 2023 and March 31, 2022

Consolidated statements of cash flows

(All amounts stated in United States Dollars, unless otherwise

stated)	-	March 31, 2023	March 31, 2022
A. Operating activities			
Loss before tax		(559,826)	(252,801)
Adjustments to reconcile loss before tax to net cash	flows:		
Amortization expense		119,439	119,439
Finance costs		42,500	13,274
Working capital adjustments:			
Inventories		616,484	(620,627)
Trade receivable		410,603	527,986
Other current assets		(5,351)	(5,763)
Trade payables		(654,444)	(791,438)
Other financial liabilities		(2,783)	-
Net cash flows used in operating activities	(A)	(33,378)	(1,009,930)
C. Financing activities			
Proceeds of loan from related party		-	850,000
Net cash provided by financing activities	(C)	-	850,000
Net decrease in cash and cash equivalents	(A+B+C)	(33,378)	(159,930)
Cash and cash equivalents at the beginning		217,811	377,741
Cash and cash equivalents at the end	-	184,433	217,811

For the year ended

Consolidated Financial Information March 31, 2023 and March 31, 2022

Consolidated statements of changes in equity

(All amounts stated in United States Dollars except number of shares, unless otherwise stated)

	Attributable to	the equity holder			
Particulars	Member's equity	Accumulated deficit	Total member's equity	Non-controlling interest	Total equity
For the year ended March 31, 2022					
As of April 01, 2021	1,600,000	(447,117)	1,152,883	(34,804)	1,118,079
Loss for the year	-	(163,263)	(163,263)	(55,260)	(218,523)
As of March 31, 2022	1,600,000	(610,380)	989,620	(90,064)	899,556
For the year ended March 31, 2023					
As of April 01, 2022	1,600,000	(610,380)	989,620	(90,064)	899,556
Loss for the year	-	(419,313)	(419,313)	(280,195)	(699,508)
As of March 31, 2023	1,600,000	(1,029,693)	570,307	(370,259)	200,048

Consolidated Financial Information March 31, 2023 and March 31, 2022

NOTE 1 - ORGANIZATION AND NATURE OF OPERATIONS

Fermenta Biotech USA LLC ("FBUL" or "the Company" or "the Parent Company") incorporated on May 27, 2020 in the State of Texas, United States, is a holding company. Fermenta Biotech Limited ("FBL India") a public listed India company, is the Ultimate Parent Company of FBUL.

On December 01, 2020, the Company acquired 52% membership interest in AGD Nutrition LLC ("the subsidiary" or "the acquiree"), a company based in Texas for a total consideration of \$ 1,291,251. AGD Nutrition LLC is engaged in the business of marketing and developing nutritional ingredients used in feed, food, pharmaceutical, and nutraceutical applications.

On December 09, 2020, the name of the subsidiary was changed to Fermenta USA LLC.

The Company conducts business through its subsidiary, namely, Fermenta USA LLC ("FUSA").

These Consolidated Financial Information comprise the Parent Company and its subsidiary (together referred to as "the Group"), the details of which are set out above.

The Consolidated Financial Information has been prepared in conformity with the accounting policies of Fermenta Biotech Limited, which are in accordance with the recognition and measurement principles of Indian Accounting Standard notified under section 133 of the Companies Act 2013 ('the Act') and other accounting principles generally accepted in India. The Consolidated Financial Information have been prepared to facilitate the FBL India in preparation of its consolidated financial statements. The Consolidated Financial Information includes the disclosures as required under Ind AS to the extent it facilitates and is applicable for preparation of FBL India's consolidated financial statements.

NOTE 2 - GOODWILL

On December 01, 2020, the Company acquired 52% of the membership of AGD Nutrition LLC, a company based in Texas for a total consideration of \$1,291,251.

The Company elected to measure the non-controlling interest in the acquiree at the proportionate share of its interest in the acquiree's identifiable net assets.

Goodwill arising on acquisition was \$ 900,845.

As of	
March 31, 2023	March 31, 2022
900,845	900,845
SS	
-	-
900,845	900,845
3	March 31, 2023 900,845 -

Consolidated Financial Information March 31, 2023 and March 31, 2022

NOTE 3 - OTHER INTANGIBLE ASSETS

	As of	
Customer relationships	March 31, 2023	March 31, 2022
Gross block		
Opening balance	597,194	597,194
Additions	-	-
Closing balance	597,194	597,194
Amortisation		
Opening balance	159,252	39,813
Amortisation	119,439	119,439
Closing balance	278,691	159,252
Net book value	318,503	437,942

Other intangible assets include Customer Relationships acquired through business combinations. The useful life of the Customer Relationships is estimated to be 5 years.

NOTE 4 - INVENTORIES

As of	
March 31, 2023	March 31, 2022
721,969	1,338,453
721,969	1,338,453
	March 31, 2023 721,969

Goods-in-transit included in the inventory balance is \$101,442 as of March 31, 2023. (March 31, 2022: \$666,816)

NOTE 5 - TRADE RECEIVABLES

	As of	
	March 31, 2023	March 31, 2022
Unsecured trade receivables		
Undisputed, considered good	187,734	654,036
Related party receivables	55,699	-
	243,433	654,036

Particulars	Outstanding for following periods from due date of payment		
	Less than 6 months	Upto 1 year	Total
(i) Undisputed trade receivables	– considered good		
March 31, 2023	187,734	-	187,734
March 31, 2022	654,036	-	654,036
(ii) Related party receivables			
March 31, 2023	41,199	14,500	55,699
March 31, 2022	-	-	-

Consolidated Financial Information March 31, 2023 and March 31, 2022

NOTE 6 - CASH AND CASH EQUIVALENTS

	As of	
	March 31, 2023	March 31, 2022
Balances with banks	184,433	217,811
	184,433	217,811

NOTE 7 - OTHER CURRENT ASSETS

	As of	
	March 31, 2023	March 31, 2022
Prepaid expenses	50,489	45,138
Others	450	450
	50,939	45,588

NOTE 8- MEMBER'S EQUITY AND OTHER EQUITY

A MEMBER'S EQUITY

	As of	
	March 31, 2023	March 31, 2022
At the beginning	1,600,000	1,600,000
Member's contribution during the year	-	-
Outstanding at the end	1,600,000	1,600,000

B Accumulated deficit

	As of	
	March 31, 2023	March 31, 2022
Accumulated deficit		
At the beginning of the year	(610,380)	(447,117)
Loss for the year	(419,313)	(163,263)
Balance at the end of the year	(1,029,692)	(610,380)

NOTE 9- BORROWINGS

	As of	
	March 31, 2023	March 31, 2022
Loan from related party (Unsecured)	850,000	850,000
	850,000	850,000

On December 08, 2021, the Company has obtained a borrowing in the amount of \$ 850,000 from the Ultimate Parent Company. The interest rate on this borrowing is 5% compounded annually, payable annually on 31st day of December. The term length of the loan is upto February 01, 2033. The interest expense for the year amounted to \$ 42,500 (March 31, 2022: \$ 13,274).

Consolidated Financial Information March 31, 2023 and March 31, 2022

NOTE 10- TRADE PAYABLES

	As of	
	March 31, 2023	March 31, 2022
Due of related parties (Refer Note 20)	1,241,516	1,862,939
Dues of creditors other than MSME	75,567	108,588
	1,317,083	1,971,527

Particulars	Outstanding for following periods from due date of payment		
	Less than 6 months	Upto 1 year	Total
March 31, 2023	814,903	502,180	1,317,083
March 31, 2022	1,744,788	226,739	1,971,527

NOTE 11 - OTHER FINANCIAL LIABILITIES

	As of	
	March 31, 2023	March 31, 2022
Interest accrued but not due on borrowings	52,979	13,274
Accrued payroll tax liability	12	-
	52,991	13,274

NOTE 12- REVENUE FROM OPERATIONS

	For the year ended	
	March 31, 2023	March 31, 2022
Sale of products	4,389,234	4,696,135
Commission income	32,555	-
	4,421,789	4,696,135
Disaggregated revenue information		
Revenue recognized at a point in time	4,421,789	4,696,135
	4,421,789	4,696,135
NOTE 13- OTHER INCOME		
	For the yea	

	March 31, 2023	March 31, 2022
Insurance claim received		100,000
	-	100,000

Consolidated Financial Information March 31, 2023 and March 31, 2022

NOTE 14- CHANGES IN INVENTORIES OF TRADED GOODS

	For the ye	For the year ended	
	March 31, 2023	March 31, 2022	
Opening inventory			
Traded goods	1,338,453	717,826	
(A)	1,338,453	717,826	
Closing inventory			
Traded goods	721,969	1,338,453	
(B)	721,969	1,338,453	
Decrease (increase) in inventory (C) = (A) - (B)	616,484	(620,627)	

NOTE 15- EMPLOYEE BENEFITS EXPENSE

	For the year ended	
	March 31, 2023	March 31, 2022
Salaries and wages	377,501	347,581
	377,501	347,581

NOTE 16- AMORTIZATION EXPENSE

	For the year ended	
	March 31, 2023	March 31, 2022
Amortization of intangible assets (Refer Note 3)	119,439	119,439
	119,439	119,439

NOTE 17- FINANCE COSTS

For the year	For the year ended	
March 31, 2023	March 31, 2022	
42,500	13,274	
42,500	13,274	

NOTE 18- OTHER EXPENSES

	For the year ended	
	March 31, 2023	March 31, 2022
Freight and forwarding charges	377,725	388,719
Commission on sales	18,245	9,771
Professional and legal fees	104,592	129,260
Payment to auditors (Refer note below)	25,506	24,000
Insurance	59,337	60,245
Travelling and conveyance	17,617	6,205
Printing and stationery	3,321	1,005
Postage and telephone	9,477	6,277
Rent	19,230	19,412
Miscellaneous expenses	55,615	31,524
Bank charges	46	113
Bad debt expense	-	145,477
-	690,711	822,008

Consolidated Financial Information March 31, 2023 and March 31, 2022

Details of payments to auditors:

	For the year ended	
Particulars	March 31, 2023 March 31, 2022	
Payment to auditors		
As auditor:		
Audit fees	25,506	24,000
Total	25,506	24,000

NOTE 19- TAXATION

	For the yea	ar ended
	March 31, 2023	March 31, 2022
Tax expense (benefit)		
(a) Amounts recognised in profit and loss		
Current tax	-	-
Deferred tax expense (benefit)	139,682	(34,278)
	139,682	(34,278)
(b) Reconciliation of effective tax rate		
Loss before tax	(559,826)	(252,801)
Tax using the Company's domestic tax rate: 21%)	(117,563)	(53,087)
Tax effect of:		
Meals and entertainment	1,654	-
Loss allocable to non-controlling interest	52,478	18,809
Virtual uncertainty	203,113	-
Tax expense (benefit) as per profit or loss	139,682	(34,278)
(c) Movement in deferred tax balances		
Deferred tax asset		
Identified intangibles	20,289	11,594
Net operating loss	201,126	144,905
Interest expense - IRC Sec 267	11,126	-
	232,541	156,498
Deferred tax liabilities		
Goodwill	(29,428)	(16,816)
Deferred tax assets not recognised	(203,113)	-
	(232,541)	(16,816)
Net deferred tax assets	-	139,682

Space intentionally left blank

Consolidated Financial Information March 31, 2023 and March 31, 2022

NOTE 20- RELATED PARTY TRANSACTIONS

Related party relationships are as follows:

Ultimate Parent Company:

Fermenta Biotech Limited

Associate Company: Fermenta Biotech GmBH

Non-controlling interest holder:

Reyn Capital LLC

		For the y	ear ended
Nature of transaction	Name of related party	March 31, 2023	March 31, 2022
Purchases of products	Fermenta Biotech Limited	1,735,537	2,664,036
Commission income/ purchases of products	Fermenta Biotech GmBH	32,555	324,225
Expenses incurred on behalf of the Company	Fermenta Biotech Limited	-	3,000
Expenses incurred on behalf of the Company	Fermenta Biotech GmBH	53,199	2,500

Balances as of March 31, 2023 and March 31, 2022

		As of		
Particulars	Name of related party	March 31, 2023	March 31, 2022	
Trade payables	Fermenta Biotech Limited	1,241,516	1,538,714	
Trade payables	Fermenta Biotech GmBH	-	324,225	
Trade receivables	Fermenta Biotech GmBH	55,699	-	

Space intentionally left blank

Consolidated Financial Information March 31, 2023 and March 31, 2022

NOTE 21 - FINANCIAL RISK MANAGEMENT OBJECTIVE AND POLICIE1

The Group is exposed to credit risk, liquidity risk and market risk. The Group's financial risk management is an integral part of how to plan and execute its business strategies. The Board of Directors review and agree policies for managing each of these risks, which are summarised below.

Market risk

Market risk is the risk of loss of future earnings, fair values or future cash flows that may result from adverse changes in market rates and prices (such as interest rates, foreign currency exchange rates, commodity prices and equity price risk). Market risk is attributable to all market risk-sensitive financial instruments, all foreign currency receivables and payables and all short term and long-term borrowings. The Company is exposed to market risks related to foreign exchange rate risk, commodity rate risk, interest rate risk and other price risks, such as equity price risks. Thus, the Group's exposure to market risk is a function of borrowing activities, revenue generating and operating activities in foreign currencies.

Foreign currency risk

Foreign currency risk is the risk that the fair value or future cash flows of an exposure will fluctuate because of changes in foreign exchange rates. The Group's exposure to the risk of changes in foreign exchange rates relates primarily to the Group's operating activities (when revenue or expense is denominated in a foreign currency). The Group does majority of its transaction in its functional currency which is USD. Accordingly, the Group is not exposed to foreign currency risk.

Credit risk

Credit risk is the risk of financial loss, if a customer or counterparty to a financial instrument fails to meet its contractual obligations and arises principally from the Group's receivables from customers, loans and other financial assets. Credit risk is managed through credit approvals, establishing credit limits and continuously monitoring the creditworthiness of counterparty to which the Group grants credit terms in the normal course of business. Cash balances in bank accounts are insured by the Federal Deposit Insurance Corporation ("FDIC") up to \$250,000 for each insured bank for each account per depositor.

The following table details the Group's exposure to credit risk

Particulars	As of				
raruculars	March 31, 2023	March 31, 2022			
Trade receivables	243,433	654,036			
Cash and cash equivalents	184,433	217,811			

Liquidity risk

Liquidity risk is the risk that the Group will not be able to settle or meet its obligations as they fall due. The Group's policy on liquidity risk is to maintain sufficient liquidity in the form of cash and investment in liquid banks deposits to meet the Group's operating requirements with an appropriate level of headroom. In addition, processes and policies related to such risks are overseen by senior management. Management monitors the Group's net liquidity position through rolling forecasts on the basis of expected cash flows.

The table below summarizes the maturity profile of the Group's financial liabilities based on contractual undiscounted payments

Consolidated Financial Information March 31, 2023 and March 31, 2022

Particulars	Total	Upto 1 year	1 to 3 years	3 to 5 years	5 years & above
As of March 31, 2023					
Trade payable	1,317,083	1,277,467	39,616	-	-
Borrowings	850,000	-	-	-	850,000
As of March 31, 2022					
Trade payable	1,971,527	1,744,788	226,739	-	-
Borrowings	850,000	-	-	-	850,000

Impact of COVID 19

The macro economic impact of the COVID-19 pandemic is uncertain, and continues to evolve, with potential disruption to financial markets including to currencies, interest rates, borrowing costs and the availability of debt financing. In addition, global stress in the markets brought on by the COVID-19 crisis is being felt globally through lack of liquidity in foreign funding markets. In this environment, the Group has already taken measures to manage its liquidity and capital carefully until the crisis is over. The Group's management has been closely monitoring the cash flows and forecasts on a timely manner to maintain a reasonably healthy balance sheet during this time and beyond. As at the date of signature of these consolidated financial information, management notes that the Group has sufficient liquidity to meet its obligations as they become due and that there are no doubts surrounding the Group's ability to continue as a going concern for the foreseeable future. Further, the Group would be supported by the Ultimate Parent Company if required in order to ensure sufficient liquidity and ability to continue as a going concern.

Management has assessed that the COVID-19 outbreak will not have a material adverse impact on the future results of the Group and accordingly no impairment indicators on the Group's non-financial assets exist as of March 31, 2023.

NOTE 22 - CAPITAL MANAGEMENT

For the purpose of the Group's capital management, capital includes member's equity and accumulated deficit. The primary objective of the Group's capital management is to maximise the value of its members.

The Group manages its capital structure and makes adjustments in light of changes in economic conditions and the requirements of the financial covenants.

The Group's objectives when managing capital are to:

• safeguard their ability to continue as a going concern, so that they can continue to provide returns for members and benefits for other stakeholders, and

• maintain an optimal capital structure to reduce the cost of capital.

In order to maintain or adjust the capital structure, the Group may adjust the amount of distributions to member or return capital to its member. The Group monitors capital for consistency with others in the industry.

The Group monitors capital using a gearing ratio, which is net debt divided by total equity plus net debt. The Group includes within net debt, interest bearing loans and borrowings, less cash and cash equivalents, excluding discontinued operations.

The Ultimate Parent Company will continue to provide financial support to the Group to meet its capital requirements.

Consolidated Financial Information March 31, 2023 and March 31, 2022

	As o	f
Particulars	March 31, 2023	March 31, 2022
Borrowings (Refer note 9)	850,000	850,000
Less: Cash and cash equivalents (Refer note 6)	(184,433)	(217,811)
Net debt - A	665,567	632,189
Equity (Member's equity + Accumulated deficit + Non- controlling interest)	200,048	899,556
Total Equity - B	200,048	899,556
Capital and net debt $(A + B) = C$	865,615	1,531,745
Gearing ratio - C/A	130%	242%

NOTE 23 - EVENTS AFTER THE REPORTING PERIOD

Subsequent events have been evaluated through the date the financial statements were available to be issued. Based on the evaluation, the Company is not aware of any events or transactions that would require recognition or disclosure in the financial statements.

FERMENTA BIOTECH GMBH Statement Of Balance Sheet And Profit And Loss Of The Component

Balance Sheet as at 31.03.2023

(Section)	liculars		Note No	For the year ended Mar 31, 2023	Amount IN EUR For the year ender Mar 31, 2022
I	ASSETS				
(1)	Non-current assets				10
(' /	(a) Property, plant and equipment		3	-	_
	(b) Capital work-in-progress		4	- ¹	_
	(c) Right-of-use assets		5	-	
	(d) Investment property		6		-
	(e) Goodwill			-	-
	(f) Other Intangible assets		7	11.901,84	348.626,00
	(g) Intangible assets under development		8		-
	(h) Investments				*
	i) Investments in subsidiaries		9A	· •	-
	ii) Investments in an associate		9B	÷.	-
	(I) Financial assets				
	(i) Investments		9C	· ·	- E-
	(ii) Share application money		10	-	· · · -
	(iii) Loans		11	-	-
	(iv) Other financial assets		12	-	-
	(J) Deferred tax assets (net)		48C	-	-
	(k) Non-current tax assets (net)		13	-	-
	(J) Other non-current assets		14	-	-
				11.901,84	348.626,0
~	2				1.5
2)	Current assets				
	(a) Inventories		15	1.777,462,00	3.026.719,8
	(b) Financial Assets	11.5			
	(I) Investments		10		
	(ii) Trade receivables		16	132.232,00	627,550,8
	(iii) Cash and cash equivalents		17	145.342,60	96,587,3
	(iv) Bank balances other than (iii) above		18	-	-
	(v) Loans		19	-	
	(vi) Others (to be specified)	1 . F	20		-
	(c) Current Tax Assets (Net)			010 010 00	150 000 7
	(d) Other current assets	-	21	219.919,36	152.002,78
083		Total Assets		2.274.955,96 2.286.857,80	3,902.860,88 4.251.486,88
-		10111100010		212001007,00	4.201.400,00
	EQUITY AND LIABILITIES	2			
	Equity				
	(a) Equity Share Capital		22	1.000.000,00	25,000,00
	(b) Other Equity		23	(4.891.945,08)	(2.000.545,9
		10		(3.891.945,08)	(1.975.545,9
	Equity attributable to the owners of the company			(3.891.945,08)	(1.975,545,9
	Non Controlling Interest	2.1.1			
				(3,891,945,08)	(1.975.545,9
				(3,891,945,08)	(1.975.545,9
	Liabilities			(3.891.945,08)	(1.975.545,9
0				(3.891.945,08)	(1.975.545,9
1)	Non-current liabilities	. ė		(3.891.945,08)	(1.975.545,9
1)	Non-current Ilabilities (a) Financial liabilities		24	(3.891.945,08)	(1.975.545,9
)	Non-current Ilabilities (a) Financial liabilities (l) Borrowings		24	(3.891.945,08)	(1.975.545,9
)	Non-current liabilities (a) Financial liabilities (l) Borrowings (li) Lease liabilities		25	(3.891.945,08)	(1.975.545,9
)	Non-current Ilabilities (a) Financial Ilabilities (I) Borrowings (II) Lease Ilabilities (III) Other financial Ilabilities		25 46	(3.891.945,08) 	(1.975.545,9 - - -
)	Non-current Ilabilities (a) Financial liabilities (i) Borrowings (ii) Lease liabilities (iii) Other financial liabilities (b) Provisions		25	(3.891,945,08) 	(1.975.545,9 - - - -
)	Non-current liabilities (a) Financial liabilities (l) Borrowings (ii) Lease liabilities (iii) Other financial liabilities (b) Provisions (c) Deferred tax liabilities (Net)		25 46 26	(3.891,945,08) - - - -	(1.975.545,9 - - - -
)	Non-current Ilabilities (a) Financial liabilities (i) Borrowings (ii) Lease liabilities (iii) Other financial liabilities (b) Provisions		25 46		
)	Non-current liabilities (a) Financial liabilities (l) Borrowings (ii) Lease liabilities (iii) Other financial liabilities (b) Provisions (c) Deferred tax liabilities (Net)		25 46 26	(3.891.945,08)	(1.975.545,9 - - - - - -
	Non-current Ilabilities (a) Financial liabilities (b) Borrowings (ii) Lease liabilities (iii) Other financial liabilities (b) Provisions (c) Deferred tax liabilities (Net) (d) Other non-current liabilities		25 46 26		
	Non-current llabilities (a) Financial llabilities (l) Borrowings (ii) Lease llabilities (iii) Other financial llabilities (b) Provisions (c) Deferred tax llabilities (Net) (d) Other non-current llabilities Current llabilities		25 46 26		
	Non-current Ilabilities (a) Financial liabilities (i) Borrowings (ii) Lease liabilities (iii) Other financial liabilities (b) Provisions (c) Deferred tax liabilities (Net) (d) Other non-current liabilities Current liabilities (a) Financial liabilities		25 46 26 27		
	Non-current llabilities (a) Financial liabilities (l) Borrowings (li) Lease liabilities (ii) Other financial liabilities (b) Provisions (c) Deferred tax liabilities (Net) (d) Other non-current liabilities Current llabilities (a) Financial liabilities (l) Borrowings		25 46 26 27 27		
	Non-current Ilabilities (a) Financial liabilities (b) Borrowings (ii) Lease liabilities (iii) Other financial liabilities (b) Provisions (c) Deferred tax liabilities (Net) (d) Other non-current liabilities Current Ilabilities (a) Financial liabilities (b) Borrowings (i) Lease liabilities		25 46 26 27		
	Non-current Ilabilities (a) Financial liabilities (i) Borrowings (ii) Lease liabilities (iii) Other financial liabilities (b) Provisions (c) Deferred tax liabilities (Net) (d) Other non-current liabilities (a) Financial liabilities (i) Borrowings (ii) Lease liabilities (iii) Trade payables		25 46 26 27 27 28 46		
	Non-current Ilabilities (a) Financial liabilities (i) Borrowings (ii) Lease liabilities (iii) Other financial liabilities (b) Provisions (c) Deferred tax liabilities (Net) (d) Other non-current liabilities (d) Other non-current liabilities (a) Financial liabilities (i) Borrowings (ii) Lease liabilities (iii) Trade payables A) Total outstanding dues of micro and small enterpries and	nall enterories an	25 46 26 27 28 46 29 & 52		
	Non-current Ilabilities (a) Financial liabilities (i) Borrowings (ii) Lease liabilities (iii) Other financial liabilities (b) Provisions (c) Deferred tax liabilities (Net) (d) Other non-current liabilities (d) Other non-current liabilities (a) Financial liabilities (i) Borrowings (ii) Lease liabilities (iii) Trade payables A) Total outstanding dues of micro and small enterpries and B) Total outstanding dues to creditors other than micro and sr	nall enterpries an	25 46 26 27 28 46 29 & 52 29		
)) ?)	Non-current IIabilities (a) Financial liabilities (l) Borrowings (li) Lease liabilities (iii) Other financial liabilities (b) Provisions (c) Deferred tax liabilities (Net) (d) Other non-current liabilities (d) Other non-current liabilities (a) Financial liabilities (l) Borrowings (li) Lease liabilities (li) Irade payables A) Total outstanding dues of micro and small enterpries and B) Total outstanding dues to creditors other than micro and sr (iv) Other financial liabilities	nall enterpries an	25 46 26 27 28 46 29 & 52 29 30	5.929,271,00	6.053.770,7
	Non-current Ilabilities (a) Financial liabilities (i) Borrowings (ii) Lease liabilities (iii) Other financial liabilities (b) Provisions (c) Deferred tax liabilities (Net) (d) Other non-current liabilities (d) Other non-current liabilities (a) Financial liabilities (i) Borrowings (ii) Lease liabilities (iii) Trade payables A) Total outstanding dues of micro and small enterpries and B) Total outstanding dues to creditors other than micro and sr (W) Other financial liabilities (b) Other current liabilities	nall enterpries an	25 46 26 27 28 46 29 & 52 29 30 31	5.929,271,00	6.053.770,7
	Non-current IIabilities (a) Financial liabilities (l) Borrowings (li) Lease liabilities (iii) Other financial liabilities (b) Provisions (c) Deferred tax liabilities (Net) (d) Other non-current liabilities (d) Other non-current liabilities (a) Financial liabilities (l) Borrowings (li) Lease liabilities (li) Irade payables A) Total outstanding dues of micro and small enterpries and B) Total outstanding dues to creditors other than micro and sr (iv) Other financial liabilities	nall enterpries an	25 46 26 27 28 46 29 & 52 29 30	5.929,271,00	6.053.770,79
	Non-current Ilabilities (a) Financial liabilities (i) Borrowings (ii) Lease liabilities (iii) Other financial liabilities (b) Provisions (c) Deferred tax liabilities (Net) (d) Other non-current liabilities (a) Financial liabilities (i) Borrowings (ii) Lease liabilities (ii) Trade payables A) Total outstanding dues of micro and small enterpries and B) Total outstanding dues to creditors other than micro and sr (iv) Other financial liabilities (b) Other current liabilities (c) Provisions (d) Current Tax Liabilities (Net)	nall enterpries an	25 46 26 27 28 46 29 & 52 29 30 31 32	5.929,271,00	
	Non-current Ilabilities (a) Financial liabilities (i) Borrowings (ii) Lease liabilities (iii) Other financial liabilities (b) Provisions (c) Deferred tax liabilities (Net) (d) Other non-current liabilities (d) Other non-current liabilities (a) Financial liabilities (b) Borrowings (c) Borrowings (c) Borrowings (c) Borrowings (c) Borrowings (c) Provisions (c) Provisions	nall enterpries an	25 46 26 27 28 46 29 & 52 29 30 31 32	5.929.271,00 24.748,81 224.783,07	6.053.770,78

COESSLED + PAR NER DMBH Witterhangsonitungsgebylischaft Steuerheigsburgsgebylischaft Neuer Vall 48 - 20354 Hanburg Teil Nr. 040 / 37 85010

Fermenta BIOTECH GmbH

Annexure II

Statement Of Balance Sheet And Profit And Loss Of The Component FERMENTA BIOTECH GMBH

				Quarter ended	Amount IN EUR Year ended			
	Partiuclars	Note No	For Quarter ended 31.03.2023	For Quarter ended 31.12.2022	For Quarter ended 31.03.2022	For the year ended 31.03.2023	For the year ended 31.03.2022	
Sales			A	В	С	Α	В	
	Revenue from Operations Other income	34 35	-9.192,47 22.403,37	558.141,09 4.674,86	308.705,24	921.518,53 58.484,76	1.005.804,72 4.433,00	
1	Total Income (I+II)	1	13.210,90	562.815,95	308.705,24	980.003,29	1.010.237,72	
V	Expenses Cost of materials consumed Purchase of stock in trade Changes in inventories of finished	36	1.161.901,01	107.461,49	-417.428,26 -	2.731.718,86	1.240.131,65 -	
	goods, stock-in-trade and work-in-	37	-662.266,70	582,935,20	749.728,55	32.551,20	313.453,45	
	progress Employee benefits expense Finance costs	38 39	34.584,78	34.447,62	34.447,62 -	138.045,61 -	117.597,42	
	Depreciation and amortisation expense	40	952,96	277.956,03	28.589,98	336.724,16	115.947,85	
	Other expenses Total Expenses (IV)	41	137.186,81 672.358,86	205.138,24 1.207.938,58	147.750,10 543.087,99	632.362,63 3.871.402,46	726.240,01 2.513.370,38	
,	Profit / (loss) before exceptional items and tax (III-IV)		-659.147,96	-645.122,63	-234.382,75	-2.89 <mark>1</mark> .399,17	-1.503.132,66	
() ()	Exceptional items Profit / (loss) before tax (V-VI)		-659.147,96	-645.122,63	-234.382,75	-2.891.399,17	-1.503.132,66	
111	Tax expense: 1) Current tax 2) Deferred tax	48C			_			
(Profit / (loss) for the period from continuing operations (VII-VIII)		-659.147,96	-645.122,63	-234.382,75	-2.891.399,17	-1.503.132,66	
: 11	Profit / (loss) from discontinued operations before tax Tax expense of discontinued operations	*					÷.	
11	Profit / (loss) from Discontinued operations (after tax) (X-XI)		-	-	1 <u>-</u>	-		
111	Profit / (loss) for the period (IX+XII)		-659.147,96	-645.122,63	-234.382,75	-2.891.399,17	-1,503,132,66	
IV	Other Comprehensive Income A (I) Items that will not be realessified to conflict class (ii) Income tax relating to items that will not be reclassified to profit or loss (I) Items that may be reclassified							
	(ii) Income tax relating to items that may be reclassified to profit or loss				1			
v	Total comprehensive income for the period (XIII+XIV) (Comprising Profit (Loss) and Other Comprehensive income for the		-659.147,96	-645.122,63	-234.382,75	-2.891.399,17	-1.503.132,66	
					200	4. T		
	Profit for the year attributable to Owners of the company Non Controlling Interest		-659.147,96	-645.122,63 -	-234.382,75	-2.891.399,17 -	-1.503.132,66	
	Total other comprehensive Income/(Loss) for the year Owners of the company Non Controlling Interest							
	Total comprehensive Income/(Loss) for the year attributable to Owners of the company Non Controlling Interest		-659.147,96 -	-645.122,63	-234,382,75	-2.891.399,17 -	-1.503,132,66	

COESSLER / PARINER Green Wintschaftsprüfungsgesellschaft Steuerbeinstungsgesellschaft Neuer Walt 43- 2035/i Handburg Teil. Nr. 1040 / 3786010

Fermenta BIOTECH GmbH

FERMENTA BIOTECH GMBH CIN:- NA Standalone Cash Flow Statement for the year ended March 31, 2023

fbi

					March 31, 2023	(' in EUF March 31, 20
CASH FLOWS FROM OPERATING ACTIVITIES					March 91, 2025	March 51, 20
Profit before tax					(2.221.222.17)	
					(2.891.399,17)	(608,477,5
Adjustments for :						
Depreciation and amortisation expense					336.724,16	115.947,8
let unrealised foreign exchange (gain)						
oss on sale / write off, of property, plant and equipment (ne	ι)					
Allowance for doubtful debts						
share based payments to employees						
Finance costs						
nterest income						
Dividend income						
iabilities / provisions no longer required written back						
Trado receivable and advances written off						
let (gain)/Loss on fair value changes of derivatives measured	1 at FVTPL					
perating profit before working capital changes					(2.554.675,01)	(492.529,3
· · · · ·					1 A A	
lovements in working capital:						
Increase) in trade receivables					495.318,86	(612.270,8
Decrense/(increase) in inventories					1.249.257,88	368.299,
Increase) / decrease in other assets					(67.916,58)	(136.878,4
ncrease / (decrease) in trade payables					(124.499,75)	3.146.874,8
ncrease in provisions					194.993,07	29.790,0
Decrease) / increase in other liabilities					(118,723,23)	143.472,0
				-	(926,244,76)	2.446.756,9
acome taxes paid						
				-		
iet cash generated from operation (A)				-	(926,244,76)	2.446,756,9
ASH FLOWS FROM INVESTING ACTIVITIES						
ayments for purchase of property, plant and equipment	investment property	capital work-in-progress				95.843,8
tangible assets and intangible assets under development	.,	, espirat from a program,				55,645,6
rocceds on sale of property, plant and equipment						
itercorporate deposits received back						
terest received						
oan given to a subsidiary						
urchase of investments in a subsidiary						
lividend received						
eposits (placed with) /received back from a financial institut	ion (net)					
eposits received back from /(placed with) banks not consider		shualanta (nat)				
eposits received back from /(placed with) ballks hot consider	red as cash and cash equ	irvulents (net)				
and the standard state one				-		
et cash used in investing activities (B)				-	-	95.843,8
ASH FLOWS FROM FINANCING ACTIVITIES						
roceeds from long term borrowings			÷			(2.116.017,7
epayment of long term borrowings						(335.000,0
						(333.000,0
et Increase in short term borrowings						
crease in share capital					975.000,00	-
ephyment of Lease Liabilities						
ividends paid						
et cash used in financing activities (C)				· · · ·	975,000,00	(2.451.017,7
et (decrease) / increase in cash and cash equivalents (A)+	-(R)+(C)				48.755,24	91.583,0
ash and cash equivalents at the beginning of the year					96.587,36	5.004,1
ish and cash equivalents at the end of the year					145.342,60	96.587,2
amparante of each and each equivalents					÷	
omponents of cash and cash equivalents						
Cash on hand						
Balances with banks						
					145.342,60	96.587,2
In current accounts	ess than 3 months					1
In current accounts In deposits accounts with original maturity for le						
In deposits accounts with original maturity for le				-	145.342,60	96,587.2
In deposits accounts with original maturity for le ash and eash equivalents (Refer Note 17)		2-6- N-1- 29)		-	145.342,60	96.587,2
In deposits accounts with original maturity for le		Refer Note 28)		-	145.342,60	96.587,2 96.587,2

See accompanying notes to the Standalone financial statements 1-70

(A)ES 1/1 Mill A VELSAN 17

Fermenta BIOTECH GmbH

FERMENTA	BIOTECH	GMBH

CIN:- NA Standalone Statement of Changes in Equity for the year ended March 31, 2023

(a) Equity share capital	÷			(' in EUR)
			5 ¹ 1	March 31, 2023	March 31, 2022
	Balance at the beginning of the year Add: Issue of shares pursuant to scheme of amalgamation			25.000,00	25.000,00
	Add: Issue of shares			975.000.00	
	Balance at the end of the year			1.000.000,00	25.000,00

(b) Other equity

	Reserves and Surplus								Total	
		Unrealised (loss) on dilution	Capital redemption reserve	Capital reserve pursuant to amalgamation	Capital reserve	General reserve	Share options outstanding nccount	Retained earnings	Equity instruments through OCI	
Balance as at April 01, 2021 Profit for the year Recognition of share based payments Other comprehensive income for the year			р 21	×		3		(497.413,25) (1.503.132,66)		(497.413,2 (1.503,132,60
Bulance as at March 31, 2022 Profit for the year Payment of dividend (Gross) Recognition of share based payments Other comprehensivo income for the year		-					E.	(2.000.545,91) (2.891.399,17)	-	(2.000.545,9 (2.891.399,1
Balance as at March 31, 2023		-	-	-	-			(4.891.945,08)	-	(4.891.945,0

See accompanying notes 1-70 to the Standalone financial statements In terms of our report attached

GUESS ELL, PARTINEN SASSA Without on a market and Without of the onlying geodestant Report of a marging geodestant Report of a market of the mark and we with a strategy of

Fermenta BIOTECH GmbH

fbi

3 Property, plant and equipment

FERMENTA BIOTECH GMBH CIN--NA Notes to the Standalone financial statements for the year ended March 31, 2023

fbi

(' in EUR)

Particulars	Freehold land	Buildings	Plant and equipment	Furniture and fixtures	Vehicles	Leasehold Improvements	Total
At cost or deemed cost as at April 01, 2021							
Additions		100 C		÷			
Disposals		1		- 1 - 1 - 1 - 1 - 1 - 1 - 1 - 1 - 1 - 1			
Balance as at March 31, 2022	-	2 1 se	-	-	-	-	
Additions Disposals	1.00		- ¹		Ť,		
Balance as at March 31, 2023	-	-	÷	-	-	-	
Accumulated depreciation		N. 8	· · · · · ·				
As at April 01, 2021	-	12					
Depreciation expense						5	
Disposals	-						
Balance as at March 31, 2022			. · · · ·	-		-	
Depreciation expense Disposals	1				5		E
Balance as at March 31, 2023	-	1	-		-	-	
Carrying amount		÷.,				¹	
As at March 31, 2022	-	-	-	-	-	-	
As at March 31, 2023	-	-		-	- *.		•

GOESSI EL + March Mert UkrEH Witschollsprüfungsgesellschaft Steuerberatungsgesellschaft Neuer Wall 43 - 20354 Hamburg Tel. Nr. C40 / 27 (2023)

Fermenta BIOTECH GmbH

FERMENTA BIOTECH GMBH CIN- NA Notes to the Standalone financial statements for the year ended March 31, 2023

4 Capital work-in-progress

	March 31, 2023	March 31, 2022
Project in progress	10 A	
Projects temporarily suspended	-	· · · · ·
Total	-	·

Ageing of Capital work-in-progress

Capital work-in-progress	Less than 1 Year	1-2 years	2-3 years	More than 3 years	Total
Balance as at March 31, 2022				·	
Project in progress		1			
Projects temporarily suspended					
Balance as at March 31, 2023					
Project in progress					-
Projects temporarily suspended					-

CWIP completion schedule for project overdue: as at March 31, 2023

	To be completed in			Total	
Project overduc	Less than 1 Year	1-2 years	2-3 years	More than 3 years	Tomi
Copacity enhancement of Biotech Plant at Kullu Plant					
Modification of existing Admin office and expansion of ground floor at Dahej plant			É,		
Others		13			-

COESSIERF 出版的 化新生 Witterhaltsmillangsgesellschaf Stenchersterigegesellschaf Neuer Viell al. 20364 Neutang Teil Mr. (1407) 47449-90

Fermenta BIOTECH GmbH

10000000000000000000000000000000000000		
FERMENTA	BIOTECH	GMBH

5

CIN:- NA Notes to the Standalone financial statements for the year ended March 31, 2023

Particulars	Leasehold land	Buildings	Vehicles	Total
At cost as at April 01, 2021		1.1		
Additions				
Disposals				
Balance as at March 31, 2022				
Additions	1. A 1.		<u>8</u>	
Disposala				
Balance as at March 31, 2023				
Accumulated depreciation				1
		1 (c)		
as at April 01, 2021		2		
Disposals				
salance as at March 31, 2022			·····	
Depreciation expense				
Disposals			12 C	
alance as at March 31, 2023				
'arrying amount				
s at March 31, 2022				
s at March 31, 2023				

WUESDIELS COMPSGesellschaft Wirtschaft Defüngsgesellschaft Steuerberatungsgesellschaft Neuer Wall 43 - 20354 Hemburg Tel. Nr. 040 / 3750210

Fermenta BIOTECH GmbH

c/o InterGest Germany GmbH Straßenbahnring 13 20251 Hamburg

fb2 ('in EUR)

FERMENTA	BIOTECH	GMBH

CIN:- NA Notes to the Standalone financial statements for the year ended March 31, 2023

fbi ('in EUR)

6 Investment property Buildings Particulars Freehold land Plant and equipment Total At cost or deemed cost as at April 01, 2021 Additions Balance as at March 31, 2022 Additions Disposal Balance as at March 31, 2023 Accumulated depreciation As at April 01, 2021 Depreciation expense Balance as at March 31, 2022 Depreciation expense Balance as at March 31, 2023 --Carrying amount As at March 31, 2022 As at March 31, 2023

Note 5. - Goodwill

	March 31, 2023	March 31, 2022	
Deemed cost			
Accumulated impairment losses			
		-	

Title deeds of immovable property not held in the name of the company:

	Relevant line item in the Balance Sheet	Description of item of property	Gross Value of property	Title deed held in the name of	Whether title deed holder is a promoter, director or relative of promoter/director or employce of promoter/director	Property held since which date	Renson for not being held in the name of the company
	Investment property						
•		у . Т					



Fermenta BIOTECH GmbH c/o InterGest Germany GmbH Straßenbahnring 13 20251 Hamburg

7 Other Intangible assets

Flat

(' in EUR)

			(Libbre
Particulars	Computer software	Product know -how	Total
At cost or deemed cost as at April 01, 2021	23,185,00	560,417,85	583,602,85
Additions			-
Balance as at March 31, 2022	23.185,00	560.417,85	583,602,85
Additions		-	÷
Balance as at March 31, 2023	23,185,00	560,417,85	583,602,85
Accumulated amortisation		2	
As at April 01, 2021	3,864,35	115.164,65	119,029,00
Amortisation expense	3,567,73	112.380,12	115,947,85
Balance as at March 31, 2022	7.432,08	227,544,77	234.976,85
Amortisation expense	3.851,08	332.873,08	336.724,16
Balance as at March 31, 2023	11,283,16	560.417,85	571.701,01
Carrying amount			
As at March 31, 2022	15.752,92	332.873,08	348,626,00
As at March 31, 2023	11.901,84	-	11.901,84

8 Intangible assets under development

<u>``</u>	March 31, 2023	March 31, 2022
Project in progress	1	
Projects temporarily suspended		
Total	-	
		•

Ageing of Intangible assets under development

Intangible assets under development	Less than 1 Year	1-2 years	2-3 years	More than 3 years	Total
Balance as at March 31, 2022		1		E1	
Project in progress					-
Projects temporarily suspended	5 C		1		-
	1		1		-6
Balance as at March 31, 2023					
Project in progress		•			-
Projects temporarily suspended				3 C	

There is no variation in respect of assets/projects forming part of intangible assets under development and which have become overdue compared to their original plans or where cost is exceeded compared to original plans.

NER GARH GDESSLEJ Winschung Studtungsgesellschaft Steucher abingsgesellschaft Neuer Mall 43 - 20354 Hantburg 福. 际: 040 / 3789010

Fermenta BIOTECH GmbH

Notes to the Standalone financial statements for the year ended March 31, 2023

fbl

(`in EUR)

			March	31, 2023	March 3	1,2022
9A	Investments in subsidiaries - in equity instruments unquoted (Fully paid less impairment in the value of investments, if any)	up) (At cost	e S			
b)						
	Equity shares of `/- (as at March 31, 202x: Equity shares of `/-	each)				
	Less: Impairment in the value of investment					
		11		-1		-
				-		-
	Aggregate amount of unquoted investments before impairment			-		-
	Aggregate amount of impairment in value of investments			1		-
Not	tes					
1						
		1.0				

CRESSLER, + PARTNER CHAPH visibilitati en la superiori estata Visibilitati estata estata estata Visibilitati estata estata estata Visibilitati estata estata estata estata Visibilitati estata Visibilitati estata est Fermenta BIOTECH GmbH c/o InterGest Germany GmbH Straßenbahnring 13

20251 Hamburg

CIN:- NA

9B

Notes to the Standalone financial statements for the year ended March 31, 2023

fbl

(' in EUR) March 31, 2023 March 31, 2022 Investment in associate - In equity instruments Unquoted (Fully paid up) (At cost less impairment in value of investments, if any) __ Equity shares of `__/- (as at March 31, 202x: __ Equity shares of `__/- each) Less: Impairment in the value of investment Aggregate amount of unquoted investments before impairment. Aggregate amount of impairment in value of investments. OGIOH

alungsgesellschaft Steuenberatu agsgeseilschaft Neuer Walf 13 · 20354 Hamburg Tel. Nr. 040 / 3786010

Fermenta BIOTECH GmbH

CIN:- NA

Notes to the Standalone financial statements for the year ended March 31, 2023

fbl

(` in EUR)

			in the second		
		Marcl	h 31, 2023	March 31,	202
Investments (non-current)	12		-st., ¹⁸		
Investment in other entities - In equity instruments:					
Unquoted Investments (all fully paid up)					
Investments in equity instruments at FVTOCI					
Equity shares of `/- (as at March 31, 202x:Equity shares of	`/- each)				
Less: Impairment in the value of investment					
Total aggregate unquoted investments (A)					-
Quoted Investment (all fully paid)					
Investment in equity instruments at FVTOCI					
Equity shares of ` (as at March 31, 202x:Equity shares of	`/- each)				
Total aggregate quoted investments (B)			<u> </u>		-
Total Non-current investments (A+B)					
Aggregate carrying value of unquoted investments before impairs Aggregate amount of quoted investments and market value thereo					-
Aggregate amount of impairment in value of investments			_ £		-
NOR ESS ET ANOTHER COMM	1	K			

Fermenta BIOTECH GmbH

FEL (' in EUR)

10 Share application money

Total	
Total	
Total -	
	-
Loans (Non-current)	
March 31, 2023	March 31, 2022
Loan to employees, considered good - unsecured	
Inter corporate deposit - considered doubtful - unsecured	
Less : Allowance for doubtful inter corporate deposit	
Loan to a subsidiary	
Total -	-
	e.
All Parties Promoters 1	Related Parties
Related Parties	
Aggregate of loans/advances in nature of loans	
- Repayable on demand (A)	
- Agreement does not specify any terms or period of repayment (B)	* .
Total	
Percentage of loans /advances in nature of loans to the total loans	
* The amounts reported are at gross amounts, without considering provisions made.	
Amount outstanding as at year end	
Name of entity - (Associate)	-
Name of entity - (wholly owned subsidiary)	-
Name of entity - (Others)	-
Maximum amount outstanding during the year	
Name of entity - (Associate) - Name of entity - (wholly owned subsidiary) -	-
Name of entity - (Others)	-
The Inter corporate deposit was granted to an associate and wholly owned subsidiary for the purpose of their business (Refer Note 68)	
Movement in the Allowance for doubtful inter corporate deposit	
Balance at the beginning of the year	-
Addition during the year - Written back during the year -	-
Written off during the year -	-
Balance at the end of the year -	·
Other financial assets (Non-current)	
March 31, 2023	March 31, 2022
Security deposits	
Bank deposits with remaining maturity of more than 12 months* Deposits with a financial institution with remaining maturity of more than 12 months #	
Interest accrued but not due from banks	
Interest accrued out not due notific ballks	
Interest accrued but not due from a financial institution	
Interest accrued but not due from a financial institution Others	
Interest accrued but not due from a financial institution Others Total -	-
Interest accrued but not due from a financial institution Others Total - *This includes deposits	
Interest accrued but not due from a financial institution Others Total - *This includes deposits kept for fund based bank guarantee with Bank of Baroda	n an
Interest accrued but not due from a financial institution Others Total - *This includes deposits	
Interest accrued but not due from a financial institution Others Total - *This includes deposits kept for fund based bank guarantee with Bank of Baroda kept for fund based bank guarantee with Union Bank of India	
Interest accrued but not due from a financial institution Others Total - *This includes deposits kept for fund based bank guarantee with Bank of Baroda kept for fund based bank guarantee with Union Bank of India # Fixed deposits are placed with Bajaj Finance Limited	- March 31, 2022
Interest accrued but not due from a financial institution Others Total - This includes deposits kept for fund based bank guarantee with Bank of Baroda kept for fund based bank guarantee with Union Bank of India # Fixed deposits are placed with Bajaj Finance Limited Non-current tax assets (net)	- March 31, 2022
Interest accrued but not due from a financial institution Others Total Total This includes deposits kept for fund based bank guarantee with Bank of Baroda kept for fund based bank guarantee with Union Bank of India # Fixed deposits are placed with Bajaj Finance Limited Non-current tax assets (net) March 31, 2023	- March 31, 2022
Interest accrued but not due from a financial institution Others Total - Total - This includes deposits kept for fund based bank guarantee with Bank of Baroda kept for fund based bank guarantee with Union Bank of India # Fixed deposits are placed with Bajaj Finance Limited Non-current tax assets (net) March 31, 2023	- March 31, 2022 -
Interest accrued but not due from a financial institution Others Total - *This includes deposits kept for fund based bank guarantee with Bank of Baroda kept for fund based bank guarantee with Union Bank of India # Fixed deposits are placed with Bajaj Finance Limited Non-current tax assets (net) Mnrch 31, 2023 Advance income-tax Total -	-
Interest accrued but not due from a financial institution Others Total - *This includes deposits kept for fund based bank guarantee with Bank of Baroda kept for fund based bank guarantee with Union Bank of India # Fixed deposits are placed with Bajaj Finance Limited Non-current tax assets (net) March 31, 2023 Advance income-tax Total - GOESSLER + PRINER CASH Wirtschalter in the precedence in the precedenc	a BIOTEC
Interest accrued but not due from a financial institution Others Total - *This includes deposits kept for fund based bank guarantee with Bank of Baroda kept for fund based bank guarantee with Union Bank of India # Fixed deposits are placed with Bajaj Finance Limited Non-current tax assets (net) March 31, 2023 Advance income-tax Total - GOESSLER + PARINER GENT	a BIOTEC
Interest accrued but not due from a financial institution Others Total *This includes deposits kept for fund based bank guarantee with Bank of Baroda kept for fund based bank guarantee with Union Bank of India # Fixed deposits are placed with Bajaj Finance Limited Non-current tax assets (net) March 31, 2023 Advance income-tax Total COESSLER + PARTNER COESH Notice that provide the advance of the advance	ta BIOTEC
Interest accrued but not due from a financial institution Others Total - *This includes deposits kept for fund based bank guarantee with Bank of Baroda kept for fund based bank guarantee with Union Bank of India # Fixed deposits are placed with Bajaj Finance Limited Non-current tax assets (net) March 31, 2023 Advance income-tax Total - GOESSLER + PARTNER Cont Number Vali 43 - 20354 Hainburg Tot. Nr. 040 / 378@010 Stra	a BIOTEC

CIN: NA Notes to the Standalone financial statements for the year ended March 31, 2023



14 Other assets (Non-current) March 31, 2023 March 31, 2022 Capital advances Advances recoverable in cash or kind Unsecured, considered good Unsecured, considered doubtful Less: Allowance for doubtful advances Deferred rent Balance with government authorities Prepaid expenses Total 15 Inventories March 31, 2023 March 31, 2022 (At lower of cost and net realisable value) Raw materials and packing materials (includes stock in transit of `EUR) (as at March 31, 2022: `EUR) 187.849,50 1.404.556,18 Work-in-progress (includes stock in transit of `EUR) (as at March 31, 2022: `EUR) Finished goods (includes stock in transit of 'EUR) (as at March 31, 2022: 'EUR) Stores and spares (includes stock in transit of 'EUR) (as at March 31, 2022: 'EUR) 1.589.612,50 1.622.163,70 Total 1.777.462,00 3.026.719,88

GOFESSER - CONSISTENT Winsertur versiter Signs of sectors State alternatur y sign of local set Mater West of 20304 Meantang · 例。社。940/37789/146

Fermenta BIOTECH GmbH

Total

Notes to the Standalone financial statements for the year ended March 31, 2023

16 Trade receivables (unsecured)

Undisputed Trade receivables - considered good

Undisputed Trade Receivables - credit impaired Disputed Trade Receivables - considered good

Disputed Trade Receivables - credit Impaired

March 31, 2023 March 31, 2022 132,232,00 627.550,86 Undisputed Trade Receivables - which have significant increase in credit risk Disputed Trade Receivables - which have significant increase in credit risk 132,232,00 627.550,86 Less : Allowance for doubtful debts (Expected credit loss allowance) 132,232,00 627.550,86

		Outstand	ling for the follo	wing period fr	om due date of	payments	<u>.</u>
Particulars	Not Due	Less than 6 months	6 months-1 year	1-2 years	2-3 years	More than 3 years	Total
(i) Undisputed Trade receivables – considered good	132,232,00	7					132,232,00
(ii) Undisputed Trade Receivables – which have significant increase in credit risk							6. j
iii) Undisputed Trade Receivables – credit impaired							-
(iv) Disputed Trade Receivables – considered good		1.1					-
(v) Disputed Trade Receivables – which have significant increase in credit risk		1.1					
(vi) Disputed Trade Receivables – credit Impaired	8						
Total	132,232,00	-	-	- <u>-</u>	-	-	132.232,00

Ageing of trade receivables : as at March 31, 2022 Outstanding for the following period from due date of payments Particulars Less than 6 6 months-1 More than 3 Not Due 1-2 years 2-3 years Total months year years (i) Undisputed Trade receivables -- considered good 612.270,86 15.280,00 627.550,86 (ii) Undisputed Trade Receivables - which have significant increase in credit risk iii) Undisputed Trade Receivables - credit impaired (iv) Disputed Trade Receivables - considered good (v) Disputed Trade Receivables - which have significant increase in credit (vi) Disputed Trade Receivables - credit Impaired Total 612.270,86 15.280,00 (0,01) 0,01 627.550,86

Movement in the expected credit loss allowance Balance at the beginning of the year Addition during the year Written off during the year Reversal during the year Balance at the end of the year

> OUT.SOL.H + PETIMEN GMBH Wirtschaftsgeführengesollschaft Steuerbezeitungsgesollschaft Neuer Weil 43 - 20364 Hemburg Tel. Nr. 040 / 3786010

Fermenta BIOTECH GmbH

c/o InterGest Germany GmbH Straßenbahnring 13 20251 Hamburg



(' in EUR)

Notes to the Standalone financial statements for the year ended March 31, 2023

fbi ('in EUR)

Cash and cash equivalents	· · ·		
		March 31, 2023	March 31, 2022
Balances with banks			. 9
In current accounts		145.342,60	96.587,36
In deposit accounts with original mat	turity for less than 3 months		
Cash on hand			
Total	<u></u>	145.342,60	96.587,36
Bank balances other than cash and c	ash equivalents		
		March 31, 2023	March 31, 2022
Balances with banks			
In Unpaid Dividend accounts			
In escrow account			
In deposit accounts with original mat	urity for more than 3 months but less than 12 months	*	

Total

CONFERENCE X + JANFUNGEN CONFERENCE Version of the second s

Fermenta BIOTECH GmbH

19 Loans (Current)

			Ma	rch 31, 2023	March 31, 202
Unsecured, considered good					
Inter corporate deposit					
Loans to employees					
Total				-	
	Cir I			an a	H
# The inter-corporate deposits were granted to the entity for t	ne purpose or its business.				
Other financial assets (Current)			B		
4 ⁻	1		Mai	reh 31, 2023	March 31, 202
Interest accrued but not due On fixed deposits from banks					
On fixed deposits with a financial institution					
On Inter corporate deposits (Refer Note 65)					
Deposits with a financial institution					
Expenses recoverable from related parties					
Interest receivable from a subsidiary					
Others					
Unsecured, considered good					
Unsecured, considered doubtful					
		-		-	
Total					
Other current assets		1 - 2 - -		1	
Other current assets		ê .	Mar	rch 31, 2023	March 31, 202
Other current assets Advance for supply of goods and services (Refer Note 68)			Mar	reh 31, 2023	March 31, 202
к ^{а с}			Mar	reh 31, 2023	March 31, 202
Advance for supply of goods and services (Refer Note 68)			Mar	reh 31, 2023	March 31, 202
Advance for supply of goods and services (Refer Note 68) Considered good			Mar	reh 31, 2023	March 31, 202
Advance for supply of goods and services (Refer Note 68) Considered good Considered doubtful Less: Allowance for doubtful advances			Mar	reh 31, 2023	March 31, 202
Advance for supply of goods and services (Refer Note 68) Considered good Considered doubtful Less: Allowance for doubtful advances Deferred rent			Mar	-	March 31, 202
Advance for supply of goods and services (Refer Note 68) Considered good Considered doubtful Less: Allowance for doubtful advances Deferred rent Prepaid expenses			Mar	reh 31, 2023 - 6.362,17	
Advance for supply of goods and services (Refer Note 68) Considered good Considered doubtful Less: Allowance for doubtful advances Deferred rent Prepaid expenses Unamortised lease rent SLM			Мпл	-	
Advance for supply of goods and services (Refer Note 68) Considered good Considered doubtful Less: Allowance for doubtful advances Deferred rent Prepaid expenses Unamortised lease rent SLM Travel advances to employees			Мпл	-	
Advance for supply of goods and services (Refer Note 68) Considered good Considered doubtful Less: Allowance for doubtful advances Deferred rent Prepaid expenses Unamortised lease rent SLM Travel advances to employees Export incentive receivables			Мпл	-	
Advance for supply of goods and services (Refer Note 68) Considered good Considered doubtful Less: Allowance for doubtful advances Deferred rent Prepaid expenses Unamortised lease rent SLM Iravel advances to employees Export incentive receivables Considered good			Мпл	-	
Advance for supply of goods and services (Refer Note 68) Considered good Considered doubtful Less: Allowance for doubtful advances Deferred rent Prepaid expenses Unamortised lease rent SLM Iravel advances to employees Export incentive receivables Considered good Considered doubtful			Mar	-	
Advance for supply of goods and services (Refer Note 68) Considered good Considered doubtful Less: Allowance for doubtful advances Deferred rent Prepaid expenses Unamortised lease rent SLM Iravel advances to employees Export incentive receivables Considered good	les		Mar	6,362,17	
Advance for supply of goods and services (Refer Note 68) Considered good Considered doubtful Less: Allowance for doubtful advances Deferred rent Prepaid expenses Unamortised lease rent SLM Travel advances to employees Export incentive receivables Considered good Considered doubtful Less: Allowance for doubtful export incentive receivab	les		Mar	6,362,17	5.068,
Advance for supply of goods and services (Refer Note 68) Considered good Considered doubtful Less: Allowance for doubtful advances Deferred rent Prepaid expenses Unamortised lease rent SLM Iravel advances to employees Export incentive receivables Considered good Considered doubtful	les		Mar	6,362,17	5.068,
Advance for supply of goods and services (Refer Note 68) Considered good Considered doubtful Less: Allowance for doubtful advances Deferred rent Prepaid expenses Unamortised lease rent SLM Travel advances to employees Export incentive receivables Considered good Considered doubtful Less: Allowance for doubtful export incentive receivab Balances with government authorities Total		-	Mar	6.362,17	5.068,
Advance for supply of goods and services (Refer Note 68) Considered good Considered doubtful Less: Allowance for doubtful advances Deferred rent Prepaid expenses Unamortised lease rent SLM Travel advances to employees Export incentive receivables Considered good Considered doubtful Less: Allowance for doubtful export incentive receivab Balances with government authorities Total		23.	Mar	6.362,17	5.068,
Advance for supply of goods and services (Refer Note 68) Considered good Considered doubtful Less: Allowance for doubtful advances Deferred rent Prepaid expenses Unamortised lease rent SLM Travel advances to employees Export incentive receivables Considered good Considered doubtful Less: Allowance for doubtful export incentive receivab Balances with government authorities Total Movement in the Allowance for doubtful advances and ex Balance at the beginning of the year			Mar	6.362,17	5.068,
Advance for supply of goods and services (Refer Note 68) Considered good Considered doubtful Less: Allowance for doubtful advances Deferred rent Prepaid expenses Unamortised lease rent SLM Travel advances to employees Export incentive receivables Considered good Considered doubtful Less: Allowance for doubtful export incentive receivab Balances with government authorities Total Movement in the Allowance for doubtful advances and ex Balance at the beginning of the year Addition during the year			Mar	6.362,17	5.068,
Advance for supply of goods and services (Refer Note 68) Considered good Considered doubtful Less: Allowance for doubtful advances Deferred rent Prepaid expenses Unamortised lease rent SLM Travel advances to employees Export incentive receivables Considered good Considered doubtful Less: Allowance for doubtful export incentive receivab Balances with government authorities Total Movement in the Allowance for doubtful advances and ex Balance at the beginning of the year			Mar	6.362,17	March 31, 202 5.068, - 146.934, 152.002,7

COESSLER # PARTNEH OMBH Wirtschaftsendlungsgesellschaft Steuer Veal 43 - 20354 Hamburg Tel. Nr. 040 / 3756010

Fermenta BIOTECH GmbH d/o InterGest Germany GmbH

Straßenbahnring 13 20251 Hamburg



('in EUR)

22

Equity share capital

FBL ('in EUR)

							March 31, 2023	March 31, 202
Authorised	E					3		
							1.000.000,00	25.000,0
							1.000.000,00	25.000,0
· · · · · · · · · · · · · · · · · · ·								
Issued, subscribed and fully paid-up								
Fermenta Biotech Linuited (100000 @ 1 EUR)							1.000.000,00	25.000,0
							1.000.000,00	25.000,0
						5		20100010
(a) Reconciliation of shares outstanding at th	e beginning and at t	he end of the year						
					March 31, 2		March	1 31, 2022
			. 11		No of Equity Shares	' In EUR	No of Equity Shares	'In EUR
					· .			
At the beginning of the year	· .	5 12	· · · · · ·		25,000	25,000	25.000	25,00
At the end of the year	a.	· · · · · · · · · · · · · · · · · · ·		2 G 2	1.000.000	1.000.000	25.000	25.00

(DESS) EU (PARTNES) (ASSE Whitschop (Dange assailschut) Statuy (Statuy) (Dange assailschut) Neuer Veol 43 - 20864 Hemberg Veol, Nr. D40 / 3786010

Fermenta BIOTECH GmbH

c/o InterGest Germany GmbH Straßenbahnring 13 20251 Hamburg

Strai:

22 Equity share capital

(b) Details of shareholders holding more than 5% equity shares in the Company Name of the shareholders March 31, 2023 March 31, 2022 % Holding No. of Equity Shares No. of Equity Shares % Holding Fermenta Biotech Limited 1.000.000 25.000 100 100 (c) Shares held by Holding Company Out of the equity shares issued by the Company, shares held by its Holding Company are as below: March 31, 2023 No. of Equity Shares Name of the shareholders March 31, 2022 No. of Equity Shares % Holding % Holding ` Fermenta Biotech Limited 1.000.000 100,001 25.000 100,003 (d) Details of Shures held by promoters at the end of the year March 31, 2023 Morch 31, 2022 Name of promoters No. of Equity Shar % Holding No. of Equity Shares % Holding % Change during the yea % Change during the year Fermenta Biotech Limited 1.000.00 100,0 25.00 100,0

(e) Rights, preferences and restrictions

GOESSLER - PERTINER GMBH Wirtschartschungsgesellechaft Steuerberatungsgesellschaft Neuer Wall 43 - 20354 Hentzing Tel. Nr. 040 / 3780010

Fermenta BIOTECH GmbH

Fermenta Blotech Limited (Formerly known as DIL Limited) CIN: NA Notes to the Standalone financial statements for the year ended March 31, 2023

23 Other equity									(' in EUR)
				Reserves an	d Surplus		13	Items of other comprehensive Income	Total
	Unrealised (loss) on dilution	Capital redemption reserve	Capital reserve pursuant to amalgamation	Capital reserve	General reserve	Share options outstanding account	Retained earnings	Equity Instruments through OCI	
Balance as at April 01, 2021	1 K. 1			1.0			(497.413,25)		(497.413,25)
Profit for the year	•						(1.503.132,66)		(1.503,132,66)
Recognition of share based payments	k .						4		
Other comprehensive income for the year	-						80 C		-
Balance as at March 31, 2022	-	-	-	-	-	· ·	(2.000.545,91)		(2.000.545,91)
Profit for the year		100 A					(2.891.399,17)	14	(2.891.399,17)
Payment of dividend (gross)			-			k 1			-
Recognition of share based payments									-
Other comprehensive income for the year							1. I.		-
Balance as at March 31, 2023	- 1 ²	-	-	-"	-	-	(4.891.945,08)	-	(4.891.945,08)

Description of nature and purpose of each reserve Unrealised gain/(loss) on dilution: Capital redemption reserve : Capital reserve pursuant to amalgamation : Capital reserve: ' General reserve:

Share options outstanding account :

Retained earnings:

Equity instruments through other comprehensive income:

COESSLER ; AND STR WAR With a characterization of the second 联战,040/封闭的140

Fermenta BIOTECH GmbH

Fbi

Notes to the Standalone financial statements for the year ended Murch 31, 2023

fbi

(' in EUR) 24 Borrowings (Non-current) March 31, 2023 March 31, 2022 Non-current Current Non-current Current Secured Term Loans From Banks From others Amount disclosed under the head "Borrowings (Current)" (Refer Note 28) Total

Notes a)

b)

的印刷 605.2.3 1 Wirtscheitzburtingsgeseitschuft Steuer von aufingsgeseitschuft Neuer Wall 33 · 20954 Hamfang Teil. Nr. 040 / 37 56010

Fermenta BIOTECH GmbH

25 Other financial liabilities (Non current)

Fbi (' in EUR)

March 31, 2023 March 31, 2022 Deposits from tenants 26 Provisions (Non-current) March 31, 2023 March 31, 2022 Provisions for employee benefits:

Gratuity Compensated absences

Total

Total

制制的制度 GOESSLEF 02 Walanda Y NBAS SEA 12 - 20356 Profess

Fermenta BIOTECH GmbH

27 Other linbilities (Non current)

Notes to the Standalone financial statements for the year ended March 31, 2023

Flat

(' in EUR)

1	March 31, 2023	March 31, .	2022
1	· ·	ж. 	2
: 			
	-		
			• •
	March 31, 2023	March 31,	2022
1			
	-	1	-

Annalist - Antitil R Given Steam of an angegee allocation Neuer 2011 137 20354 Hentung Tel. Nr. 040 / 3766010

Fermenta BIOTECH GmbH

Notes to the Standalone financial statements for the year ended March 31, 2023

29 Trade payables (Current)

1	1 k l	 18	March 31, 2023	March 31, 2022
Dues of micro and small enterprises (MSME) (Refer Note 52)				
Dues of creditors other than MSME			5.929.271,00	6.053.770,75
Disputed dues of MSME				
Disputed dues of creditors other than MSME				
Total		A 4	5,929,271,00	6.053.770,75

Ageing of trade payables: as at March 31, 2023

Particulars	Not due	Outstanding	The second se			
Particulars	Rotatie	Less than 1 year	1-2 years	2-3 years	More than 3 years	Total
Dues of MSME						· ·
Dues of creditors other than MSME		5.929.271,00				5.929.271,00
Disputed dues of MSME						-
Disputed dues of creditors other than MSME		1.1.1.1				-
Total	-	5.929.271,00	-	-	÷ -	5.929.271,00

Ageing of trade payables: as at March 31, 2022

Particulars	Not due	Outstanding				
	Not due	Less than 1 year	1-2 years	2-3 years	More than 3 years	Total
Dues of MSME					1.	8 -2
Dues of creditors other thanMSME		6.053.770,75			1	6.053.770,75
Disputed dues of MSME	× 21 - 2		×	2		. : -
Disputed dues of creditors other than MSME						2-
Total	-	6.053.770,75	-	-	-	6.053.770,75

CONCERNING PROPERTY AND A CONCERNING CONCERNINCE CONCERNING CONCERNING CONCERNING CONCERNING CONCERNINCERNING CONCERNINCERNINCERNINCERNINCERONCERNINCONCERNINCERNINCERNINCERNINCE CONCERNINCONCERNINCO Wale rolling from for solver the Normal Andreas Andreas Normal Andreas No. No. 040 / 2788000

Fermenta BIOTECH GmbH

c/o InterGest Germany GmbH Straßenbahnring 13 20251 Hamburg (`in EUR)

Flet

Notes to the Standalone financial statements for the year ended March 31, 2023

fbi

(' in EUR)

30 Other financial liabilities (Current)

is from tenants accrued but not duo on borrowings					and the second
to employees / directors					
others			2 M	-	
		8.1	- · · · ·	-	
		2			2
current liabilities					
			March 31, 2023	Mnrch 31, 2022	
1	2		8		
es from customers					
			24,748,81	143.472,04	
advances to employees					
Tana - management of the second s	in and the second statement of the		24.748,81	143.472,04	
*					
ons (Current)					
currenty					
* U			March 31, 2023	March 31, 2022	
ons for employee benefit:					
Compensated absences					
Provisions					
			224.783,07	29,790,00	
		2	224.783,07	29,790,00	1
t tax liabilities (net)			. 1	1	
	current liabilities ess from customers ty dues ty dues the rent advances to employees ons (Current) ons for employee benefit: Compensated absences Provisions Dther Provisions	tives not designated as hedge ned dividend others current liabilities current liabilities ces from customers ry dues d rent advances to employees ons (Current) ons for employee benefit: Compensated absences Provisions Dther Provisions	tives not designated as hedge ned dividend others current liabilities current liabilities cs from customers ry dues d rent advances to employees ons (Current) ons for employee benefit: Compensated absences Provisions Dther Provisions	tives not designated as hedge ned dividend others current liabilities current liabilities current liabilities current liabilities current of the set	tives not designated as hedge odiers odiers </td

ODESSLER - PARTNER CHEM Wirtschaft gefungsgesellschaft Steuer verafungsgesellschaft Neuer Wall 43 - 20354 Hamburg Tel. Nr. 040 / 3736010

Fermenta BIOTECH GmbH

CIN: NA

Notes to the Standalone financial statements for the year ended March 31, 2023



(`in EUR)

		March 31, 2023		March 31, 202
		11111 CH 31, 2023		
Sale of products		921.518,53		1.005.804,
Rent Income				
Amortised deferred rent				
Service income (infrastructure support services to tenants)			
Sale of services				
Other operating revenues				
Export incentive				
Scrap sales				
Total		921.518,53		1.005.804,
Other income			i.	
		March 31, 2023		March 31, 202
Interest income on financial assets carried at amortise	ed cost:			
Bank deposits				
Other financial assets				
Other Interioral assess				
Dividend income on investment in equity instrument.		2		
designated as at fair value through other comprehensive				
Foreign exchange gain (net)	· · · ·	50 404 76		
		58.484,76		
Net gain on fair value changes of derivatives at FVTPL				
Insurance claims	. S			
Liabilities / provisions no longer required written back	K:			
From Trade receivables				
From Others		I		4.433,0
				4.433,0
Miscellaneous income	<u>.</u>			3
Total		58.484,76	te te constant a constant la constant de	4.433,0
Cost of materials consumed				
	 4 4 4 	March 31, 2023		March 31, 202
Inventories of raw materials / packing materials at the beg	inning of the year	1.404.556,00		1.459.402,1
	mining of the year			
Add : Purchases		1.515.012,67		1.185.285,5
Less : Inventories of raw materials / packing materials at t Total	ne end of the year	187.849,81		1.404.556,0
		2.731.718,86		1.240.131,6

Fermenta BIOTECH GmbH

CIN: NA

Notes to the Standalone financial statements for the year ended March 31, 2023



(' in EUR)

37 Changes in inventories of finished goods, stock-in-trade and work-in-progress

		March 31, 2023		March 31, 2022
	******			1. j.
Inventories at the end of the year				
Work-in-progress				
Finished goods		1.589.612,50		1.622.163,7
		1.589.612,50		1.622.163,7
Inventories at the beginning of the year				
Work-in-progress		÷		
Finished goods		1.622.163,70		1.935.617,1
		1.622.163,70		1.935.617,1
		32,551,20		313.453,4
Employee benefits expense				
1. 12	:	March 31, 2023		March 31, 202
Salaries and wages		138.045,61		117.597,4
Contribution to provident and other funds [Refer	Note 471	150.0+5,01		117,397,4
Gratuity expense [Refer Note 47]				
Share based payments to employees [Refer Note	601			
Staff welfare expenses				
Total		138.045,61		117.597,4
Finance costs	•	· · · · · · · · · · · · · · · · · · ·		3. 2.
		March 31, 2023		March 31, 202
Interest on	a na			
Term loans				
Loans repayable on demand				
Liabilities carried at amortised cost (Unwind	ling of interest)			
Lease liabilities				
Others				
Other borrowing costs	1	<u>,</u>		
Total		-		-
		: 1		
Depreciation and amortisation expense	2.		1	5,5 3
1 14		March 31, 2023		March 31, 202
Depreciation on property, plant and equipment			1	
Depreciation on right-of-use assets				
Depreciation of investment property				
Amortisation of intangible assets		336.724,16		115.947,8
Total		336.724,16		115.947,8

GOESSI, EU, PARTNER (2015) Wintschart og Hangsgesensen ett Steuersberatungsgesensen ett Neuer Wall 02 20354 Hamburg Tel. Nr. 040 / 3768010 Fermenta BIOTECH Gmbb c/o InterGest Germany GmbH Straßenbahnring 13 20251 Hamburg

CIN: NA

Notes to the Standalone financial statements for the year ended March 31, 2023

Fbl

(`in EUR)

41 Other expenses

			March 31, 2023		March 31, 2022
Processing charges			8.678,54		257.949,26
Freight and forwarding charges		• <u>`</u> 2	166.659,47		154.568,71
Commission on sales			78.400,75		10.165,60
Rent (including lease rentals)			50.067,80		14.854,75
Insurance			11.715,71		18.556,55
Travelling and conveyance			15.613,84		7.631,45
Professional and legal fees			248.110,16		230.307,14
Payment to auditors			19.247,80		11.054,47
Postage and telephone			760,54		668,25
Printing and stationery			86,46		168,62
Bank charges			4.420,41		1.017,23
Donations			132,88		170,00
Miscellaneous expenses			28.468,27		10.032,98
Total	 		632.362,63	6. ¹	726.240,01

nio Mall 13 - 2015-1 Hamburg Tel, P.P. MAC / 1756-2010

Fermenta BIOTECH GmbH c/o InterGest Germany GmbH Straßenbahnring 13 20251 Hamburg

Fermenta Blotech Limited (Formerly known as DIL Limited) CIN: NA Notes to the Standalone financial statements for the year ended March 31, 2023

42 Related parties disclosures as per Ind AS 24

c) Associate NA

NA

A)	Names of the related	parties and description of relationships

	Country of Incorporation	Proportion of ownership interest as at			
		March 31, 2023	March 31, 2022		
n) Holding Company:					
Fermenta Biotech Limited	India	100%	100%		
Subsidiaries:	- E				
NA		1			
b) Key Management Personnel					
Name of Key Management Personnel	· Designation				
Ms. Viviano Spethmonn	Managing Director				

d) Enterprises under significant influence of key management personnel or their relatives:

GOESSI ER + PARTNER GMBH Widschaltszührigsgesellschaft Steuer Vall 43 - 20354 Hamburg Tel. Nr. 040 / 3786010

Co Inter Gest Germany GmbH Strabenbahnring 13

20251 Hamburg

Fermenta Biotech Limited (Formerly known as DIL Limited)
CIN: NA
Notes to the Standalone financial statements for the year ende

(in EUR)

	Related party transactions:							
Yo.	Particulars		Holding Company		nries	Key management personnel*	Enterprise significantly influenced by KMP or their relatives	Associate
	[Remuneration to Directors and Key Management Personnel (including commission)* - MD	e e	36.000,00 (36.000,00)				5	
	2 Commission to non-executive directors (excluding statutory levy)	1						
	3 Directors sitting fees			3				
	4 Rent and service Income	11 				an a Alia		
	5 Rent puld	а 1						
	6 Expenditure Incurred on hehalf of related parties Fermenta Biotech Ltd Produst Registration fees in SAG Chile	e	1.728,13 (-)					
	7 Sale of products							
	Fermenta USA LLC			E	(-)		÷.	
	Fermenta Biotech Ltd.	E.	(22.500,00)					
	8 Purchase of raw materials and packing materials							
	Fermenta Biotech Ltd.	e	817.200,00 (1.092.600,00)					
							6	
	9 Commission on Sules							
	Fermenta USA LLC in USD			\$	32.555,00			

Fermenta BIOTECH GmbH c/o InterGest Germany GmbH Straßenbahnring 13 20251 Hamburg

法保持 ((d. 1.5)) Version Sternet Green Statistics Sternet Statistics Statistics New Mr. 1941 (1970) ola y Hanlang

Fermenta Blotech Limited (Formeriv known as DIL Limited) CIN: NA Notes to the Standalone financial statements for the year ended March 31, 2023					('in EUR)
Sr.No. Particulars	Holding Company	Subsidiaries	Key management personnel*	Enterprise significantly influenced by KMP or their relatives.	Associates
9 Interest on Ioan given 10 Investment made					
11 Lonns given					

(Figures in brackets are the corresponding figures in respect of the previous year.)

* The remuneration to the key managerial personnel does not include the provisions made for gratuity and leave benefits, as they are determined on an actuarial basis for the company as a whole.

¢risili (iniCH opgazellschaft Stouenteran ngsgesallachaft Neuer Wall 43 · 20354 Hamburg Tel. Nr. 040 / 3766010

Fermenta Blotech Limited (Formerly known as DIL Limited)

C Fermenta BIOTECH GmbH c/o InterGest Germany GmbH Straßenbahnring 13 20251 Hamburg

Fermenta Blotech Limited (Formerly known as DLL Limited) CIN: NA Notes to the Standalone financlai statements for the year ended March 31, 2023 C) Dalance outstanding as at the end of the year :

March 31, 2023 March 31, 2022 a. Trade payables and reimbursement payables Subsidiary / Holding Fermenta USA LLC \$ 55.699,18 0,00 Fermenta Biotech Ltd. 4.540.384,70 112.000,00 e s 3.721.402,57 es 112.000,00 b. Trade receivables and reimbursement receivables Subsidiary / Holding Fermenta USA LLC 280.328,30 e -€ Fermenta Biotech Ltd. E 22.500,00 E 22.500,00 e. Allowance for doubtful debts/advances Associate d. Deposit from tenants e. Provision for diminution in value of investments Associate Subsidiary f. Other financial liabilities Key management personnel g. Inter corporate deposits Associate h. Lonn given Subsidiary

Whattenty Stone for the Newsy Wall 45 Vir sinniang FRM. No. 1440 / 37000010

Fermenta BIOTECH GmbH connerGest Germany GmbH Straßenbahnring 13 20251 Hamburg



FERMENTA BIOTECH GMBH fel CIN: NA Notes to the Standalone financial statements for the year caded March 31, 2023 (' in EUR) 43 Commitments and Contingent liabilities March 31, 2023 March 31, 2022 (i) Commitments: (ii) Contingent liabilities: 44 Payment to nuditors excluding statutory levies March 31, 2023 March 31, 2022 For audit For limited review For other services 19.247.80 11.054,47 Reinbursement of expenses 19.247,80 11.054,47 45 Earnings per share (EPS): The following table sets forth the computation of basic and diluted earnings per share : March 31, 2023 March 31, 2022

Profit for the year used for computation of basic and diluted earnings per share (' in Lakhs) Weighted average number of equity shares used in calculating basic EPS [Refer Note 22(a)] Effect of dilutive potential equity shares

Weighted average number of equity shares used in calculating diluted EPS Basic earnings per equity share [nominal value of share ' 5 (March 31, 2022: ' ##)] Diluted earnings per equity share [nominal value of share ' 5 (March 31, 2022: ' ##)]

- 11 60653.93 lenet Wirtschaft Steuenversion yosellachaft Neuer Mail 43 - 20354 Hamburg Tell. Nr. 040 / 3780010

Fermenta BIOTECH GmbH c/o InterGest Germany GmbH Straßenbahnring 13 20251 Hamburg

flet (' in EUR)

46 Leases

(A) Assets taken on operating lease

March 31, 2023 March 31, 2022 Depreciation charge for right-of-use assets Expenses relating to leases of low-value assets accounted for on straight line basis (included in Rent expenses in Note 41) Total cash outflow for leases Maturity analysis of lease liabilities (on undiscounted basis) Less than one year One to five years More than five years Weighted average incremental borrowing rate applied to lease liabilities recognised in the balance sheet at the date. The following is the summary of practical expedients elected on initial application: i) The Company has not reassessed whether a contract is or contains a lease at the date of initial application. ii) The Company has utilised the exemptions provided for short-term leases (less than a year) and leases for low value assets. iii) The Company has utilised hindsight in determining the lease terms where contracts contained options to extend or terminate the lease. iv) Initial direct costs are excluded from the measurement of right-of-uso assets at the date of initial application The difference between the operating lease commitments as of March 31, 2019, disclosed applying Ind AS 17 and the value of the lease liability recognised in the balance sheet at the date of initial application is primarily on account of inclusion of extension options reasonably certain to be exercised, in measuring the lease liability in accordance with Ind AS 116. General description of significant leasing agreements

(i) Refundable interest free deposits have been given under lease agreements.

(ii) Some of the agreements provide for early termination by either party with a specified notice period / renewal with conditions

(B) Assets given on operating lease

Particulars

March 31, 2023 March 31, 2022

a) Rent income recognised in the Standalone statement of profit and loss for the year

 b) Future minimum lease income under the non-cancellable leases in the aggregate and for each of the following periods:
 i) Not later than one year ii) Later than one year and not later than five years iii) More than five years

GOEDSI ER + PARTDEER OMDEN Wirtschalter of ungenerschieden Stearer beskeren gereiner hen Neuro Well 43 - 503066 Heartam 翻、这、中心(赤网的神

Fermenta BIOTECH GmbH

flet

March 31, 2023

(in EUR)

March 31, 2022

Notes to the Standalone financial statements for the year ended March 31, 2023

47 Employee benefits

CIN: NA

(I)

The Company operates following employee benefit plans

Defined contribution plans: Provident fund, superannuation fund, employee state insurance scheme (ESIC) and labour welfare fund.

- (II) Defined benefit plan: Gratuity (funded)
- (III) Other long term benefit plan: Compensated absences (unfunded)

I) Defined contribution plan

The Company operates defined contribution retirement benefit plans for all qualifying employees of the Company. The contribution to defined contribution plan, recognised as expenses in the Standalone statement of profit and loss for the year is as under (Refer Note 38).

Employer's contribution to provident fund

Employer's contribution to superannuation fund

Employer's contribution to ESIC and Employees Deposit Linked Insurance (EDLI)

Employer's contribution to labour welfare fund

II) Defined benefit plan

The Company operates a defined benefit plan, viz., gratuity.

In respect of Gratuity, a defined benefit plan, contributions are made to LIC's Recognised Group Gratuity Fund Scheme. It is governed by the Payment of Gratuity Act, 1972. Under the Gratuity Act, employees are entitled to specific benefit at the time of retirement or termination of the employment on completion of five years or death while in employment. The level of benefit provided depends on the member's length of service and salary at the time of retirement/termination. Provision for Gratuity is based on actuarial valuation done by an independent actuary as at the year end. Each year, the Company reviews the level of funding in the gratuity fund.

(a) Movements in the present value of the defined benefit obligation are as follows:

	*		March 31, 2023	March 31, 2022
Opening defined benefit obligation				
Interest cost				
Current service cost				
Benefits paid				
Actuarial (Gain)/loss on obligations - due to cha	anges in financial assumptions			
Actuarial (Gain)/loss on obligations - due to cha	anges in demographic assumptions			
Actuarial (Gain)/loss on obligations - due to cha	anges in experience adjustment			
Closing defined benefit obligation				-
Movements in the fair value of the plan asset	ts are as follows:			
5 ₁₁ 10 - 10	De Cla	52	March 31, 2023	March 31, 2022
Opening fair value of plan assets		* _ ¹ .		
Employer's contributions				
Interest income				

Remeasurement gain / (loss) :

Return on plan assets (excluding amounts included in net interest expense)

Benefit paid

(b)

Closing fair value of plan assets

Never year 41 20354 Hernburg Teil, Nr. 040 / 3766010

Fermenta BIOTECH GmbH

0,00

0,00

CIN: NA

d)

e)

f)

Notes to the Standalone financial statements for the year ended March 31, 2023

47 Employee benefits

c) Reconciliation of fair value of plan assets and defined benefit obligation:

The amount included in the Standalone financial statements arising from the Company's obligation in respect of its defined benefit obligation plan is as follows:

			March 31, 2023	March	31, 2022
Fair value of plan assets	ana ang ang ang ang ang ang ang ang ang		· · · · · ·		-
Present value of defined benefit obligation			- ¹		-
Amounts recognised in the Standalone balance sheet surplus/(deficit)		1	-	1	-
The amount recognised in Standalone statement of profit and loss in respe	ct of the defined benef	fit plan are	e as follows:		
			March 31, 2023	March	31, 2022
Current service cost	2				
Net interest expense / (income) Components of defined benefit costs recognised in Standalone statement of	f profit and loss		-		-
The amount recognised in other comprehensive income in respect of the de	efined benefit plan is a	s follows:	· . 2		
			March 31, 2023	March	31, 2022
Remeasurement on the net defined benefits liability:				4	
Return on plan assets (excluding amounts included in net interest expense)			-		-
Actuarial gains /(losses) arising from changes in financial assumptions			-		-
Actuarial gains /(losses) arising from changes in demographic assumptions			-		-
Actuarial gains /(losses) arising from changes in experience adjustments					-
Components of defined benefit recognised as income / (loss) in other compa	rehensive income	1 · ·		1	-
The principal assumptions used for the purpose of the actuarial valuations	are as follows:			1	
			March 31, 2023	March	31, 202
Discount rate (per annum)	8		7,05%		6,80%
Salary escalation rate (per annum)			5,00%		5,00%
		11	7.050/		6 0.00

Salary escalation rate (per a	nnum)		5,00%	5,00%
Expected rate of return on p	lan assets (per annum)		7,05%	6,80%
Retirement Age			58 Years	58 Years
Mortality rate			Indian Assured lives	Indian Assured lives
			Mortality (2012-14)	Mortality (2012-14)
Leaving Service (age group	5)		21-30 years- 4%	21-30 years- 4%
			31-40 years - 3%	31-40 years - 3%
			41-50 years - 2%	41-50 years - 2%
			Above 50 years - 1%	Above 50 years - 1%

The estimates of rate of escalation in salary considered in actuarial valuation, take into account inflation, seniority, promotion and other relevant factors including supply and demand in the employment market. The above information is certified by the actuary.

The expected rate of return on plan assets is considered as per declaration from Life Insurance Corporation of India (LIC). The expected contributions for defined benefit plan for the next financial year is `#### Lakhs (March 31, 2022: `#### Lakhs).

(Udt Sai Cho, KARTINSH MASAN Minisch als Zugen Opgeweiter und Steuer heiter 2 - 20152 Hendrag BH, N. 040 / 37856170 Fermenta BIOTECH GmbH c/o InterGest Germany GmbH Straßenbahnring 13 20251 Hamburg

fbl

('in EUR)

CIN: NA Notes to the Standalone financial statements for the year ended March 31, 2023

47 Employee benefits

g) Maturity analysis of projected benefit obligation

			March 31, 2023	March 31, 2022
Expected benefits for Year 1				
Expected benefits for Year 2				
Expected benefits for Year 3				
Expected benefits for Year 4				
Expected benefits for Year 5				
Expected benefits for Year 6				
Expected benefits for Year 7				
Expected benefits for Year 8				
Expected benefits for Year 9				
Expected benefits for Year 10 and a	bove			

) The major categories of plan assets as a percentage of the fair value of total plan assets are as follows:

		March 31, 2023	March 31, 2022
Insurer managed funds			- Internet and the second second

i) Sensitivity analysis

Significant actuarial assumptions for determination of the defined benefit obligation are discount rate and expected salary increase. The sensitivity analysis below has been determined based on reasonably possible changes of the assumptions occurring at end of year, while holding all other assumptions constant. The result of sensitivity analysis is given below:

	March 31, 2023 (Decrease)/increase in DBO*	March 31, 2022 (Decrease)/increase in DBO*
Discount rate (- 0.50%)	4,33%	4,53%
Discount rate (+ 0.50%)	-4,02%	-4,20%
Salary escalation rate (- 0.50%)	-3,90%	-4,01%
Salary escalation rate (+ 0.50%)	4,17%	4,30%
*'DBO: Defined benefit obligation		

j) Inherent risks:

The inherent risk for the Company mainly are adverse salary growth or demographic experience or inadequate returns on underlying plan assets can result in an increase in cost of providing these benefits to employees in future. Since the benefits are lump sum in nature the plan is not subject to any longevity risks.

III) Other long term benefit plan

MALES DEC 040 19 19 Marcel Party 19 - 2024 Headbard Storethered with 29 - 2024 Headbard Marcel and 2024 Headbard Marcel Party 19 - 2024 M

Fermenta BIOTECH GmbH c/o InterGest Germany GmbH

Straßenbahnring 13 20251 Hamburg



(' in EUR)

CIN	IMENTA BIOTECH GMBH NA s to the Standalone financial statements for the year ended March 31, 2023		Ebi
48	Income tax		(' in EUR)
48A	Tax expense recognised in the Standalone statement of profit and loss and other comprehensive income consists of:		
	Particulars	March 31, 2023	March 31, 2022
	Tax expenses:		
	Current tax		
	Deforred tax charge		
	Income tax expense recognised in the Standalone statement of profit and loss	-	
	Tax expense recognised in other comprehensive income		
	Total Tax expense	-	-
		Lesson contraction and the second second	

48B A reconciliation of income tax expense to the amount computed by applying the statutory income tax rate to the profit before income tax is summarised below:

Particulars			March 31, 2023	March 31, 2022
Profit before tax				
Enacted income tax rat	te in India (%) #			
Income tax expense ca	lculated at enacted income tax rate			
Effect of tax on:				
	Impact of change in tax rates on Deferred tax assets			
	Expenses disallowed under income Tax			
	Income that is exempt from tax			
	Incremental deduction on account of research and development			
	Differential tax effect due to effective tax rate difference			
	Others			
			<u>.</u> 6	

Total income tax expense

Tax expenses recognised in Standalone statement of profit and loss Tax expense recognised in other comprehensive income Total tax expense

(UMES) EX a PASTRER (MM) Appendix Consecutive Statutes (Consecutive) Mark Water (Construction Rel. Nr. 1940 / With 16

Fermenta BIOTECH GmbH

48 Income tax

48C The major components of deferred tax liabilities/(assets) arising on account of temporary differences are as follows:

	March 31, 2023			5. C
Particulars	April 01, 2022	Statement of profit and loss	Other comprehensive income	March 31, 2023
(1) Components of deferred tax linbilities (net) Deferred tax linbilities Property, plant and equipment and intangible assets: Impact of difference between written down value as per baoks of account and income tax			3 ⁶	. ¹
Deferred (ax assets Expenses olaimed for tax purpose on payment basis				
Allowance for doubtful debts and advances	4			
Allowance for impairment in the value of non current investment and share application money MAT Credit entitlement				
Others		1		
Deferred tax charge/(credit)			-	· · · · · · · · · · · · · · · · · · ·
Net deferred tax assets	-	8		-

	March 31, 2022			
Particulars	April 01, 2021	Statement of profit and loss	Other comprehensive income	March 31, 2022
(I) Components of deferred tax liabilities (net) Deferred (ax liabilities Property, plant and equipment and intangible assets: Impact of difference between written down value as per books of account and income tax				
Deferred tax assets Expenses claimed for tax purpose on payment basis Allowance for doubtful debts and advances Allowance for impairment in the value of non current investment and share				
Autovance for impairment in the value of non current investment and share application money MAT Credit entitlement Dthers	- 1			
Deferred tax charge/(credit)			-	······································
Net deferred tax assets		2		

48D Details of unused tax losses and unabsorbed tax depreciation for which deferred tax assets have not been recognised;

Particulars Unused tax losses (capital in naturo)

(約日日 GDESSLER Wirtsch fillioster Nexter Walt 43/ 20354 Hamburg Nexter Walt 43/ 20354 Hamburg N. Nr. 040 / 3766010

March 31, 2023

March 31, 2022

Fermenta BIOTECH GmbH c/o InterGest Germany GmbH Straßenbahnring 13 20251 Hamburg



(' in EUR)

CIN: NA Notes to the Standalone financial statements for the year ended March 31, 2023

49 Research and development expenditure

50 Commission and Director sitting fees

51 Details of CSR expenditure

1		March 31, 2023			March 31, 2022		
Gross amount required to be spent by the Company							
Particulars	In cash	Yet to be paid in cash	Total	In cash	Yet to be paid in cash	Total	
Amount spent during the year # i) Construction/acquisition of any asset ii) On purposes other than (i) above	×						

Nature of CSR activities undertaken

Notice of CCD antidutes	22		An	iount Spent
Nature of CSR activities			March 31, 2023	March 31, 2022
Promoting health care including preventive health care			 1	
Contribution for the benefit of armed forces veterans				
Contribution towards animal protection/ welfare				2
Social welfare and Covid care support				
Covid care support				
Promoting health care			19 (B)	
Promoting education				
Protection of art and culture				
Administrative Overheads				1

The information regarding Micro and Small Enterprises has been determined to the extent such parties have been identified on the basis of information available with the Company. This has been relied upon by the auditors.

52 Disclosures under the Micro, Small and Medium Enterprises Development Act, 2006

March 31, 2023

a (i) Principal amount remaining unpaid to any supplier at the end of the accounting year (ii) Interest due on above

The Total of (i) and (ii)

b The amount of interest paid by the buyer in terms of Section 16 of the Micro, Small and Medium Enterprises Development Act, 2006 (27 of 2006) along with the amounts of the payment made to the supplier beyond the appointed day during each accounting year

c The amount of interest due and payable for the period of delay in making payment (which have been paid but beyond the appointed day during the year) but without adding the interest specified under the Micro, Small and Medium Enterprises Development Act, 2006

d The amount of interest accrued and remaining unpaid at the end of each accounting year; and

e The amount of further interest remaining due and payable even in the succeeding years, until such date when the interest dues above are actually paid to the small enterprises for the purpose of disallowance as a deductible expenditure under Section 23 of the Micro, Small and Medium Enterprises Development Act, 2006

(MASER PARKS CON Westernation for the second Neuro War 49 - 2030/ Constants **腕 (kg (40) / 約1891年**

Fermenta BIOTECH GmbH

c/o InterGest Germany GmbH Straßenbahnring 13 20251 Hamburg



March 31, 2022

CIN: NA

Notes to the Standalone financial statements for the year ended March 31, 2023

53A Categories of the financial instruments

	Particulars	5			March 31, 2023	March 31, 2022
a)	Financial assets		999 999 999 999 999 999 999 999 999 99	······································	adi VY ABADA MANARAYA YA MANARANA MANARANA	
	Financial assets measured at fair value through Other	comprehensive	income			
	Investments in equity instruments -quoted				· · ·	-
	Investments in equity instruments -unquoted					
	Financial assets measured at amortised cost					
	(i) Trade receivables				132,232,00	627.550,86
	(ii) Cash and cash equivalents				145.342,60	96.587,36
	(iii) Bank balances other than (ii) above				-	-
	(iv) Share application money				-	-
	(iv) Loans				-	
	(v) Other financial assets				-	-
	Total Financial assets		1. T. T.		277.574,60	724.138,22
b)	Financial liabilities measured at amortised cost					
	(i) Borrowings					
	(ii) Lease liabilities					
	(iii) Trade payables				5.929.271,00	6.043.750,75
	(iv) Other financial liabilities				24,748,81	143.472,04
	Financial liabilities measured at fair value through pro	fit or loss				
	Derivatives not designated as hedge					
	1 - 1					
	Total Financial liabilities		1		5.954.019,81	6.187.222,79
						. Y
53B	Reconciliation of Level 3 fair value measurements:					
	Particulars		1. s. 1		March 31, 2023	March 31, 2022
	Opening balance				-	-
	Total gains or (losses)					
	Recognised in standalone statement of profit and loss	. 1			-	, a", <u>-</u>
	Closing balance					
	Crosing Datance				24	-

54 Patents and Knowhow

GOESSIER PHATEER CHEH Wintering ithing sgr Steury Frankrigsgesetteenant Neuer Wall 43 - 20354 Hamburg Tel. Nr. 040 / 3786010

Fermenta BIOTECH GmbH c/o InterGest Germany GmbH Straßenbahnring 13 20251 Hamburg



55 Fair value

Fair value hierarchy

Fair value of financial assets and financial liabilities that are not measured at fair value but fair value disclosures are required :

5 S	1.00	Carrying	Carrying value		lue
		March 31, 2023	March 31, 2022	March 31, 2023	March 31, 2022
Financial assets					1
Trade receivables		132,232,00	627.550,86	132,232,00	627.550,86
Cash and cash equivalents		145,342,60	96.587,36	145.342,60	96.587,36
Bank balances other than cash and cash equivalents					
Loans					
Other financial assets			81		
Total assets		277,574,60	724.138,22	277,574,60	724.138,22
Financial liabilities Trade payables		5.929.271,00	6.053.770,75	5.929.271,00	6.043.750,75
Lease liabilities					
Borrowings					
Other financial liabilities		24.748,81	143.472,04	24.748,81	143.472,04
Derivatives not designated as hedge					
Total liabilities		5.954.019,81	6.197.242,79	5.954.019,81	6,187,222,79

The financial assets above do not include investments in subsidiaries which are measured at cost, investments in mutual funds measured at fair value through profit and loss and investments in equity instruments measured at fair value through OCI.

The directors consider that the carrying amounts of financial assets and financial liabilities recognised in the standalone financial statements approximate their fair values.

	March 3	1, 2023	March 31, 2022	
	Fair Value	Fair value hierarchy	1545 BY 1297 KI	Fair value hierarchy
Financial assets measured at fair value through Other comprehensive income				
Investments in equity shares-quoted		Level 1		Lovel 1
Investments in equity shares-unquoted		Level 3	i.	Level 3
Financial Liabilities measured at fair value through profit or loss			1.1	
Derivatives not designated as hedge	· · · ·	Level 2		. Level 2

脱上、风、小包/山口的自己/16

Fermenta BIOTECH GmbH

MANAGEMENT ACCOUNT

FOR THE YEAR ENDED 31ST MARCH, 2023

G I BIOTECH PRIVATE LIMITED BALANCE SHEET AS AT MARCH 31, 2023

BREAKCE SHEET AS AT MAKOT ST, 2023		MARCH 31, 2023	March 31, 2022
	Notes	٠.	*
ASSETS			
NON-CURRENT ASSETS			
a) Property, Plant and Equipment	3	-	84,422.00
c) Non-current tax assets (net)	4	•	155,731.00
		5 	240,153.00
CURRENT ASSETS			
a) Financial Assets			
i) Cash and Cash Equivalents	5	€(15,959.29
b) Other current assets	6	a :	10,000.00
			25,959.29
TOTAL		-	266,112.29
EQUITY AND LIABILITIES			
EQUITY			
a) Equity Share Capital	7	87,321.71	100,000.00
b) Other equity	8	(87,321.71)	166,052.29
LIABILITIES		·	
NON-CURRENT LIABILITIES			
a) Deferred tax liability (net)	9	:=:	60.00
		••••••••••••••••••••••••••••••••••••••	60.00
CURRENT LIABILITIES			
a) Financial Liabilities			
ii) Trade payables			
 A) Total outstanding dues of micro and small enterprises 		-	
 B) Total outstanding dues of creditors other than micro and small enterprises 			-
b) Other current liabilities			
		(=)	
TOTAL			266,112.29



STATEMENT OF PROFIT AND LOSS FOR THE PERIOD ENDED MARCH 31, 2023

		MARCH 31, 2023	March 31, 2022
	Notes		
Income:			
Revenue from operations) .)	<u>ia</u>
Other income	10	÷	10,000.00
Total revenue (I)			10,000.00
Expenses:			
Depreciation and amortization expense	11		62,654.00
Other expenses	12	253,374.00	708.00
Total (II)		253,374.00	63,362.00
Profit/(Loss) before tax		(253,374.00)	(53,362.00)
Tax expense:			
Current tax		1 7 3	
Deferred tax		2 5	(12,351.00)
Total tax expense			(12,351.00)
Profit/(Loss) for the year		(253,374.00)	(41,011.00)
Earning per share (equity shares, par value Rs 10 each)	13		
Computed on the basis of total profit for the year			
Basic / Diluted (`.)		(25.34)	(4.10)



CASH FLOW STATEMENT FOR THE PERIOD ENDED MARCH 31, 2023

PARTICULARS	M	ARCH 31, 2023	March 31, 2022
A. Cash flow from operating activities			
Profit before tax		-	(53,362.00
Adjustment to reconcile profit before tax to net cash flows:			
Depreciation and amortization expense		-	62,654.00
Operating profit before working capital changes		•	9,292.00
Movements in working capital :			
Decrease/(increase) in other assets		÷	
Increase/(decrease) in trade payables		5	(10,000.00
Cash generation used in operations		2	(708.00
Direct taxes paid (net of refunds)			-
Net cash flow used in operating activities	(A)		(708.00
B. Cash flow from investing activities			
Net cash flow from/(used in) investing activities	(B)	•	
C. Cash flow from financing activities			
Net cash flow from/ (used in) in financing activities	(C)	•	
2			
Net increase/(decrease) in cash and cash equivalents	(A+B+C)	2	(708.00
Cash and cash equivalents at the beginning of the year			16,667.29
Cash and cash equivalents at the end of the year	: <u></u>		15,959.29
Components of cash and cash equivalents			
With scheduled banks on:			
Current account		2	15,959.29
Total cash and cash equivalents (Refer Note 5)		•	15,959.29

Note

1) Cash flow statement has been prepared under indirect method as set out in the Accounting Standard (AS-3)

"Cash Flow Statements" as specified by Companies (Accounts) Rules, 2014.

2) Previous year's figures have been regrouped/rearranged wherever necessary.



NOTES TO FINANCIAL STATEMENTS FOR THE PERIOD ENDED MARCH 31, 2023

Note 3. - Property, Plant and Equipment

	Plant and equipment
Net Block	
At April 1, 2021	-
Additions	-
Disposal	
At Mar 31, 2022	· · · · · · · · · · · · · · · · · · ·
Depreciation	
Charge for the period	-
Disposal	
At December 31, 2022	
Net Block	·
At March 31, 2022	
At December 31, 2022	-

÷.

	MARCH 31, 2023	March 31, 2022
Note 4- Non-current tax assets (net)		S.
MAT credit entitlement	094	64,159.00
Advance income-tax (net of provision for taxation)		91,572.00
	<u></u>	155,731.00
	MARCH 31, 2023	March 31, 2022
	3	300
Note 5 Cash and Cash Equivalents		
Balances with banks:		
With scheduled banks on:		
Current account	380	15,959.29
		15,959.29



NOTES TO FINANCIAL STATEMENTS FOR THE PERIOD ENDED MARCH 31, 2023

Note 6 - Other current assets			
Security Deposits			10,000.00
			10,000.00
		MARCH 31, 2023	March 31, 2022
Note 7 - Equity Share capital:			
Authorised Shares:			
50000 (March 31, 2022 - 50000) Equity Shares of `.10/- each		500,000.00	500,000.00
		500,000.00	500,000.00
		·	
Issued, Subscribed and fully paid up shares:		400 000 00	100 000 00
10000 (March 31, 2022 - 10000) Equity Shares of `.10 each fully paid-up		100,000.00 (12,678.29)	100,000.00
Less: Payment to Shareholders in lie of clsoure (FBL)		87,321.71	100,000.00
			·
a) Details of shareholders holding more than 5% shares in the Company			
Name of the shareholder	MARCH	31, 2023	March 31, 2022
Equity shares of `. 10/- each fully paid,	No of Shares	% holding in the class	% holding in the class
Fermenta Biotech Limited	10,000	100.00%	62.50%
Ronator Investments Limited (Holding Purchase buy FBL on 16.12.2022)	5 ≣ (37.50%
b) Shares held by holding company			
Out of equity shares issued by the Company, shares held by its holding Company are as below.			
		MARCH 31, 2023	March 31, 2022
			·
Fermenta Biotech Limited		100 000	00 505 55
10,000 (March 31, 2022 - 10,000) Equity shares of `. 10/- each		100,000.00	62,500.00

MARCH 31, 2023

.

March 31, 2022

÷

Statement of Changes in Equity for the period ended 31 December, 2022

Note 8 - Other equity

(a) Equity shares of Rs. 10 each issued, subscribed and fully paid

		No of Shares	•
a)	Balance at the beginning of the reporting period - 1 April 2022	10,000	100,000.00
b)	Changes in equity share capital during the period	<u>1</u>	*
C)	Balance at the end of the reporting period - 31 December 2022	10,000	100,000.00

(b) Other equity

	Reserves and surplus Retained Earnings
Balance at the beginning of the reporting period - 01 April 2021	207,063.29
Loss for the year	(41,011.00)
Balance at the end of the reporting period 31 March 2022	166,052.29
Balance at the beginning of the reporting period - 01 April 2022	166,052.29
Loss for the period	(253,374.00)
Balance at the end of the reporting period 31 December 2022	(87,321.71)

NOTES TO FINANCIAL STATEMENTS FOR THE PERIOD ENDED MARCH 31, 2023

	MARCH 31, 2023	March 31, 2022
Note 9 - Deferred tax liability (net): *		
Deferred tax liability		
Fixed assets: Impact of difference between tax depreciation and depreciation/ amortization charged for the financial reporting		60.00
Gross deferred tax liability	(e) 	60.00
Deferred tax asset		
Gross deferred tax asset		:/#I
Net deferred tax liability	· · · ·	60.00
* In absence of virtual certainty the Company has not recognized deferred tax assets (DTA)/deferred tax liability (DTL) on timing differences arising from disallowance of accumulated depreciation and other items.		
	MARCH 31, 2023	March 31, 2022
		e e e e e e e e e e e e e e e e e e e
ote 10 - Other income:		
Miscellaneous Income		
Previous year provision written back		10,000.00
		1990 - 19900 - 19900 - 19900 - 19900 - 1990 - 1990 - 1990 - 1990 - 1990 - 1990
	MARCH 31, 2023	March 31, 2022
ote 11 - Depreciation and amortization expense		
Depreciation of Property, Plant and Equipment	, ·	62,654.00
		62,654.00
	MARCH 31, 2023	March 31, 2022
ate 12 Other expenses	2	3
ote 12 - Other expenses: Rates and taxes		
		-
Insurance		
Legal and professional charges		25
Payment to auditors (Audit fees)		-
Filing Fees	8	100 100
Sundry Balances no longer Payable	253,374.00	25
Miscellaneous expenses	- 253,374.00	708.00
	MARCH 31, 2023	March 31, 2022
ote 13 - Earnings per share (EPS):		
The following table sets forth the computation of basic and diluted earnings per share :		
Basic/Diluted		
Net profit for the year attributable to equity shareholders	(253,374.00)	(41,011.00)
	(200,014.00)	10,000
Weighted average number of equity shares of Rs 10 each used for calculation of basic earnings per share (adjusted for partly paid shares)	10,000	

Note 14 -

Application for strike off of G. I. Biotech Private Limited was made to Ministry Of Corporate Affairs before March 31, 2023, however the, status on Ministry of Corporate Affairs website is 'Under Process of Striking off'.

